# Patent

## Title
3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof

## Abstract

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

## Background
RELATED APPLICATIONS
This application is a continuation application of U.S. patent application Ser. No. 14/847,371, filed Sep. 8, 2015, which claims the benefit of U.S. Provisional Application No. 62/047,406, filed Sep. 8, 2014, which is incorporated herein by reference in its entirety.


BACKGROUND
Technical Field
This disclosure relates to inhibitors of one or more proteins in the Wnt pathway, including inhibitors of one or more Wnt proteins, and compositions comprising the same. More particularly, it concerns the use of an azaindazole compound or salts or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Background
The Wnt growth factor family includes more than 10 genes identified in the mouse and at least 19 genes identified in the human. Members of the Wnt family of signaling molecules mediate many short- and long-range patterning processes during invertebrate and vertebrate development. The Wnt signaling pathway is known for its role in the inductive interactions that regulate growth and differentiation, and it also plays roles in the homeostatic maintenance of post-embryonic tissue integrity. Wnt stabilizes cytoplasmic β-catenin, which stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin D1. In addition, misregulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers. The Wnt pathway has also been implicated in the maintenance of stem or progenitor cells in a growing list of adult tissues including skin, blood, gut, prostate, muscle, and the nervous system.
SUMMARY
The present disclosure provides methods and reagents, involving contacting a cell with an agent, such as an azaindazole compound, in a sufficient amount to antagonize a Wnt activity, e.g., to reverse or control an aberrant growth state or correct a genetic disorder due to mutations in Wnt signaling components.
Some embodiments disclosed herein include Wnt inhibitors containing an azaindazole core. Other embodiments disclosed herein include pharmaceutical compositions and methods of treatment using these compounds.
One embodiment disclosed herein includes a compound having the structure of Formula I:




as well as prodrugs and pharmaceutically acceptable salts thereof.
In some embodiments of Formula (I):

    
    
        R1 is selected from the group consisting of -heteroaryl(R4)q and -heterocyclyl(R5)h;
        R2 is selected from the group consisting of H and halide;
        R3 is selected from the group consisting of -heteroaryl(R6)q, -heterocyclyl(R7)h, and -aryl(R8)k;
        each R4 is one substituent attached to the heteroaryl and is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R9)h, —(C1-4 alkylene)pcarbocyclyl(R10)j, —(C1-4 alkylene)paryl(R11)k, —NHC(═O)R12, —NR13R14, —(C1-6 alkylene)NR15R16, and —OR22;
        each R5 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
        each R6 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —OCH3, —CN, and —C(═O)R17;
        each R7 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —CN, and —OCH3;
        each R8 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —CN, —OCH3, —(C1-6 alkylene)pNHSO2R17, —NR13(C1-6 alkylene)NR13R14, —(C1-6 alkylene)pNR13R14, and —OR25;
        each R9 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, —(C1-4 alkyl), halide, —CF3, and —CN;
        each R10 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
        each R11 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
        each R12 is independently selected from the group consisting of —(C1-9 alkyl), -heteroaryl(R18)q, -aryl(R19)k, —CH2aryl(R19)k, -carbocyclyl(R20)j, —CH2carbocyclyl(R20)j, —(C1-4 alkylene)pNR23R24, -heterocyclyl(R21)h, and —CH2heterocyclyl(R21)h;
        each R13 is independently selected from the group consisting of H and —(C1-6 alkyl);
        each R14 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j;
        each R15 is independently selected from the group consisting of H and —(C1-6 alkyl);
        each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j;
        each R17 is a —(C1-6 alkyl);
        each R18 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
        each R19 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
        each R20 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
        each R21 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
        each R22 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R21)h, —(C1-4 alkylene)pcarbocyclyl(R20)j, —(C1-4 alkylene)paryl(R19)k, and —(C1-6 alkylene)pNR23R24;
        each R23 is independently selected from the group consisting of H and —(C1-6 alkyl);
        each R24 is independently selected from the group consisting of H and —(C1-6 alkyl);
        each R25 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R21)h, and —(C1-6 alkylene)pNR23R24;
        each p is independently 0 or 1;
        each q is independently 0 to 4;
        each h is independently 0 to 10;
        each k is independently 0 to 5; and
        each j is independently 0 to 12.
    
    


Some embodiments include stereoisomers and pharmaceutically acceptable salts of a compound of Formula (I).
Some embodiments include pro-drugs of a compound of Formula (I).
Some embodiments of the present disclosure include pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient.
Other embodiments disclosed herein include methods of inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins by administering to a patient affected by a disorder or disease in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, cell cycling and mutations in Wnt signaling components, a compound according to Formula (I). Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation and correct a genetic disorder due to mutations in Wnt signaling components.
Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, osteochondrodysplasia, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-Amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.
Some embodiments of the present disclosure include methods to prepare compounds of Formula (I).
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.


DETAILED DESCRIPTION
Provided herein are compositions and methods for inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins. Other Wnt inhibitors and methods for using the same are disclosed in U.S. application Ser. Nos. 12/852,706; 12/968,505; 13/552,188; 13/800,963; 13/855,874; 13/887,177 13/938,691; 13/938,692; 14/019,103; 14/019,147; 14/019,940; 14/149,948; 14/178,749; 14/331,427; and Ser. No. 14/334,005; and U.S. Provisional Application Ser. Nos. 61/232,603; 61/288,544; 61/305,459; 61/620,107; 61/642,915; and 61/750,221, all of which are incorporated by reference in their entirety herein.
Some embodiments provided herein relate to a method for treating a disease or disorder including, but not limited to, cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, osteoarthritis, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.
In some embodiments, non-limiting examples of bone and cartilage diseases which can be treated with the compounds and compositions provided herein include bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressive, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), osteochondritis dissecans, osteochondroma (bone tumor), osteopetrosis, relapsing polychondritis, and Salter-Harris fractures.
In some embodiments, pharmaceutical compositions are provided that are effective for treatment of a disease of an animal, e.g., a mammal, caused by the pathological activation or mutations of the Wnt pathway. The composition includes a pharmaceutically acceptable carrier and a compound as described herein.
Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
As used herein, “alkyl” means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents. Alkyl groups can be saturated or unsaturated (e.g., containing —C═C— or —C≡C— subunits), at one or several positions. In some embodiments, alkyl groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).
As used herein, “alkylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen, such as methylene, ethylene, n-propylene, iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-pentylene, iso-pentylene, sec-pentylene and neo-pentylene. Alkylene groups can either be unsubstituted or substituted with one or more substituents. Alkylene groups can be saturated or unsaturated (e.g., containing —C═C— or —C≡C— subunits), at one or several positions. In some embodiments, alkylene groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).
As used herein, “carbocyclyl” means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings. Carbocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.
As used herein, “lower alkyl” means a subset of alkyl having 1 to 3 carbon atoms, which is linear or branched. Examples of lower alkyls include methyl, ethyl, n-propyl and isopropyl. Likewise, radicals using the terminology “lower” refer to radicals having 1 to about 3 carbons in the alkyl portion of the radical.
As used herein, “aryl” means a mono-, bi-, tri- or polycyclic group with only carbon atoms present in the ring backbone having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic. Aryl groups can either be unsubstituted or substituted with one or more substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydro-1H-indenyl, and others. In some embodiments, the aryl is phenyl.
As used herein, “arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. In some embodiments, arylalkyl groups contain a C1-4alkyl moiety. Exemplary arylalkyl groups include benzyl and 2-phenethyl.
As used herein, the term “heteroaryl” means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S. Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[4,3-c]pyridine, pyrazolo[4,3-b]pyridinyl, tetrazolyl, chromane, 2,3-dihydrobenzo[b][1,4]dioxine, benzo[d][1,3]dioxole, 2,3-dihydrobenzofuran, 2,3-dihydrobenzo[b][1,4]oxathiine, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, pyranyl, pyrazinyl, and pyrimidinyl.
As used herein, “halo”, “halide” or “halogen” is a chloro, bromo, fluoro, or iodo atom radical. In some embodiments, a halo is a chloro, bromo or fluoro. For example, a halide can be fluoro.
As used herein, “haloalkyl” means a hydrocarbon substituent, which is a linear or branched, alkyl, alkenyl or alkynyl substituted with one or more chloro, bromo, fluoro, and/or iodo atom(s). In some embodiments, a haloalkyl is a fluoroalkyls, wherein one or more of the hydrogen atoms have been substituted by fluoro. In some embodiments, haloalkyls are of 1 to about 3 carbons in length (e.g., 1 to about 2 carbons in length or 1 carbon in length). The term “haloalkylene” means a diradical variant of haloalkyl, and such diradicals may act as spacers between radicals, other atoms, or between a ring and another functional group.
As used herein, “heterocyclyl” means a nonaromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others. In some embodiments, the heterocyclyl is selected from azetidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and tetrahydropyridinyl.
As used herein, “monocyclic heterocyclyl” means a single nonaromatic cyclic ring comprising at least one heteroatom in the ring system backbone. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others.
The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more non-hydrogen atoms of the molecule. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Substituents can include, for example, —(C1-9 alkyl) optionally substituted with one or more of hydroxyl, —NH2, —NH(C1-3 alkyl), and —N(C1-3 alkyl)2; —(C1-9 haloalkyl); a halide; a hydroxyl; a carbonyl [such as —C(O)OR, and —C(O)R]; a thiocarbonyl [such as —C(S)OR, —C(O)SR, and —C(S)R]; —(C1-9 alkoxyl) optionally substituted with one or more of halide, hydroxyl, —NH2, —NH(C1-3 alkyl), and —N(C1-3 alkyl)2; —OPO(OH)2; a phosphonate [such as —PO(OH)2 and —PO(OR′)2]; —OPO(OR′)R′′; —NRR′; —C(O)NRR′; —C(NR)NR′R′′; —C(NR′)R′′; a cyano; a nitro; an azido; —SH; —S—R; —OSO2(OR); a sulfonate [such as —SO2(OH) and —SO2(OR)]; —SO2NR′R′′; and —SO2R; in which each occurrence of R, R′ and R′′ are independently selected from H; —(C1-9 alkyl); C6-10 aryl optionally substituted with from 1-3R′′′; 5-10 membered heteroaryl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R′′′; C3-7 carbocyclyl optionally substituted with from 1-3 R′′′; and 3-8 membered heterocyclyl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R′′′; wherein each R′′′ is independently selected from —(C1-6 alkyl), —(C1-6 haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C1-6 alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C1-6 alkyl). In some embodiments, the substituent is selected from —(C1-6 alkyl), —(C1-6 haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C1-6 alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C1-6 alkyl).
As used herein, when two groups are indicated to be “linked” or “bonded” to form a “ring”, it is to be understood that a bond is formed between the two groups and may involve replacement of a hydrogen atom on one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled artisan will recognize that such rings can and are readily formed by routine chemical reactions. In some embodiments, such rings have from 3-7 members, for example, 5 or 6 members.
The skilled artisan will recognize that some structures described herein may be resonance forms or tautomers of compounds that may be fairly represented by other chemical structures, even when kinetically, the artisan recognizes that such structures are only a very small portion of a sample of such compound(s). Such compounds are clearly contemplated within the scope of this disclosure, though such resonance forms or tautomers are not represented herein.
The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.
The term “administration” or “administering” refers to a method of providing a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally, subcutaneously, intravenously, intralymphatic, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic device. The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, the disease involved, and the severity of the disease.
A “diagnostic” as used herein is a compound, method, system, or device that assists in the identification or characterization of a health or disease state. The diagnostic can be used in standard assays as is known in the art.
The term “mammal” is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep, pigs, goats, and non-human primates, but also includes many other species.
The term “pharmaceutically acceptable carrier”, “pharmaceutically acceptable diluent” or “pharmaceutically acceptable excipient” includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, N.J. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (2010); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 12th Ed., The McGraw-Hill Companies.
The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable. In many cases, the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Many such salts are known in the art, for example, as described in WO 87/05297. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
“Solvate” refers to the compound formed by the interaction of a solvent and a compound as provided herein or a salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.
“Patient” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the patient is a human.
A “therapeutically effective amount” or “pharmaceutically effective amount” of a compound as provided herein is one which is sufficient to achieve the desired physiological effect and may vary according to the nature and severity of the disease condition, and the potency of the compound. “Therapeutically effective amount” is also intended to include one or more of the compounds of Formula I in combination with one or more other agents that are effective to treat the diseases and/or conditions described herein. The combination of compounds can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease. This amount can further depend upon the patient's height, weight, sex, age and medical history.
A therapeutic effect relieves, to some extent, one or more of the symptoms of the disease.
“Treat,” “treatment,” or “treating,” as used herein refers to administering a compound or pharmaceutical composition as provided herein for therapeutic purposes. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, ameliorating the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder, and/or reducing the severity of symptoms that will or are expected to develop.
“Drug-eluting” and/or controlled release as used herein refers to any and all mechanisms, e.g., diffusion, migration, permeation, and/or desorption by which the drug(s) incorporated in the drug-eluting material pass therefrom over time into the surrounding body tissue.
“Drug-eluting material” and/or controlled release material as used herein refers to any natural, synthetic or semi-synthetic material capable of acquiring and retaining a desired shape or configuration and into which one or more drugs can be incorporated and from which incorporated drug(s) are capable of eluting over time.
“Elutable drug” as used herein refers to any drug or combination of drugs having the ability to pass over time from the drug-eluting material in which it is incorporated into the surrounding areas of the body.
The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
Compounds
The compounds and compositions described herein can be used as anti-proliferative agents, e.g., anti-cancer and anti-angiogenesis agents, and/or as inhibitors of the Wnt signaling pathway, e.g., for treating diseases or disorders associated with aberrant Wnt signaling. In addition, the compounds can be used as inhibitors of one or more kinases, kinase receptors, or kinase complexes. Such compounds and compositions are also useful for controlling cellular proliferation, differentiation, and/or apoptosis.
Some embodiments of the present disclosure include compounds of Formula I:




or salts, pharmaceutically acceptable salts, or prodrugs thereof.

In some embodiments, R1 is selected from the group consisting of -pyridinyl(R4) and -pyrimidinyl(R5).
In some embodiments, R1 is selected from the group consisting of -heteroaryl(R4)q and -heterocyclyl(R5)h.
In some embodiments, R1 is selected from the group consisting of -piperidinyl(R5)h and -tetrahydropyridinyl(R5)h.
In some embodiments, R1 is selected from the group consisting of -pyridinyl(R4), -pyrimidinyl(R4)q, -pyrazinyl(R4)q, -pyrazolyl(R4)q, and -imidazolyl(R4)q.
In some embodiments, R2 is selected from the group consisting of H and halide.
In some embodiments, R3 is selected from the group consisting of -heteroaryl(R6)q, -heterocyclyl(R6)h, and -aryl(R8)k.
In some embodiments, R3 is selected from the group consisting of -pyridinyl(R6)q, -imidazolyl(R6)q, -furanyl(R6)q, -thiophenyl(R6)q, -piperidinyl(R7)h, -piperazinyl(R7)h, and -phenyl(R8)k.
In some embodiments, R4 is one substituent attached to the pyridinyl and is independently selected from the group consisting of H, halide, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R9)h, —(C1-4 alkylene)pcarbocyclyl(R10)j, —(C1-4 alkylene)paryl(R11)k, —NHC(═O)R12, —NR13R14, and —(C1-6 alkylene)NR15R16.
In some embodiments, each R4 is one substituent attached to the heteroaryl and is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R9)h, —(C1-4 alkylene)pcarbocyclyl(R10)j, —(C1-4 alkylene)paryl(R11)k, —NHC(═O)R12, —NR13R14, —(C1-6 alkylene)NR15R16, and —OR22.
In some embodiments, each R4 is one substituent attached to the heteroaryl and is independently selected from the group consisting of F, -Me, -Et, —(CH2)heterocyclyl(R9)h, -heterocyclyl(R9)h, —(CH2)carbocyclyl(R10), —(CH2)aryl(R11)k, —NHC(═O)(C1-5 alkyl), —NHC(═O)phenyl(R19)k, —NHC(═O)(CH2)phenyl(R19)k, —NHC(═O)carbocyclyl(R20)j, —NHC(═O)(CH2)heterocyclyl(R21)h, —NH2, —N(C1-3 alkyl)2, —NH(C1-4 alkyl), —(CH2)N(C1-3 alkyl)2, —(CH2)NH(C1-4 alkyl), —OH, —O(C1-3 alkyl), —Ocarbocyclyl(R20)j, —Oheterocyclyl(R21)h, —O(CH2CH2)heterocyclyl(R21)h, —O(CH2CH2)N(C1-3 alkyl)2, and —O(CH2)phenyl(R19)k.
In some embodiments, R5 is one substituent attached to the pyrimidinyl and is independently selected from the group consisting of H, halide, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R9)h, —(C1-4 alkylene)pcarbocyclyl(R10), —(C1-4 alkylene)paryl(R11)k, —NHC(═O)R12, —NR13R14, and —(C1-6 alkylene)NR15R16.
In some embodiments, each R5 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R6 is one substituent attached to the heteroaryl and is independently selected from the group consisting of H, —(C1-6 alkyl), halide, —CF3, —OCH3, —CN, and —C(═O)R17.
In some embodiments, each R6 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —OCH3, —CN, and —C(═O)R17.
In some embodiments, each R6 is one substituent attached to the heteroaryl and is independently selected from the group consisting of -Me, -Et, F, —CF3, —OCH3, —CN, and —C(═O)(C1-3 alkyl).
In some embodiments, each R7 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of H, —(C1-6 alkyl), halide, —CF3, —CN, and —OCH3.
In some embodiments, each R7 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —CN, and —OCH3.
In some embodiments, each R8 is one substituent attached to the aryl and is independently selected from the group consisting of H, —(C1-6 alkyl), halide, —CF3, —CN, —OCH3, —(C1-6 alkylene)pNHSO2R17, —NR13(C1-6 alkylene)NR13R14, and —(C1-6 alkylene)pNR13R14.
In some embodiments, each R8 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —CN, —OCH3, —(C1-6 alkylene)pNHSO2R17, —NR13(C1-6 alkylene)NR13R14, —(C1-6 alkylene)pNR13R14, and —OR25.
In some embodiments, each R8 is one substituent attached to the aryl and is independently selected from the group consisting of -Me, -Et, F, —CF3, —CN, —OCH3, —(CH2CH2)NHSO2(C1-3 alkyl), —NH(CH2CH2)N(C1-3 alkyl)2, —OH, —O(C1-3 alkyl), —O(CH2CH2)heterocyclyl(R21)h, and —O(CH2CH2)N(C1-3 alkyl)2.
In some embodiments, each R9 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of H, —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R9 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R9 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, Me, Et, F, Cl, and —CF3.
In some embodiments, each R10 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of H, —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R10 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R10 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF3.
In some embodiments, each R11 is one substituent attached to the aryl and is independently selected from the group consisting of H, —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R11 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R11 is one substituent attached to the aryl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF3.
In some embodiments, each R12 is independently selected from the group consisting of —(C1-9 alkyl), -heteroaryl(R18)q, -aryl(R19)k, —CH2aryl(R19)k, -carbocyclyl(R20)j, and —CH2carbocyclyl(R20)j.
In some embodiments, each R12 is independently selected from the group consisting of —(C1-9 alkyl), -heteroaryl(R18)q, -aryl(R19)k, —CH2aryl(R19)k, -carbocyclyl(R20)j, —CH2carbocyclyl(R20)j, —(C1-4 alkylene)pNR23R24, -heterocyclyl(R21)h, and —CH2heterocyclyl(R21)h.
In some embodiments, each R12 is independently selected from the group consisting of —(C1-5 alkyl), -phenyl(R19)k, —(CH2)phenyl(R19)k, -carbocyclyl(R20)j, —(CH2)carbocyclyl(R20)j, —(CH2)N(C1-3 alkyl)2, and —(CH2)heterocyclyl(R21)h.
In some embodiments, each R13 is independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, each R13 is independently selected from the group consisting of H and —(C1-3 alkyl).
In some embodiments, each R14 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j.
In some embodiments, each R14 is independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j. 
In some embodiments, each R15 is independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, each R15 is independently selected from the group consisting of H and —(C1-3 alkyl).
In some embodiments, each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j.
In some embodiments, each R16 is independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j.
In some embodiments, each R17 is independently a —(C1-6 alkyl).
In some embodiments, each R17 is independently a —(C1-3 alkyl).
In some embodiments, each R18 is one substituent attached to the heteroaryl and is independently selected from the group consisting of H, —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R18 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R18 is one substituent attached to the heteroaryl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF3.
In some embodiments, each R19 is one substituent attached to the aryl and is independently selected from the group consisting of H, —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R19 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R19 is one substituent attached to the aryl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF3.
In some embodiments, each R20 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of H, —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R20 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R20 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF3.
In some embodiments, each R21 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN.
In some embodiments, each R21 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF3.
In some embodiments, R22 is selected from the group consisting of H, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R21)h, —(C1-4 alkylene)pcarbocyclyl(R20)j, —(C1-4 alkylene)paryl(R19)k, and —(C1-6 alkylene)pNR23R24.
In some embodiments, R22 is selected from the group consisting of H, -Me, -Et, -iPr, -heterocyclyl(R21)h, —(CH2CH2)heterocyclyl(R21)h, -carbocyclyl(R20)j, —(CH2)phenyl(R19)k, and —(CH2CH2)N(C1-3 alkyl)2.
In some embodiments, each R23 is independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, each R23 is independently selected from the group consisting of Me and Et.
In some embodiments, each R24 is independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, each R24 is independently selected from the group consisting of Me and Et.
In some embodiments, R25 is selected from the group consisting of H, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R21)h, and —(C1-6 alkylene)pNR23R24.
In some embodiments, R25 is selected from the group consisting of H, -Me, -Et, -iPr, —(CH2CH2)heterocyclyl(R21)h, and —(CH2CH2)N(C1-3 alkyl)2.
In some embodiments, each p is independently 0 or 1.
In some embodiments, each q is independently 1 to 4.
In some embodiments, each h is independently 1 to 10.
In some embodiments, each k is independently 1 to 5.
In some embodiments, each j is independently 1 to 12.
In some embodiments, each p is independently 0 or 1; in some embodiments, each p is 0; in some embodiments, each p is 1.
In some embodiments, each q is independently 0 to 4; in some embodiments, each q is 0; in some embodiments, each q is 1; in some embodiments, each q is 2; in some embodiments, each q is 3; in some embodiments, each q is 4.
In some embodiments, each h is independently 0 to 10; in some embodiments, each h is 0; in some embodiments, each h is 1; in some embodiments, each h is 2; in some embodiments, each h is 3; in some embodiments, each h is 4.
In some embodiments, each k is independently 0 to 5; in some embodiments, each k is 0; in some embodiments, each k is 1; in some embodiments, each k is 2; in some embodiments, each k is 3.
In some embodiments, each j is independently 0 to 12; in some embodiments, each j is 0; in some embodiments, each j is 1; in some embodiments, each j is 2; in some embodiments, each j is 3; in some embodiments, each j is 4.
In some embodiments, each R4 is one substituent attached to the heteroaryl and is selected from the group consisting of —(C1-3 alkyl), —CH2heterocyclyl(R9)h, —NHC(═O)R12, —NR13R14, and —CH2NR15R16.
In some embodiments, at least one R9 is halide.
In some embodiments, R12 is selected from the group consisting of —(C1-5 alkyl), -phenyl(R19)k, —CH2phenyl(R19)k, and -carbocyclyl(R20)j.
In some embodiments, R13 and R14 are independently selected from H and —(C1-5 alkyl).
In some embodiments, R15 and R16 are independently selected from H and —(C1-5 alkyl).
In some embodiments, k is 1 or 2 and each R8 is independently a halide.
In some embodiments, k is 2, one R8 is halide and the other R8 is —CH2NHSO2R17.
In some embodiments, R17 is —(C1-3 alkyl).
In some embodiments, k is 2, one R8 is halide and the other R8 is —NHCH2CH2NR13R14.
In some embodiments, R13 and R14 are independently selected from H and —(C1-3 alkyl).
In some embodiments, R3 is selected from the group consisting of -pyridinyl(R6)q, -imidazolyl(R6)q, -furanyl(R6)q, and -thiophenyl(R6)q.
In some embodiments, q is 0 or 1, R6 is selected from the group consisting of halide, —(C1-3 alkyl), —C(═O)R17, and R17 is —(C1-2 alkyl).
In some embodiments, R3 is selected from the group consisting of -piperidinyl(R7)h and -piperazinyl(R7)h.
In some embodiments, q is 1, and R1 is selected from the group consisting of H and —(C1-3 alkyl).
In some embodiments, R2 is H; in other embodiments, R2 is halide, e.g. F.
In some embodiments, R1 is -heteroaryl(R4)q.
In some embodiments, R1 is -pyridinyl(R4)q.
In some embodiments, R1 is -pyridin-3-yl(R4)q.
In some embodiments, R1 is -pyrimidinyl(R4)q.
In some embodiments, R1 is -pyrimidin-5-yl(R4)q.
In some embodiments, R1 is -pyrimidin-5-yl(R4)q and q is 0.
In some embodiments, R1 is -pyrazinyl(R4)q.
In some embodiments, R1 is -pyrazolyl(R4)q.
In some embodiments, R1 is -pyrazol-4-yl(R4)q, q is 1, and R4 is Me.
In some embodiments, R1 is -pyrazol-4-yl(R4)q and q is 0.
In some embodiments, R1 is -imidazolyl(R4)q.
In some embodiments, R1 is -imidazol-5-yl(R4)q, q is 1, and R4 is Me.
In some embodiments, R1 is -imidazol-5-yl(R4)q, q is 2, and both R4 are Me.
In some embodiments, R1 is -heterocyclyl(R5)h.
In some embodiments, R1 is -piperidinyl(R5)h.
In some embodiments, R1 is -piperidin-4-yl(R5)h.
In some embodiments, R1 is -piperidin-4-yl(R5)h, and h is 0.
In some embodiments, R1 is -tetrahydropyridinyl(R5)h.
In some embodiments, R1 is -1,2,3,6-tetrahydropyridinyl(R5)h.
In some embodiments, R1 is -1,2,3,6-tetrahydropyridinyl(R5)h, and h is 0.
In some embodiments, R3 is -heteroaryl(R6)q.
In some embodiments, R3 is -heterocyclyl(R7)h.
In some embodiments, R3 is -piperidinyl(R7)h.
In some embodiments, R3 is -piperazinyl(R7)h.
In some embodiments, R3 is -aryl(R8)k.
In some embodiments, R3 is -pyridinyl(R6)q.
In some embodiments, R3 is -pyridin-3-yl(R6)q.
In some embodiments, R3 is -pyridin-4-yl(R6)q.
In some embodiments, R3 is -pyridin-5-yl(R6)q.
In some embodiments, R3 is -pyridin-3-yl(R6)q, q is 0.
In some embodiments, R3 is -pyridin-4-yl(R6)q, q is 0.
In some embodiments, R3 is -pyridin-5-yl(R6)q, q is 0.
In some embodiments, R3 is -imidazolyl(R6)q.
In some embodiments, R3 is -imidazol-1-yl(R6)q, q is 1, and R6 is —(C1-3 alkyl).
In some embodiments, R3 is -imidazol-1-yl(R6)q, q is 1, and R6 is methyl.
In some embodiments, R3 is -furanyl(R6)q.
In some embodiments, R3 is -furan-2-yl(R6)q.
In some embodiments, R3 is -furan-2-yl(R6)q and q is 0.
In some embodiments, R3 is -furan-3-yl(R6)q.
In some embodiments, R3 is -furan-3-yl(R6)q and q is 0.
In some embodiments, R3 is -thiophenyl(R6)q.
In some embodiments, R3 is -thiophen-2-yl(R6)q.
In some embodiments, R3 is -thiophen-2-yl(R6)q and q is 0.
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1 or 2, and each R6 is independently a halide.
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1 or 2, and R6 is F.
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1 or 2, and each R6 is independently —(C1-6 alkyl).
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1 or 2, and each R6 is independently —(C1-2 alkyl).
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1 or 2, and R6 is methyl.
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1 or 2, and R6 is —CF3.
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1 or 2, and R6 is CN.
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1, and R6 is —C(═O)R7.
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1, R6 is —C(═O)R17, and R17 is —(C1-6 alkyl).
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1, R6 is —C(═O)R17, and R17 is —(C1-4 alkyl).
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1, R6 is —C(═O)R17, and R17 is —(C1-2 alkyl).
In some embodiments, R3 is -thiophen-2-yl(R6)q, q is 1, R6 is —C(═O)R17, and R17 is methyl.
In some embodiments, R3 is -thiophen-3-yl(R6)q.
In some embodiments, R3 is -thiophen-3-yl(R6)q and q is 0.
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1 or 2, and each R6 is independently halide.
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1 or 2, and R6 is F.
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1 or 2, and each R6 is independently —(C1-6 alkyl).
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1 or 2, and each R6 is independently —(C1-2 alkyl).
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1 or 2, and R6 is methyl.
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1 or 2, and R6 is —CF3.
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1 or 2, and R6 is CN.
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1, and R6 is —C(═O)R17.
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1, R6 is —C(═O)R17, and R17 is —(C1-4 alkyl).
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1, R6 is —C(═O)R17, and R17 is —(C1-2 alkyl).
In some embodiments, R3 is -thiophen-3-yl(R6)q, q is 1, R6 is —C(═O)R17, and R17 is methyl.
In some embodiments, R3 is selected from the group consisting of:




In some embodiments, R3 is -phenyl(R8)k.
In some embodiments, R3 is -phenyl(R8)k and k is 0.
In some embodiments, R3 is -phenyl(R8)k, k is 1 or 2, and each R8 is independently a halide.
In some embodiments, R3 is -phenyl(R8)k, k is 1 or 2, and R8 is F.
In some embodiments, R3 is -phenyl(R8)k, k is 1, and R8 is F.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is a halide and the other R8 is —(C1-6 alkylene)pNHSO2R17.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is a halide and the other R8 is —(C1-4 alkylene)pNHSO2R17, and p is 1.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is a halide and the other R8 is —(C1-2 alkylene)pNHSO2R17, and p is 1.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is a halide and the other R8 is —CH2NHSO2R17.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is a halide and the other R8 is —CH2NHSO2R17, and R17 is —(C1-4 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is a halide and the other R8 is —CH2NHSO2R17, and R17 is —(C1-2 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is a halide and the other R8 is —CH2NHSO2R17, and R17 is methyl.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is F and the other R8 is —CH2NHSO2R17, and R17 is —(C1-2 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is F and the other R8 is —CH2NHSO2R17, and R17 is methyl.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NR13(C1-6 alkylene)NR13R14.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NR13(C1-s alkylene)NR13R14.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NR13(C1-4 alkylene)NR13R14.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NR13(C1-3 alkylene)NR13R14.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NR13CH2CH2NR13R14.
In some embodiments, R3 is -phenyl(R8)k, k is 2, R8 is halide and the other R8 is —NHCH2CH2NR13R14, and R13 and R14 are independently selected from —(C1-6 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NHCH2CH2NR13R14, and R13 and R14 are independently selected from —(C1-4 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NHCH2CH2NR13R14, and R13 and R14 are independently selected from —(C1-2 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —NHCH2CH2NR13R14, and R13 and R14 are both methyl.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is F and the other R8 is —NHCH2CH2NR13R14, and R13 and R14 are independently selected from —(C1-2 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is F and the other R8 is —NHCH2CH2NR13R14, and R13 and R14 are both methyl.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —OCH2CH2NR23R24.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —OCH2CH2NR23R24, and R23 and R24 are independently a —(C1-2 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —OCH2CH2NR23R24, and R23 and R24 are both methyl.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is F and the other R8 is —OCH2CH2NR23R24, and R23 and R24 are both methyl.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —CH2NHSO2R17, and R17 is —(C1-4 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —CH2NHSO2R17, and R17 is —(C1-2 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is halide and the other R8 is —CH2NHSO2R17, and R17 is methyl.
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is F and the other R8 is —CH2NHSO2R17, and R17 is —(C1-2 alkyl).
In some embodiments, R3 is -phenyl(R8)k, k is 2, one R8 is F and the other R8 is —CH2NHSO2R17, and R17 is methyl.
In some embodiments, R3 is selected from the group consisting of:




In some embodiments, R3 is -piperidinyl(R7)h.
In some embodiments, R3 is -piperidin-1-yl(R7)h.
In some embodiments, R3 is -piperidin-1-yl(R7)h and h is 0.
In some embodiments, R3 is -piperidin-1-yl(R7)h, h is 1 or 2, and each R7 is independently selected from a halide.
In some embodiments, R3 is -piperazinyl(R7)h.
In some embodiments, R3 is -piperazin-1-yl(R7)h.
In some embodiments, R3 is -piperazin-1-yl(R7)h, h is 1, and R7 is C1-3 alkyl.
In some embodiments, R3 is -piperazin-1-yl(R7)h, h is 1, and R7 is methyl.
In some embodiments, R3 is -morpholinyl(R7)h.
In some embodiments, R3 is -morpholin-1-yl(R7)h.
In some embodiments, R3 is -morpholin-1-yl(R7)h and h is 0.
In some embodiments, R3 is selected from the group consisting of:




In some embodiments, q is 0.
In some embodiments, at least one R4 is a halide.
In some embodiments, at least one R4 is a F.
In some embodiments, R4 is F.
In some embodiments, at least one R4 is —(C1-6 alkyl).
In some embodiments, at least one R4 is —(C1-5 alkyl).
In some embodiments, at least one R4 is —(C1-4 alkyl).
In some embodiments, at least one R4 is —(C1-3 alkyl).
In some embodiments, at least one R4 is —(C1-2 alkyl).
In some embodiments, R4 is a methyl.
In some embodiments, at least one R4 is —(C1-4 alkylene)pheterocyclyl(R9)h and p is 0 or 1.
In some embodiments, at least one R4 is —(C1-3 alkylene)pheterocyclyl(R9)h and p is 0 or 1.
In some embodiments, at least one R4 is —(C1-2 alkylene)pheterocyclyl(R9)h and p is 0 or 1.
In some embodiments, at least one R4 is —CH2pyrrolidinyl(R9)h.
In some embodiments, at least one R4 is —CH2pyrrolidinyl(R9)h and h is 0.
In some embodiments, R4 is a —CH2pyrrolidinyl(R9)h and h is 0.
In some embodiments, at least one R4 is —CH2pyrrolidinyl(R9)h, h is 1 or 2, and at least one R9 is halide.
In some embodiments, at least one R4 is —CH2pyrrolidinyl(R9)h, h is 1 or 2, and at least one R9 is F.
In some embodiments, R4 is a —CH2pyrrolidinyl(R9)h, h is 1 or 2, and at least one R9 is halide.
In some embodiments, R4 is —CH2pyrrolidinyl(R9)h, h is 1 or 2, and at least one R9 is F.
In some embodiments, R6 is a —CH2pyrrolidinyl(R9)h, h is 1 or 2, and each R9 is F.
In some embodiments, at least one R4 is —CH2piperidinyl(R9)h.
In some embodiments, at least one R4 is —CH2piperidinyl(R9)h and h is 0.
In some embodiments, R4 is a —CH2piperidinyl(R9)h and h is 0.
In some embodiments, at least one R4 is —CH2piperidinyl(R9)h and at least one R9 is halide.
In some embodiments, at least one R4 is —CH2piperidinyl(R9)h and at least one R9 is F.
In some embodiments, at least one R4 is —CH2piperidinyl(R9)h, h is 1 or 2, and at least one R9 is halide.
In some embodiments, at least one R4 is —CH2piperidinyl(R9)h, h is 1 or 2, and at least one R9 is F.
In some embodiments, R4 is —CH2piperidinyl(R9)h, h is 1 or 2, and each R9 is a halide.
In some embodiments, R4 is —CH2piperidinyl(R9)h, h is 1 or 2, and each R9 is F.
In some embodiments, R4 is a —CH2piperidinyl(R9)h, h is 1 or 2, and each R9 is F.
In some embodiments, R4 is a




In some embodiments, at least one R4 is —(C1-4 alkylene)pcarbocyclyl(R10)j.
In some embodiments, at least one R4 is —(C1-4 alkylene)pcarbocyclyl(R10)j and j is 0 or 1.
In some embodiments, at least one R4 is —(C1-3 alkylene)pcarbocyclyl(R10)j and j is 0 or 1.
In some embodiments, at least one R4 is —(C1-2 alkylene)pcarbocyclyl(R10)j and j is 0 or 1.
In some embodiments, at least one R4 is —CH2carbocyclyl(R10)j.
In some embodiments, R4 is a —CH2carbocyclyl(R10)j.
In some embodiments, at least one R4 is —(C1-4 alkylene)paryl(R1)k and k is 0 or 1.
In some embodiments, at least one R4 is —(C1-3 alkylene)paryl(R11)k and k is 0 or 1.
In some embodiments, at least one R4 is —(C1-2 alkylene)paryl(R11)k and k is 0 or 1.
In some embodiments, at least one R4 is —CH2aryl(R11)k.
In some embodiments, at least one R4 is —CH2phenyl(R11)k.
In some embodiments, R4 is a —CH2phenyl(R11)k.
In some embodiments, at least one R4 is —NHC(═O)R12.
In some embodiments, R4 is a —NHC(═O)R12.
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-9 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-8 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-7 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-6 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-5 alkyl).
In some embodiments, R4 is a —NHC(═O)R12 and R12 is —(C1-5 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-4 alkyl).
In some embodiments, R4 is a —NHC(═O)R12 and R12 is —(C1-4 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-3 alkyl).
In some embodiments, R4 is a —NHC(═O)R12 and R12 is —(C1-3 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C1-2 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C2-5 alkyl).
In some embodiments, R4 is a —NHC(═O)R12 and R12 is —(C2-5 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —(C3-4 alkyl).
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is -aryl(R19)k.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is -phenyl(R19)k, and k is 0.
In some embodiments, R4 is a —NHC(═O)R12, R12 is -phenyl(R19)k, and k is 0.
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is —CH2 aryl(R19)k.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is —CH2phenyl(R19)k, and k is 0.
In some embodiments, R4 is —NHC(═O)R12, R12 is —CH2phenyl(R19)k, and k is 0.
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is -heteroaryl(R18)q.
In some embodiments, at least one R4 is —NHC(═O)R12 and R12 is -carbocyclyl(R20)j.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is -carbocyclyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is -cyclopropyl(R20)j, and j is 0.
In some embodiments, R4 is a —NHC(═O)R12, R12 is -cyclopropyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is -cyclobutyl(R20)j, and j is 0.
In some embodiments, R4 is a —NHC(═O)R12, R12 is -cyclobutyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is -cyclopentyl(R20)j, and j is 0.
In some embodiments, R4 is a —NHC(═O)R12, R12 is -cyclopentyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is -cyclohexyl(R20)j, and j is 0.
In some embodiments, R4 is a —NHC(═O)R12, R12 is -cyclohexyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is —CH2carbocyclyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHC(═O)R12, R12 is —CH2cyclopropyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NR13R14.
In some embodiments, at least one R4 is —NR13R14, R13 and R14 are independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, at least one R4 is —NR13R14, and R13 and R14 are independently selected from the group consisting of H and —(C1-5 alkyl).
In some embodiments, at least one R4 is —NR13R14, and R13 and R14 are independently selected from the group consisting of H and —(C1-4 alkyl).
In some embodiments, at least one R4 is —NR13R14, and R13 and R14 are independently selected from the group consisting of H and —(C1-3 alkyl).
In some embodiments, at least one R4 is —NR13R14, and R13 and R14 are independently selected from the group consisting of H and —(C1-2 alkyl).
In some embodiments, at least one R4 is —NR13R14, and R13 and R14 are independently selected from the group consisting of H and methyl.
In some embodiments, at least one R4 is —NH2.
In some embodiments, R4 is a —NH2.
In some embodiments, at least one R4 is —NHR14 and R14 is —(C1-4 alkyl).
In some embodiments, at least one R4 is —NHR14 and R14 is —(C1-3 alkyl).
In some embodiments, at least one R4 is —NHR14 and R14 is —(C1-2 alkyl).
In some embodiments, R4 is a —NHR14 and R14 is —(C1-2 alkyl).
In some embodiments, at least one R4 is —NHR14 and R14 is —CH2aryl(R19)k.
In some embodiments, at least one R4 is —NHR14, R14 is —CH2phenyl(R19)k, and k is 0.
In some embodiments, R4 is —NHR14, R14 is —CH2phenyl(R19)k, and k is 0.
In some embodiments, at least one R4 is —NHR14 and R14 is —CH2carbocyclyl(R20)j.
In some embodiments, at least one R4 is —NHR14, R14 is —CH2cyclopropyl(R20)j, and j is 0.
In some embodiments, R4 is a —NHR14, R14 is —CH2cyclopropyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHR14, R14 is —CH2cyclobutyl(R20)j, and j is 0.
In some embodiments, R4 is a —NHR14, R14 is —CH2cyclobutyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHR14, R14 is —CH2cyclopentyl(R20)j, and j is 0.
In some embodiments, R4 is a —NHR14, R14 is —CH2cyclopentyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —NHR14, R14 is —CH2cyclohexyl(R20)), and j is 0.
In some embodiments, R4 is a —NHR14, R14 is —CH2cyclohexyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —(C1-6 alkylene)NR15R16.
In some embodiments, at least one R4 is —(C1-5 alkylene)NR15R16.
In some embodiments, at least one R4 is —(C1-4 alkylene)NR15R16.
In some embodiments, at least one R4 is —(C1-3 alkylene)NR15R16.
In some embodiments, at least one R4 is —(C1-2 alkylene)NR15R16.
In some embodiments, at least one R4 is —CH2NR15R16.
In some embodiments, R4 is a —CH2NR15R16.
In some embodiments, at least one R4 is —CH2NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, at least one R4 is —CH2NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-5 alkyl).
In some embodiments, at least one R4 is —CH2NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-4 alkyl).
In some embodiments, at least one R4 is —CH2NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-3 alkyl).
In some embodiments, at least one R4 is —CH2NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-2 alkyl).
In some embodiments, at least one R4 is —CH2NR15R16, and R15 and R16 are independently selected from the group consisting of H and methyl.
In some embodiments, R4 is a —CH2NR15R16, and R15 and R16 are independently selected from the group consisting of H and methyl.
In some embodiments, at least one R4 is —CH2NH2.
In some embodiments, R4 is a —CH2NH2.
In some embodiments, at least one R4 is —CH2NMe2.
In some embodiments, R4 is —CH2NMe2.
In some embodiments, at least one R4 is —CH2NHR16 and R16 is —(C1-4 alkyl).
In some embodiments, at least one R4 is —CH2NHR16 and R16 is —(C1-3 alkyl).
In some embodiments, at least one R4 is —CH2NHR16 and R16 is —(C1-2 alkyl).
In some embodiments, R4 is a —CH2NHR16 and R16 is —(C1-2 alkyl).
In some embodiments, at least one R4 is —CH2NHR16 and R16 is —CH2aryl(R19)k.
In some embodiments, at least one R4 is —CH2NHR16, R16 is —CH2phenyl(R19)k, and k is 0.
In some embodiments, R4 is a —CH2NHR16, R16 is —CH2phenyl(R19)k, and k is 0.
In some embodiments, at least one R4 is —CH2NHR16 and R16 is —CH2carbocyclyl(R20)j.
In some embodiments, at least one R4 is —CH2NHR16, R16 is —CH2cyclopropyl(R20)j, and j is 0.
In some embodiments, R4 is a —CH2NHR16, R16 is —CH2cyclopropyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —CH2NHR16, R16 is —CH2cyclobutyl(R20)j, and j is 0.
In some embodiments, R4 is a —CH2NHR16, R16 is —CH2cyclobutyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —CH2NHR16, R16 is —CH2cyclopentyl(R20)j, and j is 0.
In some embodiments, R4 is a —CH2NHR16, R16 is —CH2cyclopentyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —CH2NHR16, R16 is —CH2cyclohexyl(R20)j, and j is 0.
In some embodiments, R4 is a —CH2NHR16, R16 is —CH2cyclohexyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —OR22.
In some embodiments, at least one R4 is —OH.
In some embodiments, R4 is a —OH.
In some embodiments, at least one R4 is —OR22 and R22 is —(C1-3 alkyl).
In some embodiments, at least one R4 is —OR22 and R22 is —(C1-2 alkyl).
In some embodiments, at least one R4 is —OMe.
In some embodiments, R4 is a —OMe.
In some embodiments, at least one R4 is —OR22, R22 is -heterocyclyl(R21)h, and his 0.
In some embodiments, R4 is a —OR22, R22 is -heterocyclyl(R21)h, and h is 0.
In some embodiments, at least one R4 is —OR22, R22 is -carbocyclyl(R10)j, and j is 0.
In some embodiments, R4 is a —OR22, R22 is -carbocyclyl(R20)j, and j is 0.
In some embodiments, at least one R4 is —OR22, R22 is —(C1-4 alkylene)heterocyclyl(R21)h, and h is 0.
In some embodiments, at least one R4 is —OR22, R22 is —(CH2CH2)heterocyclyl(R21)h, and h is 0.
In some embodiments, R4 is a —OR22, R22 is —(CH2CH2)heterocyclyl(R21)h, and his 0.
In some embodiments, at least one R4 is —OR22, R22 is —(C1-4 alkylene)NR23R24 and R23 and R24 are independently a —(C1-4 alkyl).
In some embodiments, at least one R4 is —OR22, R22 is —(CH2CH2)NR23R24 and R23 and R24 are independently a —(C1-2 alkyl).
In some embodiments, at least one R4 is —OR22, and R22 is —(CH2CH2)NMe2.
In some embodiments, R4 is a —OR22, and R22 is —(CH2CH2)NMe2.
In some embodiments, at least one R4 is —OR22, R22 is —(C1-4 alkylene)aryl(R19)k, k is 0 or 1 and R19 is halide.
In some embodiments, at least one R4 is —OR22, R22 is —(CH2CH2)phenyl(R19)k, k is 0 or 1 and R19 is a halide.
In some embodiments, R4 is a —OR22, R22 is —(CH2CH2)phenyl(R19)k, k is 0 or 1 and R19 is a halide.
In some embodiments, at least one R4 is —OR22, R22 is —(CH2)phenyl(R19)k, k is 0 or 1 and R19 is a halide.
In some embodiments, R4 is a —OR22, R22 is —(CH2)phenyl(R19)k, k is 0 or 1 and R19 is a halide.
In some embodiments, h is 0.
In some embodiments, at least one R5 is a halide.
In some embodiments, at least one R5 is a F.
In some embodiments, at least one R5 is —(C1-6 alkyl).
In some embodiments, at least one R5 is —(C1-5 alkyl).
In some embodiments, at least one R5 is —(C1-4 alkyl).
In some embodiments, at least one R5 is —(C1-3 alkyl).
In some embodiments, at least one R5 is —(C1-2 alkyl).
In some embodiments, at least one R5 is methyl.
In some embodiments, at least one R6 is a halide.
In some embodiments, at least one R6 is a F.
In some embodiments, at least one R6 is —(C1-4 alkyl).
In some embodiments, at least one R6 is —(C1-3 alkyl).
In some embodiments, at least one R6 is —(C1-2 alkyl).
In some embodiments, at least one R6 is methyl.
In some embodiments, R6 is a methyl.
In some embodiments, at least one R6 is —C(═O)(C1-3 alkyl).
In some embodiments, at least one R6 is —C(═O)Me.
In some embodiments, R6 is a —C(═O)Me.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -phenyl(R8)k; k is 1 or 2; and R8 is F.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; and R17 is —(C1-3 alkyl).
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14; and R13 and R14 are independently selected from —(C1-3 alkyl).
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -heterocyclyl(R7)h; h is 1 or 2; and R7 is selected from the group consisting of halide and —(C1-2 alkyl).
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -phenyl(R8)k; k is 1 or 2; R8 is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; R17 is —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14; R13 and R14 are independently selected from —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is C1-3 alkyl; the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -heterocyclyl(R7)h; h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16 R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j, wherein j and k are 0; R3 is -phenyl(R8)k, wherein k is 1 or 2; R8 is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16; R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j, wherein j and k are 0; R3 is -phenyl(R8)k, wherein k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; R17 is —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16, wherein R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl), and R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j, wherein k and j are 0; R3 is -phenyl(R8)k, wherein k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14, wherein R13 and R14 are independently selected from —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16; R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j; k and j are 0; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16; R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j; k and j are 0; R3 is -heterocyclyl(R7)h; h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -phenyl(R8)k; k is 1 or 2; R8 is F; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; R17 is —(C1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -phenyl(R8)k; k is 2; and R8 is one F and the other R8 —NH(C1-6 alkylene)NR13R14; R13 and R14 are independently selected from —(C1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h, wherein h is 0-2; R9 is F; R3 is -heterocyclyl(R7)h, wherein h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is H; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -phenyl(R8)k; k is 1 or 2; and R8 is F.
In some embodiments, R2 is H; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; and R17 is —(C1-3 alkyl).
In some embodiments, R2 is H; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14; and R13 and R14 are independently selected from —(C1-3 alkyl).
In some embodiments, R2 is H; R1 is -pyrimidinyl(R4)q, wherein q is 0; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.
In some embodiments, R2 is H; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -heterocyclyl(R7)h; h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl).
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -phenyl(R8)k; k is 1 or 2; and R8 is F.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; and R17 is —(C1-3 alkyl).
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14; and R13 and R14 are independently selected from —(C1-3 alkyl).
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is —(C2-5 alkyl); R3 is -heterocyclyl(R7)h; h is 1 or 2; and R7 is selected from the group consisting of halide and —(C1-2 alkyl).
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -phenyl(R8)k; k is 1 or 2; R8 is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; R17 is —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14; R13 and R14 are independently selected from —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is C1-3 alkyl; the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —NHC(═O)R12; R12 is -carbocyclyl(R20)j; j is 0; R3 is -heterocyclyl(R7)h; h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16; R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j, wherein k and j are 0; R3 is -phenyl(R8)k, wherein k is 1 or 2; R8 is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16; R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j, wherein k and j are 0; R3 is -phenyl(R8)k, wherein k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; R17 is —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16, wherein R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl), and R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R9)k, and —CH2carbocyclyl(R20)j, wherein k and j are 0; R3 is -phenyl(R8)k, wherein k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14, wherein R13 and R14 are independently selected from —(C1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16; R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j; k and j are 0; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is selected from the group consisting of —NR13R14 and —CH2NR15R16; R13 and R15 are independently selected from the group consisting of H and —(C1-3 alkyl); R14 and R16 are independently selected from the group consisting of H, —(C1-3 alkyl), —CH2phenyl(R19)k, and —CH2carbocyclyl(R20)j; k and j are 0; R3 is -heterocyclyl(R7)h; h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -phenyl(R8)k; k is 1 or 2; R8 is F; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; R17 is —(C1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -phenyl(R8)k; k is 2; and R8 is one F and the other R8 is —NH(C1-6 alkylene)NR13R14; R13 and R14 are independently selected from —(C1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q, wherein q is 1; R4 is —CH2heterocyclyl(R9)h; h is 0-2; R9 is F; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is F; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —CH2heterocyclyl(R9)h, wherein h is 0-2; R9 is F; R3 is -heterocyclyl(R7)h, wherein h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.
In some embodiments, R2 is F; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -phenyl(R8)k; k is 1 or 2; and R8 is F.
In some embodiments, R2 is F; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —(C1-2 alkylene)pNHSO2R17; p is 1; and R17 is —(C1-3 alkyl).
In some embodiments, R2 is F; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -phenyl(R8)k; k is 2; one R8 is F and the other R8 is —NH(C1-6 alkylene)NR13R14; and R13 and R14 are independently selected from —(C1-3 alkyl).
In some embodiments, R2 is F; R1 is -pyrimidinyl(R4)q, wherein q is 0; R3 is -heteroaryl(R6)q, wherein q is 1; R6 is selected from the group consisting of halide, —(C1-2 alkyl), and —C(═O)R17; R17 is —(C1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.
In some embodiments, R2 is F; R1 is -pyrimidinyl(R4)q; q is 0; R3 is -heterocyclyl(R7)h; h is 1 or 2; R7 is selected from the group consisting of halide and —(C1-2 alkyl).
In some embodiments, R2 is H; R1 is -pyrazol-4-yl(R4)q; q is 0 or 1; R4 is —(C1-3 alkyl); R3 is -phenyl(R8)k; k is 1 or 2; and R8 is F.
In some embodiments, R2 is H; R1 is -imidazol-5-yl(R4)q; q is 1 or 2; each R4 is independently selected from —(C1-3 alkyl); R3 is -phenyl(R8)k; k is 1 or 2; and R8 is F.
In some embodiments, R2 is H; R1 is -pyridin-3-yl(R4)q; q is 1; R4 is —OR22; R22 is selected from the group consisting of H and —(C1-3 alkyl); R3 is -phenyl(R8)k; k is 1 or 2; and R8 is F.
Illustrative compounds of Formula (I) are shown in Table 1.








TABLE 1







1






 


2






 


3






 


4






 


5






 


6






 


7






 


8






 


9






 


10






 


11






 


12






 


13






 


14






 


15






 


16






 


17






 


18






 


19






 


20






 


21






 


22






 


23






 


24






 


25






 


26






 


27






 


28






 


29






 


30






 


31






 


32






 


33






 


34






 


35






 


36






 


37






 


38






 


39






 


40






 


41






 


42






 


43






 


44






 


45






 


46






 


47






 


48






 


49






 


50






 


51






 


52






 


53






 


54






 


55






 


56






 


57






 


58






 


59






 


60






 


61






 


62






 


63






 


64






 


65






 


66






 


67






 


68






 


69






 


70






 


71






 


72






 


73






 


74






 


75






 


76






 


77






 


78






 


79






 


80






 


81






 


82






 


83






 


84






 


85






 


86






 


87






 


88






 


89






 


90






 


91






 


92






 


93






 


94






 


95






 


96






 


97






 


98






 


99






 


100






 


101






 


102






 


103






 


104






 


105






 


106






 


107






 


108






 


109






 


110






 


111






 


112






 


113






 


114






 


115






 


116






 


117






 


118






 


119






 


120






 


121






 


122






 


123






 


124






 


125






 


126






 


127






 


128






 


129






 


130






 


131






 


132






 


133






 


134






 


135






 


136






 


137






 


138






 


139






 


140






 


141






 


142






 


143






 


144






 


145






 


146






 


147






 


148






 


149






 


150






 


151






 


152






 


153






 


154






 


155






 


156






 


157






 


158






 


159






 


160






 


161






 


162






 


163






 


164






 


165






 


166






 


167






 


168






 


169






 


170






 


171






 


172






 


173






 


174






 


175






 


176






 


177






 


178






 


179






 


180






 


181






 


182






 


183






 


184






 


185






 


186






 


187






 


188






 


189






 


190






 


191






 


192






 


193






 


194






 


195






 


196






 


197






 


198






 


199






 


200






 


201






 


202






 


203






 


204






 


205






 


206






 


207






 


208






 


209






 


210






 


211






 


212






 


213






 


214






 


215






 


216






 


217






 


218






 


219






 


220






 


221






 


222






 


223






 


224






 


225






 


226






 


227






 


228






 


229






 


230






 


231






 


232






 


233






 


234






 


235






 


236






 


237






 


238






 


239






 


240






 


241






 


242






 


243






 


244






 


245






 


246






 


247






 


248






 


249






 


250






 


251






 


252






 


253






 


254






 


255






 


256






 


257






 


258






 


259






 


260






 


261






 


262






 


263






 


264






 


265






 


266






 


267






 


268






 


269






 


270






 


271






 


272






 


273






 


274






 


275






 


276






 


277






 


278






 


279






 


280






 


281






 


282






 


283






 


284






 


285






 


286






 


287






 


288






 


289






 


290






 


291






 


292






 


293






 


294






 


295






 


296






 


297






 


298






 


299






 


300






 


301






 


302






 


303






 


304






 


305






 


306






 


307






 


308






 


309






 


310






 


311






 


312






 


313






 


314






 


315






 


316






 


317






 


318






 


319






 


320






 


321






 


322






 


323






 


324






 


325






 


326






 


327






 


328






 


329






 


330






 


331






 


332






 


333






 


334






 


335






 


336






 


337






 


338






 


339






 


340






 


341






 


342






 


343






 


344






 


345






 


346






 


347






 


348






 


349






 


350






 


351






 


352






 


353






 


354






 


355






 


356






 


357






 


358






 


359






 


360






 


361






 


362






 


363






 


364






 


365






 


366






 


367






 


368






 


369






 


370






 


371






 


372






 


373






 


374






 


375






 


376






 


377






 


378






 


379






 


380






 


381






 


382






 


383






 


384






 


385






 


386






 


387






 


388






 


389






 


390






 


391






 


392






 


393






 


394






 


395






 


396






 


397






 


398






 


399






 


400






 


401






 


402






 


403






 


404






 


405






 


406






 


407






 


408






 


409






 


410






 


411






 


412






 


413






 


414






 


415






 


416






 


417






 


418






 


419






 


420






 


421






 


422






 


423






 


424






 


425






 


426






 


427






 


428






 


429






 


430






 


431






 


432






 


433






 


434






 


435






 


436






 


437






 


438






 


439






 


440






 


441






 


442






 


443






 


444






 


445






 


446






 


447






 


448






 


449






 


450






 


451






 


452






 


453






 


454






 


455






 


456






 


457






 


458






 


459






 


460






 


461






 


462






 


463






 


464






 


465






 


466






 


467






 


468






 


469






 


470






 


471






 


472






 


473






 


474






 


475






 


476






 


477






 


478






 


479






 


480






 


481






 


482






 


483






 


484






 


485






 


486






 


487






 


488






 


489






 


490






 


491






 


492






 


493






 


494






 


495






 


496






 


497






 


498






 


499






 


500






 


501






 


502






 


503






 


504






 


505






 


506






 


507






 


508






 


509






 


510






 


511






 


512






 


513






 


514






 


515






 


516






 


517






 


518






 


519






 


520






 


521






 


522






 


523






 


524






 


525






 


526






 


527






 


528






 


529






 


530






 


531






 


532






 


533






 


534






 


535






 


536






 


537






 


538






 


539






 


540






 


541






 


542






 


543






 


544






 


545






 


546






 


547






 


548






 


549






 


550






 


551






 


552






 


553






 


554






 


555






 


556






 


557






 


558






 


559






 


560






 


561






 


562






 


563






 


564






 


565






 


566






 


567






 


568






 


569






 


570






 


571






 


572






 


573






 


574






 


575






 


576






 


577






 


578






 


579






 


580






 


581






 


582






 


583






 


584






 


585






 


586






 


587






 


588






 


589






 


590






 


591






 


592






 


593






 


594






 


595






 


596






 


597






 


598






 


599






 


600






 


601






 


602






 


603






 


604






 


605






 


606






 


607






 


608






 


609






 


610






 


611






 


612






 


613






 


614






 


615






 


616






 


617






 


618






 


619






 


620






 


621






 


622






 


623






 


624






 


625






 


626






 


627






 


628






 


629






 


630






 


631






 


632






 


633






 


634






 


635






 


636






 


637






 


638






 


639






 


640






 


641






 


642






 


643






 


644






 


645






 


646






 


647






 


648






 


649






 


650






 


651






 


652






 


653






 


654






 


655






 


656






 


657






 


658






 


659






 


660






 


661






 


662






 


663






 


664






 


665






 


666






 


667






 


668






 


669






 


670






 


671






 


672






 


673






 


674






 


675






 


676






 


677






 


678






 


679






 


680






 


681






 


682






 


683






 


684






 


685






 


686






 


687






 


688






 


689






 


690






 


691






 


692






 


693






 


694






 


695






 


696






 


697






 


698






 


699






 


700






 


701






 


702






 


703






 


704






 


705






 


706






 


707






 


708






 


709






 


710






 


711






 


712






 


713






 


714






 


715






 


716






 


717






 


718






 


719






 


720






 


721






 


722






 


723






 


724






 


725






 


726






 


727






 


728






 


729






 


730






 


731






 


732






 


733






 


734






 


735






 


736






 


737






 


738






 


739






 


740






 


741






 


742






 


743






 


744






 


745






 


746






 


747






 


748






 


749






 


750






 


751






 


752






 


753






 


754






 


755






 


756






 


757






 


758






 


759






 


760






 


761






 


762






 


763






 


764






 


765






 


766






 


767






 


768






 


769






 


770






 


771






 


772






 


773






 


774






 


775






 


776






 


777






 


778






 


779






 


780






 


781






 


782






 


783






 


784






 


785






 


786






 


787






 


788






 


789






 


790






 


791






 


792






 


793






 


794






 


795






 


796






 


797






 


798






 


799






 


800






 


801






 


802






 


803






 


804






 


805






 


806






 


807






 


808






 


809






 


810






 


811






 


812






 


813






 


814






 


815






 


816






 


817






 


818






 


819






 


820






 


821






 


822






 


823






 


824






 


825






 


826






 


827






 


828






 


829






 


830






 


831






 


832






 


833






 


834






 


835






 


836






 


837






 


838






 


839






 


840






 


841






 


842






 


843






 


844






 


845






 


846






 


847






 


848






 


849






 


850






 


851






 


852






 


853






 


854






 


855






 


856






 


857






 


858






 


859






 


860






 


861






 


862






 


863






 


864






 


865






 


866






 


867






 


868






 


869






 


870






 


871






 


872






 


873






 


874






 


875






 


876






 


877






 


878






 


879






 


880






 


881






 


882






 


883






 


884






 


885






 


886






 


887






 


888






 


889






 


890






 


891






 


892






 


893






 


894






 


895






 


896






 


897






 


898






 


899






 


900






 


901






 


902






 


903






 


904






 


905






 


906






 


907






 


908






 


909






 


910






 


911






 


912






 


913






 


914






 


915






 


916






 


917






 


918






 


919






 


920






 


921






 


922






 


923






 


924






 


925






 


926






 


927






 


928






 


929






 


930






 


931






 


932






 


933






 


934






 


935






 


936






 


937






 


938






 


939






 


940






 


941






 


942






 


943






 


944






 


945






 


946






 


947






 


948






 


949






 


950






 


951






 


952






 


953






 


954






 


955






 


956






 


957






 


958






 


959






 


960






 


961






 


962






 


963






 


964






 


965






 


966






 


967






 


968






 


969






 


970






 


971






 


972






 


973






 


974






 


975






 


976






 


977






 


978






 


979






 


980






 


981






 


982






 


983






 


984






 


985






 


986






 


987






 


988






 


989






 


990






 


991






 


992






 


993






 


994






 


995






 


996






 


997






 


998






 


999






 


1000






 


1001






 


1002






 


1003






 


1004






 


1005






 


1006






 


1007






 


1008






 


1009






 


1010






 


1011






 


1012






 


1013






 


1014






 


1015






 


1016






 


1017






 


1018






 


1019






 


1020






 


1021






 


1022






 


1023






 


1024






 


1025






 


1026






 


1027






 


1028






 


1029






 


1030






 


1031






 


1032






 


1033






 


1034






 


1035






 


1036






 


1037






 


1038






 


1039






 


1040






 


1041






 


1042






 


1043






 


1044






 


1045






 


1046






 


1047






 


1048






 


1049






 


1050






 


1051






 


1052






 


1053






 


1054






 


1055






 


1056






 


1057






 


1058






 


1059






 


1060






 


1061






 


1062






 


1063






 


1064






 


1065






 


1066






 


1067






 


1068






 


1069






 


1070






 


1071






 


1072






 


1073






 


1074






 


1075






 


1076






 


1077






 


1078






 


1079






 


1080






 


1081






 


1082






 


1083






 


1084






 


1085






 


1086






 


1087






 


1088






 


1089






 


1090






 


1091






 


1092






 


1093






 


1094






 


1095






 


1096






 


1097






 


1098






 


1099






 


1100






 


1101






 


1102






 


1103






 


1104






 


1105






 


1106






 


1107






 


1108






 


1109






 


1110






 


1111






 


1112






 


1113






 


1114






 


1115






 


1116






 


1117






 


1118






 


1119






 


1120






 


1121






 


1122






 


1123






 


1124






 


1125






 


1126






 


1127






 


1128






 


1129






 


1130






 


1131






 


1132






 


1133






 


1134






 


1135






 


1136






 


1137






 


1138






 


1139






 


1140






 


1141






 


1142






 


1143






 


1144






 


1145






 


1146






 


1147






 


1148






 


1149






 


1150






 


1151






 


1152






 


1153






 


1154






 


1155






 


1156






 


1157






 


1158






 


1159






 


1160






 


1161






 


1162






 


1163






 


1164






 


1165






 


1166






 


1167






 


1168






 


1169






 


1170






 


1171






 


1172






 


1173






 


1174






 


1175






 


1176






 


1177






 


1178






 


1179






 


1180






 


1181






 


1182






 


1183






 


1184






 


1185






 


1186






 


1187






 


1188






 


1189






 


1190






 


1191






 


1192






 


1193






 


1194






 


1195






 


1196






 


1197






 


1198






 


1199






 


1200






 


1201






 


1202






 


1203






 


1204






 


1205






 


1206






 


1207






 


1208






 


1209






 


1210






 


1211






 


1212






 


1213






 


1214






 


1215






 


1216






 


1217






 


1218






 


1219






 


1220






 


1221






 


1222






 


1223






 


1224






 


1225






 


1226






 


1227






 


1228






 


1229






 


1230






 


1231






 


1232






 


1233






 


1234






 


1235






 


1236






 


1237






 


1238






 


1239






 


1240






 


1241






 


1242






 


1243






 


1244






 


1245






 


1246






 


1247






 


1248






 


1249






 


1250






 


1251






 


1252






 


1253






 


1254






 


1255






 


1256






 


1257






 


1258






 


1259






 


1260






 


1261






 


1262






 


1263






 


1264






 


1265






 


1266






 


1267






 


1268






 


1269






 


1270






 


1271






 


1272






 


1273






 


1274






 


1275






 


1276






 


1277






 


1278






 


1279






 


1280






 


1281






 


1282






 


1283






 


1284






 


1285






 


1286






 


1287






 


1288






 


1289






 


1290






 


1291






 


1292






 


1293






 


1294






 


1295






 


1296






 


1297






 


1298






 


1299






 


1300






 


1301






 


1302






 


1303






 


1304






 


1305






 


1306






 


1307






 


1308






 


1309






 


1310






 


1311






 


1312






 


1313






 


1314






 


1315






 


1316






 


1317






 


1318






 


1319






 


1320






 


1321






 


1322






 


1323






 


1324






 


1325






 


1326






 


1327






 


1328






 


1329






 


1330






 


1331






 


1332






 


1333






 


1334






 


1335






 


1336






 


1337






 


1338






 


1339






 


1340






 


1341






 


1342






 


1343






 


1344






 


1345






 


1346






 


1347






 


1348






 


1349






 


1350






 


1351






 


1352






 


1353






 


1354






 


1355






 


1356






 


1357






 


1358






 


1359






 


1360






 


1361






 


1362






 


1363






 


1364






 


1365






 


1366






 


1367






 


1368






 


1369






 


1370






 


1371






 


1372






 


1373






 


1374






 


1375






 


1376






 


1377






 


1378






 


1379






 


1380






 


1381






 


1382






 


1383






 


1384






 


1385






 


1386






 


1387






 


1388






 


1389






 


1390






 


1391






 


1392






 


1393






 


1394






 


1395






 


1396






 


1397






 


1398






 


1399






 


1400






 


1401






 


1402






 


1403






 


1404






 


1405






 


1406













Administration and Pharmaceutical Compositions

Some embodiments include pharmaceutical compositions comprising: (a) a therapeutically effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.
The compounds provided herein may also be useful in combination (administered together or sequentially) with other known agents.
Non-limiting examples of diseases which can be treated with a combination of a compound of Formula (I) and other known agents are colorectal cancer, ovarian cancer, retinitis pigmentosa, macular degeneration, diabetic retinopathy, idiopathic pulmonary fibrosis/pulmonary fibrosis, and osteoarthritis.
In some embodiments, colorectal cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: 5-Fluorouracil (5-FU), which can be administered with the vitamin-like drug leucovorin (also called folinic acid); capecitabine (XELODA®), irinotecan (CAMPOSTAR®), oxaliplatin (ELOXATIN®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are FOLFOX (5-FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabine and oxaliplatin). For rectal cancer, chemo with 5-FU or capecitabine combined with radiation may be given before surgery (neoadjuvant treatment).
In some embodiments, ovarian cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Topotecan, Liposomal doxorubicin (DOXIL®), Gemcitabine (GEMZAR®), Cyclophosphamide (CYTOXAN®), Vinorelbine (NAVELBINE®), Ifosfamide (IFEX®), Etoposide (VP-16), Altretamine (HEXALEN®), Capecitabine (XELODA®), Irinotecan (CPT-11, CAMPTOSAR®), Melphalan, Pemetrexed (ALIMTA®) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are TIP (paclitaxel [Taxol], ifosfamide, and cisplatin), VeIP (vinblastine, ifosfamide, and cisplatin) and VIP (etoposide [VP-16], ifosfamide, and cisplatin).
In some embodiments, a compound of Formula (I) can be used to treat cancer in combination with any of the following methods: (a) Hormone therapy such as aromatase inhibitors, LHRH [luteinizing hormone-releasing hormone] analogs and inhibitors, and others; (b) Ablation or embolization procedures such as radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy and cryosurgery (cryotherapy); (c) Chemotherapy using alkylating agents such as cisplatin and carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy using anti-metabolites such as azathioprine and mercaptopurine; (e) Chemotherapy using plant alkaloids and terpenoids such as vinca alkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) and taxanes; (f) Chemotherapy using podophyllotoxin, etoposide, teniposide and docetaxel; (g) Chemotherapy using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, and teniposide; (h) Chemotherapy using cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and mitomycin; (i) Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate (GLEEVEC®, also known as STI-571), Gefitinib (Iressa, also known as ZD1839), Erlotinib (marketed as TARCEVA®), Bortezomib (VELCADE®), tamoxifen, tofacitinib, crizotinib, Bcl-2 inhibitors (e.g. obatoclax in clinical trials, ABT-263, and Gossypol), PARP inhibitors (e.g. Iniparib, Olaparib in clinical trials), PI3K inhibitors (eg. perifosine in a phase III trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152, (AEZS-108), Braf inhibitors (e.g. vemurafenib, dabrafenib and LGX818), MEK inhibitors (e.g. trametinib and MEK162), CDK inhibitors, (e.g. PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA® or RITUXAN®), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX®), and Bevacizumab (marketed as AVASTIN®); and (k) radiation therapy.
In some embodiments, diabetic retinopathy can be treated with a combination of a compound of Formula (I) and one or more of the following natural supplements: Bilberry, Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).
In some embodiments, idiopathic pulmonary fibrosis/pulmonary fibrosis can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: pirfenidone (pirfenidone was approved for use in 2011 in Europe under the brand name Esbriet®), prednisone, azathioprine, N-acetylcysteine, interferon-γ 1b, bosentan (bosentan is currently being studied in patients with IPF, [The American Journal of Respiratory and Critical Care Medicine (2011), 184(1), 92-9]), Nintedanib (BIBF 1120 and Vargatef), QAX576 [British Journal of Pharmacology (2011), 163(1), 141-172], and anti-inflammatory agents such as corticosteroids.
In some embodiments, a compound of Formula (I) can be used to treat idiopathic pulmonary fibrosis/pulmonary fibrosis in combination with any of the following methods: oxygen therapy, pulmonary rehabilitation and surgery.
In some embodiments, a compound of Formula (I) can be used to treat osteoarthritis in combination with any of the following methods: (a) Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and acetaminophen; (b) physical therapy; (c) injections of corticosteroid medications; (d) injections of hyaluronic acid derivatives (e.g. Hyalgan, Synvisc); (e) narcotics, like codeine; (f) in combination with braces and/or shoe inserts or any device that can immobilize or support your joint to help you keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices); (g) realigning bones (osteotomy); (h) joint replacement (arthroplasty); and (i) in combination with a chronic pain class.
In some embodiments, macular degeneration can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Bevacizumab (Avastin®), Ranibizumab (Lucentis®), Pegaptanib (Macugen), Aflibercept (Eylea®), verteporfin (Visudyne®) in combination with photodynamic therapy (PDT) or with any of the following methods: (a) in combination with laser to destroy abnormal blood vessels (photocoagulation); and (b) in combination with increased vitamin intake of antioxidant vitamins and zinc.
In some embodiments, retinitis pigmentosa can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: UF-021 (OcusevaTM), vitamin A palmitate and pikachurin or with any of the following methods: (a) with the Argus® II retinal implant; and (b) with stem cell and/or gene therapy.
Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration, including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. In some embodiments, the administration method includes oral or parenteral administration.
Compounds provided herein intended for pharmaceutical use may be administered as crystalline or amorphous products. Pharmaceutically acceptable compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols. Dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release or the like. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.
The compounds can be administered either alone or in combination with a conventional pharmaceutical carrier, excipient or the like. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α-, β, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press, London, UK. 2012).
In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.
Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. a compound provided herein and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension. If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 50 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 20 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.50 mg/Kg to about 19 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.75 mg/Kg to about 18 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.0 mg/Kg to about 17 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.25 mg/Kg to about 16 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.50 mg/Kg to about 15 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.75 mg/Kg to about 14 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 2.0 mg/Kg to about 13 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 3.0 mg/Kg to about 12 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 4.0 mg/Kg to about 11 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 5.0 mg/Kg to about 10 mg/Kg in humans.
In some embodiments, the compositions are provided in unit dosage forms suitable for single administration.
In some embodiments, the compositions are provided in unit dosage forms suitable for twice a day administration.
In some embodiments, the compositions are provided in unit dosage forms suitable for three times a day administration.
Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable for reconstitution in liquid prior to injection. The percentage of a compound provided herein contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the patient. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.
In some embodiments, the composition will comprise about 0.1-10% of the active agent in solution.
In some embodiments, the composition will comprise about 0.1-5% of the active agent in solution.
In some embodiments, the composition will comprise about 0.1-4% of the active agent in solution.
In some embodiments, the composition will comprise about 0.15-3% of the active agent in solution.
In some embodiments, the composition will comprise about 0.2-2% of the active agent in solution.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-96 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-72 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-48 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-24 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-12 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-6 hours.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m2 to about 300 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m2 to about 200 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m2 to about 100 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 10 mg/m2 to about 50 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 50 mg/m2 to about 200 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 75 mg/m2 to about 175 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 100 mg/m2 to about 150 mg/m2.
It is to be noted that concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
In one embodiment, the compositions can be administered to the respiratory tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other suitable device or technique.
In some embodiments, aerosols intended for delivery to the nasal mucosa are provided for inhalation through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 10 to about 60 microns being preferred. For nasal delivery, a larger inhaled particle size may be desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. In some embodiments, aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth. For delivery to the lung, inhaled aerodynamic particle sizes of about less than 10 μm are useful (e.g., about 1 to about 10 microns). Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.
In some embodiments, compounds of Formula (I) disclosed herein intended for respiratory delivery (either systemic or local) can be administered as aqueous formulations, as non-aqueous solutions or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates, or as dry powders. Aqueous formulations may be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose® or the AERx® systems). Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.
In some embodiments, the compositions of Formula (I) disclosed herein can be administered to the ear by various methods. For example, a round window catheter (e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873) can be used.
Alternatively, formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4,164,559).
If desired, formulations of the invention can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).
In some embodiments, compounds of Formula (I) disclosed herein intended for delivery to the ear can be administered via an implanted pump and delivery system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.
Other options include delivery via a pump through a thin film coated onto a multichannel electrode or electrode with a specially imbedded drug delivery channel (pathways) carved into the thin film for this purpose. In other embodiments the acidic or basic solid compound of Formula (I) can be delivered from the reservoir of an external or internal implanted pumping system.
Formulations of the invention also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).
Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear. In one embodiment, the formulations described herein are administered directly onto the round window membrane via transtympanic injection. In another embodiment, the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane via a non-transtympanic approach to the inner ear. In additional embodiments, the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae. 
In some embodiments, the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like.
Suppositories for rectal administration of the drug (either as a solution, colloid, suspension or a complex) can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the compound. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter, is first melted.
Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the compound provided herein, the desired dissolution rate, cost considerations, and other criteria. In one of the embodiments, the solid composition is a single unit. This implies that one unit dose of the compound is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.
Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, film-like units, foil-like units, wafers, lyophilized matrix units, and the like. In one embodiment, the solid composition is a highly porous lyophilized form. Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the compound.
On the other hand, for some applications the solid composition may also be formed as a multiple unit dosage form as defined above. Examples of multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like. In one embodiment, the solid composition is a lyophilized powder. Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the powder is capable of absorbing water very rapidly, resulting in quick dissolution. Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.
Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with a compound provided herein so that the compound is located at the outer surface of the individual particles. In this type of system, the water-soluble low molecular weight excipient may be useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the compound and, for example, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film-forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.
Also provided herein are kits. Typically, a kit includes one or more compounds or compositions as described herein. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided herein, and directions for use of the kit (e.g., instructions for treating a patient). In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer. In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more of hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma, ovarian cancer, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects and/or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.
Methods of Treatment
The compounds and compositions provided herein can be used as inhibitors and/or modulators of one or more components of the Wnt pathway, which may include one or more Wnt proteins, and thus can be used to treat a variety of disorders and diseases in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, and cell cycling. Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation, to correct a genetic disorder, and/or to treat a neurological condition/disorder/disease due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycotic and viral infections, bone and cartilage diseases, neurological conditions/diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), motor neuron disease, multiple sclerosis or autism, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects and/or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
In some embodiments, non-limiting examples of eye diseases which can be treated with the compounds and compositions provided herein include age-related macular degeneration (AMD or ARMD), rod cone dystrophy, retinitis pigmentosa (RP), acute idiopathic blind spot enlargement (AIBSE), acute zonal occult outer retinopathy (AZOOR), acute macular neuroretinopathy (AMN), multiple evanescent white dot syndrome (MEWDS), multifocal choroiditis, opticneuropathy. Further causes of photoreceptor damage that can be treated with the compounds and compositions provided herein include retinal detachment, vascular disturbance, eye tumors or extreme light damage.
With respect to cancer, the Wnt pathway is known to be constitutively activated in a variety of cancers including, for example, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer and leukemias such as CML, CLL and T-ALL. Accordingly, the compounds and compositions described herein may be used to treat these cancers in which the Wnt pathway is constitutively activated. In certain embodiments, the cancer is chosen from hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma and ovarian cancer.
Other cancers can also be treated with the compounds and compositions described herein.
More particularly, cancers that may be treated by the compounds, compositions and methods described herein include, but are not limited to, the following:
1) Breast cancers, including, for example ER breast cancer, ER− breast cancer, her2− breast cancer, her2+ breast cancer, stromal tumors such as fibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; and miscellaneous malignant neoplasms. Further examples of breast cancers can include luminal A, luminal B, basal A, basal B, and triple negative breast cancer, which is estrogen receptor negative (ER−), progesterone receptor negative, and her2 negative (her2−). In some embodiments, the breast cancer may have a high risk Oncotype score.
2) Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma; lipoma and teratoma.
3) Lung cancers, including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma; and mesothelioma.
4) Gastrointestinal cancer, including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, i's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.
5) Genitourinary tract cancers, including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma.
6) Liver cancers, including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma.
7) Bone cancers, including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochrondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.
8) Nervous system cancers, including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.
9) Gynecological cancers, including, for example, cancers of the uterus, e.g., endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma.
10) Hematologic cancers, including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenstrom's macroglobulinemia.
11) Skin cancers and skin disorders, including, for example, malignant melanoma and metastatic melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and scleroderma.
12) Adrenal gland cancers, including, for example, neuroblastoma.
Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term “tumor cell,” as provided herein, includes a cell afflicted by any one of the above identified disorders.
A method of treating cancer using a compound or composition as described herein may be combined with existing methods of treating cancers, for example by chemotherapy, irradiation, or surgery (e.g., oophorectomy). In some embodiments, a compound or composition can be administered before, during, or after another anticancer agent or treatment.
The compounds and compositions described herein can be used as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer and other diseases associated with cellular proliferation mediated by protein kinases. For example, the compounds described herein can inhibit the activity of one or more kinases. Accordingly, provided herein is a method of treating cancer or preventing or reducing angiogenesis through kinase inhibition.
In addition, and including treatment of cancer, the compounds and compositions described herein can function as cell-cycle control agents for treating proliferative disorders in a patient. Disorders associated with excessive proliferation include, for example, cancers, scleroderma, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth muscle disorders. Furthermore, such compounds may be used to prevent de-differentiation of post-mitotic tissue and/or cells.
Diseases or disorders associated with uncontrolled or abnormal cellular proliferation include, but are not limited to, the following:

    
    
        a variety of cancers, including, but not limited to, carcinoma, hematopoietic tumors of lymphoid lineage, hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system and other tumors including melanoma, seminoma and Kaposi's sarcoma.
        a disease process which features abnormal cellular proliferation, e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neurofibromatosis, atherosclerosis, arthritis, glomerulonephritis, restenosis following angioplasty or vascular surgery, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections. Fibrotic disorders such as skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; fatty liver disease (FLD); adhesions, such as those occurring in the abdomen, pelvis, spine or tendons; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis, such as fibrosis following stroke; fibrosis associated with neuro-degenerative disorders such as Alzheimer's Disease or multiple sclerosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease and radiation fibrosis.
        defective apoptosis-associated conditions, such as cancers (including but not limited to those types mentioned herein), viral infections (including but not limited to herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, autoimmune mediated glomerulonephritis, inflammatory bowel disease and autoimmune diabetes mellitus), neuro-degenerative disorders (including but not limited to Alzheimer's disease, lung disease, amyotrophic lateral sclerosis, retinitis pigmentosa, Parkinson's disease, AIDS-related dementia, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis), tendinopathies such as tendinitis and tendinosis, aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.
        genetic diseases due to mutations in Wnt signaling components, such as polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects and/or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
    
    


The compounds and compositions described herein can be used to treat neurological conditions, disorders and/or diseases caused by dysfunction in the Wnt signaling pathway. Non-limiting examples of neurological conditions/disorders/diseases which can be treated with the compounds and compositions provided herein include Alzheimer's disease, aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity disorder, auditory processing disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury, Canavan disease, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffin-Lowry syndrome, complex regional pain syndrome, compression neuropathy, congenital facial diplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorder, Cushing's syndrome, cytomegalic inclusion body disease (CIBD), Dandy-Walker syndrome, Dawson disease, de Morsier's syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phase syndrome, dementia, dermatomyositis, developmental dyspraxia, diabetic neuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia, dyscalculia, dysgraphia, dyslexia, dystonia, empty sella syndrome, encephalitis, encephalocele, encephalotrigeminal angiomatosis, encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor, Fabry's disease, Fahr's syndrome, familial spastic paralysis, febrile seizure, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Foville's syndrome, Gaucher's disease, Gerstmann's syndrome, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, gray matter heterotopia, Guillain-Barre syndrome, HTLV-1 associated myelopathy, Hallervorden-Spatz disease, hemifacial spasm, hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes zoster oticus, herpes zoster, Hirayama syndrome, holoprosencephaly, Huntington's disease, hydranencephaly, hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile phytanic acid storage disease, infantile Refsum disease, infantile spasms, inflammatory myopathy, intracranial cyst, intracranial hypertension, Joubert syndrome, Karak syndrome, Kearns-Sayre syndrome, Kennedy disease, Kinsbourne syndrome, Klippel Feil syndrome, Krabbe disease, Kugelberg-Welander disease, kuru, Lafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary (Wallenberg) syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy body dementia, lissencephaly, locked-in syndrome, Lou Gehrig's disease, lumbar disc disease, lumbar spinal stenosis, Lyme disease, Machado-Joseph disease (Spinocerebellar ataxia type 3), macrencephaly, macropsia, megalencephaly, Melkersson-Rosenthal syndrome, Meniere's disease, meningitis, Menkes disease, metachromatic leukodystrophy, microcephaly, micropsia, Miller Fisher syndrome, misophonia, mitochondrial myopathy, Mobius syndrome, monomelic amyotrophy, motor neuron disease, motor skills disorder, Moyamoya disease, mucopolysaccharidoses, multi-infarct dementia, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, muscular dystrophy, myalgic encephalomyelitis, myasthenia gravis, myelinoclastic diffuse sclerosis, myoclonic Encephalopathy of infants, myoclonus, myopathy, myotubular myopathy, myotonia congenital, narcolepsy, neurofibromatosis, neuroleptic malignant syndrome, lupus erythematosus, neuromyotonia, neuronal ceroid lipofuscinosis, Niemann-Pick disease, O'Sullivan-McLeod syndrome, occipital Neuralgia, occult Spinal Dysraphism Sequence, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus syndrome, optic neuritis, orthostatic hypotension, palinopsia, paresthesia, Parkinson's disease, paramyotonia Congenita, paraneoplastic diseases, paroxysmal attacks, Parry-Romberg syndrome, Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy, photic sneeze reflex, phytanic acid storage disease, Pick's disease, polymicrogyria (PMG), polymyositis, porencephaly, post-polio syndrome, postherpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion diseases, progressive hemifacial atrophy, progressive multifocal leukoencephalopathy, progressive supranuclear palsy, pseudotumor cerebri, Ramsay Hunt syndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome type III, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsum disease, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rhythmic movement disorder, Romberg syndrome, Saint Vitus dance, Sandhoff disease, schizophrenia, Schilder's disease, schizencephaly, sensory integration dysfunction, septo-optic dysplasia, Shy-Drager syndrome, Sjogren's syndrome, snatiation, Sotos syndrome, spasticity, spina bifida, spinal cord tumors, spinal muscular atrophy, spinocerebellar ataxia, Steele-Richardson-Olszewski syndrome, Stiff-person syndrome, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, superficial siderosis, Sydenham's chorea, syncope, synesthesia, syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst, Tay-Sachs disease, temporal arteritis, tetanus, tethered spinal cord syndrome, Thomsen disease, thoracic outlet syndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxic encephalopathy, transient ischemic attack, transmissible spongiform encephalopathies, transverse myelitis, tremor, trigeminal neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis, ubisiosis, Von Hippel-Lindau disease (VHL), Viliuisk Encephalomyelitis (VE), Wallenberg's syndrome, Werdnig, Hoffman disease, west syndrome, Williams syndrome, Wilson's disease and Zellweger syndrome.
The compounds and compositions may also be useful in the inhibition of the development of invasive cancer, tumor angiogenesis and metastasis.
In some embodiments, the disclosure provides a method for treating a disease or disorder associated with aberrant cellular proliferation by administering to a patient in need of such treatment an effective amount of one or more of the compounds of Formula (I), in combination (simultaneously or sequentially) with at least one other agent.
In some embodiments, the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis, the method comprising administering to the patient a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
In some embodiments, the method of treats a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the disorder or disease is cancer.
In some embodiments, the disorder or disease is systemic inflammation.
In some embodiments, the disorder or disease is metastatic melanoma.
In some embodiments, the disorder or disease is fatty liver disease.
In some embodiments, the disorder or disease is liver fibrosis.
In some embodiments, the disorder or disease is tendonitis.
In some embodiments, the disorder or disease is damage to a tendon which would benefit from tendon regeneration.
In some embodiments, the disorder or disease is diabetes.
In some embodiments, the disorder or disease is degenerative disc disease.
In some embodiments, the disorder or disease is osteoarthritis.
In some embodiments, the disorder or disease is diabetic retinopathy.
In some embodiments, the disorder or disease is pulmonary fibrosis.
In some embodiments, the disorder or disease is idiopathic pulmonary fibrosis (IPF).
In some embodiments, the disorder or disease is degenerative disc disease.
In some embodiments, the disorder or disease is rheumatoid arthritis.
In some embodiments, the disorder or disease is scleroderma.
In some embodiments, the disorder or disease is a mycotic or viral infection.
In some embodiments, the disorder or disease is a bone or cartilage disease.
In some embodiments, the disorder or disease is Alzheimer's disease.
In some embodiments, the disorder or disease is osteoarthritis.
In some embodiments, the disorder or disease is lung disease
In some embodiments, the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
In some embodiments, the patient is a human.
In some embodiments, the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.
In some embodiments, the cancer is chosen from: lung cancer—non-small cell, lung cancer—small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer—basal and squamous cell, skin cancer—melanoma, small intestine cancer, stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.
In some embodiments, the cancer is hepatocellular carcinoma.
In some embodiments, the cancer is colon cancer.
In some embodiments, the cancer is colorectal cancer.
In some embodiments, the cancer is breast cancer.
In some embodiments, the cancer is pancreatic cancer.
In some embodiments, the cancer is chronic myeloid leukemia (CML).
In some embodiments, the cancer is chronic myelomonocytic leukemia.
In some embodiments, the cancer is chronic lymphocytic leukemia (CLL).
In some embodiments, the cancer is acute myeloid leukemia.
In some embodiments, the cancer is acute lymphocytic leukemia.
In some embodiments, the cancer is Hodgkin lymphoma.
In some embodiments, the cancer is lymphoma.
In some embodiments, the cancer is sarcoma.
In some embodiments, the cancer is ovarian cancer.
In some embodiments, the cancer is lung cancer—non-small cell.
In some embodiments, the cancer is lung cancer—small cell.
In some embodiments, the cancer is multiple myeloma.
In some embodiments, the cancer is nasopharyngeal cancer.
In some embodiments, the cancer is neuroblastoma.
In some embodiments, the cancer is osteosarcoma.
In some embodiments, the cancer is penile cancer.
In some embodiments, the cancer is pituitary tumors.
In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is retinoblastoma.
In some embodiments, the cancer is rhabdomyosarcoma.
In some embodiments, the cancer is salivary gland cancer.
In some embodiments, the cancer is skin cancer—basal and squamous cell.
In some embodiments, the cancer is skin cancer—melanoma.
In some embodiments, the cancer is small intestine cancer.
In some embodiments, the cancer is stomach (gastric) cancers.
In some embodiments, the cancer is testicular cancer.
In some embodiments, the cancer is thymus cancer.
In some embodiments, the cancer is thyroid cancer.
In some embodiments, the cancer is uterine sarcoma.
In some embodiments, the cancer is vaginal cancer.
In some embodiments, the cancer is vulvar cancer.
In some embodiments, the cancer is Wilms tumor.
In some embodiments, the cancer is laryngeal or hypopharyngeal cancer.
In some embodiments, the cancer is kidney cancer.
In some embodiments, the cancer is Kaposi sarcoma.
In some embodiments, the cancer is gestational trophoblastic disease.
In some embodiments, the cancer is gastrointestinal stromal tumor.
In some embodiments, the cancer is gastrointestinal carcinoid tumor.
In some embodiments, the cancer is gallbladder cancer.
In some embodiments, the cancer is eye cancer (melanoma and lymphoma).
In some embodiments, the cancer is Ewing tumor.
In some embodiments, the cancer is esophagus cancer.
In some embodiments, the cancer is endometrial cancer.
In some embodiments, the cancer is colorectal cancer.
In some embodiments, the cancer is cervical cancer.
In some embodiments, the cancer is brain or spinal cord tumor.
In some embodiments, the cancer is bone metastasis.
In some embodiments, the cancer is bone cancer.
In some embodiments, the cancer is bladder cancer.
In some embodiments, the cancer is bile duct cancer.
In some embodiments, the cancer is anal cancer.
In some embodiments, the cancer is adrenal cortical cancer.
In some embodiments, the disorder or disease is a neurological condition, disorder or disease, wherein the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.
In some embodiments, the compound of Formula (I) inhibits one or more proteins in the Wnt pathway.
In some embodiments, the compound of Formula (I) inhibits signaling induced by one or more Wnt proteins.
In some embodiments, the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.
In some embodiments, the method inhibits one or more proteins in the Wnt pathway, the method comprises contacting a cell with an effective amount of a compound of Formula (I).
In some embodiments, the cell is a human cell.
In some embodiments, the human cell is a cancerous cell.
In some embodiments, the cancerous cell is a colon cancer cell.
In some embodiments, the contacting is in vitro.
In some embodiments, the compound of Formula (I) inhibits a kinase activity.
In some embodiments, the method treats a disease or disorder mediated by the Wnt pathway in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula (I) inhibits one or more Wnt proteins.
In some embodiments, the method treats a disease or disorder mediated by kinase activity in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.
In some embodiments, the method inhibits the activity of a protein kinase receptor, the method comprises contacting the receptor with an effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method prevents or reduces angiogenesis in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method prevents or reduces abnormal cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient, the method comprises administering to the patient a pharmaceutical composition comprising one or more of the compounds of claim 1 in combination with a pharmaceutically acceptable carrier and one or more other agents.
Moreover, the compounds and compositions, for example, as inhibitors of the cyclin-dependent kinases (CDKs), can modulate the level of cellular RNA and DNA synthesis and therefore are expected to be useful in the treatment of viral infections such as HIV, human papilloma virus, herpes virus, Epstein-Barr virus, adenovirus, Sindbis virus, pox virus and the like.
Compounds and compositions described herein can inhibit the kinase activity of, for example, CDK/cyclin complexes, such as those active in the G0. or G.1 stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.
Evaluation of Biological Activity
The biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art, see, e.g., WO 2001/053268 and WO 2005/009997. For example, the activity of a compound may be tested using one or more of the test methods outlined below.
In one example, tumor cells may be screened for Wnt independent growth. In such a method, tumor cells of interest are contacted with a compound (i.e. inhibitor) of interest, and the proliferation of the cells, e.g. by uptake of tritiated thymidine, is monitored. In some embodiments, tumor cells may be isolated from a candidate patient who has been screened for the presence of a cancer that is associated with a mutation in the Wnt signaling pathway. Candidate cancers include, without limitation, those listed above.
In another example, one may utilize in vitro assays for Wnt biological activity, e.g. stabilization of β-catenin and promoting growth of stem cells. Assays for biological activity of Wnt include stabilization of β-catenin, which can be measured, for example, by serial dilutions of a candidate inhibitor composition. An exemplary assay for Wnt biological activity contacts a candidate inhibitor with cells containing constitutively active Wnt/β-catenin signaling. The cells are cultured for a period of time sufficient to stabilize β-catenin, usually at least about 1 hour, and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with antibodies specific for β-catenin.
In a further example, the activity of a candidate compound can be measured in a Xenopus secondary axis bioassay (Leyns, L. et al. Cell (1997), 88(6), 747-756).
To further illustrate this invention, the following examples are included. The examples should not, of course, be construed as specifically limiting the invention. Variations of these examples within the scope of the claims are within the purview of one skilled in the art and are considered to fall within the scope of the invention as described, and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the invention without exhaustive examples.
Examples
Compound Preparation
The starting materials used in preparing the compounds of the invention are known, made by known methods, or are commercially available. It will be apparent to the skilled artisan that methods for preparing precursors and functionality related to the compounds claimed herein are generally described in the literature. The skilled artisan given the literature and this disclosure is well equipped to prepare any of the compounds.
It is recognized that the skilled artisan in the art of organic chemistry can readily carry out manipulations without further direction, that is, it is well within the scope and practice of the skilled artisan to carry out these manipulations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. These manipulations are discussed in standard texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 7th Ed., John Wiley & Sons (2013), Carey and Sundberg, Advanced Organic Chemistry 5th Ed., Springer (2007), Comprehensive Organic Transformations: A Guide to Functional Group Transformations, 2nd Ed., John Wiley & Sons (1999) (incorporated herein by reference in its entirety) and the like.
The skilled artisan will readily appreciate that certain reactions are best carried out when other functionality is masked or protected in the molecule, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in T. Greene and P. Wuts Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons (2007), incorporated herein by reference in its entirety.
Trademarks used herein are examples only and reflect illustrative materials used at the time of the invention. The skilled artisan will recognize that variations in lot, manufacturing processes, and the like, are expected. Hence the examples, and the trademarks used in them are non-limiting, and they are not intended to be limiting, but are merely an illustration of how a skilled artisan may choose to perform one or more of the embodiments of the invention.
(1H) nuclear magnetic resonance spectra (NMR) were measured in the indicated solvents on a Bruker NMR spectrometer (AvanceTM DRX300, 300 MHz for 1H or AvanceTM DRX500, 500 MHz for 1H) or Varian NMR spectrometer (Mercury 400BB, 400 MHz for 1H). Peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; dq, doublet of quartets; m, multiplet.
The following abbreviations have the indicated meanings:

    
    
        BH3-Me2S=borane dimethyl sulfide complex
        (Boc)2O=di-tert-butyl dicarbonate
        brine=saturated aqueous sodium chloride
        CDCl3=deuterated chloroform
        CD3OD=deuterated methanol
        DCAD=di-(4-chlorobenzyl)azodicarboxylate
        DCE=dichloroethane
        DCM=dichloromethane
        DEAD=diethyl azodicarboxylate
        DHP=dihydropyran
        DMAP=4-dimethylaminopyridine
        DMF=N,N-dimethylformamide
        DMSO-d6=deuterated dimethylsulfoxide
        ESIMS=electron spray mass spectrometry
        EtOAc=ethyl acetate
        EtOH=ethanol
        HCl=hydrochloric acid
        HOAc=acetic acid
        K2CO3=potassium carbonate
        KOAc=potassium acetate
        LDA=lithium diisopropylamide
        LC/MS=liquid chromatography-mass spectrometry
        MeOH=methanol
        MgSO4=magnesium sulfate
        MsCl=methanesulfonyl chloride or mesyl chloride
        MW=microwave
        NaBH4=sodium borohydride
        NaBH(OAc)3=sodium triacetoxyborohydride
        NaCNBH3=sodium cyanoborohydride
        NaHCO3=sodium bicarbonate
        NaOH=sodium hydroxide
        Na2S2O5=sodium metabisulfite or sodium pyrosulfite
        NH4OH=ammonium hydroxide
        NMR=nuclear magnetic resonance
        ON=overnight
        Pd/C=palladium(0) on carbon
        Pd(dppf)Cl2=1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride
        Pd(PPh3)4=tetrakis(triphenylphosphine)palladium(0)
        Pd(PPh3)2Cl2=bis(triphenylphosphine)palladium(II) dichloride
        PE=petroleum ether
        Pin2B2=bis(pinacolato)diboron
        PPh3=triphenylphosphine
        PPTS=pyridinium p-toluenesulfonate
        r.t.=room temperature
        SEM-Cl=2-(trimethylsilyl)ethoxymethyl chloride
        TEA=triethylamine
        TFA=trifluoroacetic acid
        THF=tetrahydrofuran
        THP=tetrahydropyran
        TLC=thin layer chromatography
        p-TsOH=p-toluenesulfonic acid
    
    


The following example schemes are provided for the guidance of the reader, and collectively represent an example method for making the compounds provided herein. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. The skilled artisan is thoroughly equipped to prepare these compounds by those methods given the literature and this disclosure. The compound numberings used in the synthetic schemes depicted below are meant for those specific schemes only, and should not be construed as or confused with same numberings in other sections of the application. Unless otherwise indicated, all variables are as defined above.
General Procedure
Compounds of Formula (I) of the present invention can be prepared as depicted in Scheme 1.




Scheme 1 describes the method for preparation of 1H-pyrazolo[3,4-b]pyridine derivatives (VIII) by reacting 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (II) with bis(pinacolato)diboron to form the borate ester (III). Suzuki coupling with various halides (IV) yields 1H-pyrazolo[3,4-b]pyridine derivatives (V). Aldehyde (V) is reacted with various 1,2-diamines (VI) to produce (VII). Final deprotection of the pyrazole nitrogen yields the desired 1H-pyrazolo[3,4-b]pyridine derivatives (VIII).
Illustrative Compound Examples
Synthesis of intermediate 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (XIX) is depicted below in Scheme 2.




Step 1

A solution of 2-chloropyridine (IX) (9.39 mL, 0.1 mol) in anhydrous THF (50 mL) was added slowly to a solution of LDA (2.0 M solution in THF/hexane/ethylbenzene, 50 mL, 0.1 mol) in THF (200 mL) stirred at −78° C. under nitrogen. The stirring was continued at −78° C. for an additional 3 h before adding acetaldehyde (6.17 mL, 0.110 mol). The solution was stirred at −78° C. for another 2 h before allowing the temperature to rise to −40° C. A solution of water (4 mL) in THF (40 mL) was added slowly to the solution. When the temperature reached −10° C., additional water (200 mL) was added to the solution. The solution was extracted with ethyl ether (3×100 mL). The combined organic phase was dried over MgSO4, filtered and evaporated under reduced pressure to get a brown viscous residue. The crude product was purified on a flash silica gel column (1:1 DCM:hexane→100% DCM) to produce 1-(2-chloropyridin-3-yl)ethanol (X) as a brown viscous oil (6 g, 38.1 mmol, 38% yield). 1H NMR (CDCl3) δ ppm 1.52 (d, J=6.41 Hz, 3H), 2.51 (brs, 1H), 5.24 (m, 1H), 7.28 (m, 1H), 7.97 (dd, J=7.72 Hz, J=1.70 Hz, 1H), 8.27 (dd, J=7.72 Hz, J=1.79 Hz, 1H).
Step 2
To a solution of 1-(2-chloropyridin-3-yl)ethanol (X) in dry acetone at −30° C. under nitrogen was added in portions chromium (VI) oxide (1.80 g, 18 mmol). The solution was further stirred 15 min at −30° C. and allowed to warm to room temperature. The solution was stirred for 3 h at room temperature before adding isopropanol (10 mL). The solution was made alkaline by slowly adding a saturated aqueous NaHCO3 solution. The solution was filtered through a bed of Celite. The solids were washed by DCM. The organic phase of the filtrate was separated and the aqueous phase extracted with DCM (2×50 mL). The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to yield 1-(2-chloropyridin-3-yl)ethanone (XI) as a brown liquid (0.72 g, 4.63 mmol, 77% yield). 1H NMR (CDCl3) δ ppm 2.71 (s, 3H), 7.35 (dd, J=7.63 Hz, J=4.80 Hz, 1H), 7.91 (dd, J=7.54 Hz, J=1.88 Hz, 1H), 8.55 (dd, J=4.71 Hz, J=1.88 Hz, 1H).
Step 3
To a solution of 1-(2-chloropyridin-3-yl)ethanone (XI) (0.311 g, 2 mmol) in n-butanol (10 mL) was added hydrazine hydrate (1.45 mL, 30 mmol). The reaction was refluxed overnight. The solution was cooled and the solvent was evaporated under vacuum. The residue was dissolved in DCM and washed successively by water and brine. The organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give 3-methyl-1H-pyrazolo[3,4-b]pyridine (XII) as a white solid (192 mg, 1.44 mmol, 72% yield). 1H NMR (CDCl3) δ ppm 2.64 (s, 3H), 7.14 (dd, J=8.01 Hz, J=4.62 Hz, 1H), 8.14 (dd, J=7.54 Hz, J=1.88 Hz, 1H), 8.59 (dd, J=4.52 Hz, J=1.32 Hz, 1H), 11.68 (brs, 1H).
Step 4
To a solution of NaOH (0.88 g, 22 mmol) in water (20 mL) was added 3-methyl-1H-pyrazolo[3,4-b]pyridine (XII) (0.4 g, 3 mmol). The suspension was heated at 80° C. until a clear solution was obtained. A solution of KMnO4 (1.73 g, 11 mmol) in water (180 mL) was added slowly over 2 h while heating the solution at 80° C. The solution was heated at 90° C. for an additional 2 h until the complete disappearance of starting material was observed by TLC. The solution was cooled to 70° C. and filtered through a pad of Celite. The solids were washed by boiling water. The combined filtrate was cooled to 0° C., acidified with conc. H2SO4 to pH=2 and extracted with n-butanol (2×10 mL). The n-butanol layer was concentrated under reduced pressure to get a white residue which was dissolved in DCM by adding minimum amount of MeOH and then filtered. The filtrate was concentrated to give 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid (XIII) as a white solid (390 mg, 2.39 mmol, 81% yield). 1H NMR (CDCl3) δ ppm 7.37 (dd, J=8.10 Hz, J=4.52 Hz, 1H), 8.47 (dd, J=7.54 Hz, J=1.88 Hz, 1H), 8.62 (dd, J=4.52 Hz, J=1.32 Hz, 1H), 14.37 (brs, 1H).
Step 5
To a solution of 1H-pyrazole[3,4-b]pyridine-3-carboxylic acid (XIII) (0.39 g, 2.4 mmol) in dry MeOH (10 mL) was added concentrated H2SO4 (4 drops) and refluxed for 6 h under nitrogen. The solution was cooled and the solvent was evaporated under vacuum. The residue was partitioned between DCM and saturated aqueous NaHCO3 solution. The organic layer was separated, dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was purified on a flash silica gel column (100% DCM→3:97 MeOH:DCM) to produce methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XIV) as a white solid (382 mg, 2.16 mmol, 90% yield). 1H NMR (CDCl3) δ ppm 4.08 (s, 3H), 7.38 (m, 1H), 8.63 (dd, J=8.10 Hz, J=1.51 Hz, 1H), 8.72 (dd, J=4.62 Hz, J=1.41 Hz, 1H); ESIMS found for C8H7N3O2 m/z 178.2 (M+H).
Step 6
A mixture of methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XIV) (0.177 g, 1 mmol), sodium acetate (0.492 g, 6 mmol) and bromine (0.308 mL, 6 mmol) in glacial acetic acid (5 mL) was heated overnight at 120° C. in a sealed tube. The solution was cooled and poured into water. The solids formed were filtered, washed with water and dried at room temperature under vacuum. The crude product was purified on a flash silica gel column (100% DCM→2:98 MeOH:DCM) to produce methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XV) as a white solid (78 mg, 0.31 mmol, 30% yield). 1H NMR (CDCl3) δ ppm 3.95 (s, 3H), 8.62 (d, J=3.01 Hz, 1H), 8.73 (d, J=3.01 Hz, 1H); ESIMS found for C8H6BrN3O2 m/z 256.3 (M+H).
Step 7
A suspension of methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XV) (70 mg, 0.27 mmol) in aqueous 1N NaOH solution (20 mL) was heated at 90° C. for 3 h until the solution became clear. The solution was then cooled to 0° C. and acidified with a 10% HCl solution. The solids formed were filtered, washed with cold water and dried at room temperature under vacuum to give 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid (XVI) as a white solid (60 mg, 0.25 mmol, 92% yield). 1H NMR (CDCl3) δ ppm 8.58 (d, J=3.01 Hz, 1H), 8.66 (d, J=3.01 Hz, 1H); ESIMS found for C7H4BrN3O2 m/z 242.1 (M+H).
Step 8
To a solution of 5-bromo-1H-pyrazole[3,4-b]pyridine-3-carboxylic acid (XVI) (0.242 g, 1 mmol) in dry DMF (5 mL) was added CDI (0.178 g, 1.1 mmol) and heated for 3 h at 65° C. under nitrogen. The solution was cooled to room temperature and N,O-dimethyl hydroxylamine hydrochloride (0.107 g, 1.1 mmol) was added to the solution. The solution was again heated for 3 h at 65° C. under nitrogen. The solution was cooled and the solvent was evaporated under reduced pressure. The residue was dissolved in DCM, washed successively with a 10% HCl solution, a saturated aqueous NaHCO3 solution and brine. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure to produce 5-bromo-N-methoxy-N-methyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide (XVII) as a white solid (260 mg, 0.91 mmol, 92% yield). 1H NMR (CDCl3) δ ppm 3.55 (s, 3H), 3.78 (s, 3H), 8.59 (d, J=3.01 Hz, 1H), 8.67 (d, J=3.01 Hz, 1H); ESIMS found for C9H9BrN4O2 m/z 285.4 (M+H).
Step 9
To a solution of 5-bromo-N-methoxy-N-methyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide (XVII) (0.250 g, 0.88 mmol) in dry DCM (10 mL) was added 3,4-dihydro-2H-pyran (0.179 mL, 1.98 mmol) and PPTS (22 mg, 0.08 mmol) and refluxed 5 h under nitrogen. Another equivalent of 3,4-dihydro-2H-pyran (0.179 mL, 1.98 mmol) and PPTS (22 mg, 0.08 mmol) was added and the solution was further heated at refluxed overnight under nitrogen. The solution was cooled, diluted with DCM, washed subsequently with a saturated aqueous NaHCO3 solution and brine. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to give 5-bromo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide (XVIII) as a viscous liquid (302 mg, 0.82 mmol, 93% yield). 1H NMR (CDCl3) δ ppm 1.51-1.62 (m, 2H), 1.91-2.13 (m, 2H), 2.33-2.44 (m, 2H), 3.40 (s, 3H), 3.66 (m, 1H), 3.75 (s, 3H), 3.87-3.98 (m, 1H), 6.07 (dd, J=10.07 Hz, J=2.52 Hz, 1H), 8.57 (d, J=3.01 Hz, 1H), 8.73 (d, J=3.01 Hz, 1H); ESIMS found for C14H17BrN4O3 m/z 369.4 (M+H).
Step 10
To a solution of 5-bromo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide (XVIII) (0.290 g, 0.78) in dry THF (5 mL) stirred at 0° C. under nitrogen was added lithium aluminum hydride (36 mg, 0.94 mmol). The solution was further stirred at 0° C. for 30 min. The reaction was quenched with a 0.4 N NaHSO4 solution (10 mL). The solution was extracted with DCM (3×15 mL). The combined organic layer was washed subsequently with water and brine. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to produce 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (XIX) as a viscous liquid (218 mg, 0.70 mmol, 91% yield). 1H NMR (CDCl3) δ ppm 1.52-1.74 (m, 2H), 1.95-2.18 (m, 2H), 2.37-2.49 (m, 2H) 3.87-3.98 (m, 1H), 3.99 (m, 1H), 6.18 (dd, J=10.20 Hz, J=2.39 Hz, 1H), 8.73 (d, J=3.01 Hz, 1H), 8.85 (d, J=3.01 Hz, 1H), 10.16 (s, 1H); ESIMS found for C12H12BrN3O2 m/z 310.4 (M+H).
Preparation of intermediate N-(5-bromopyridin-3-yl)pivalamide (XXII) is depicted below in Scheme 3.




Step 1

To a solution of 3-amino-5-bromo pyridine (XX) (1.0 g, 5.78 mmol) in dry pyridine (10 mL) was added pivaloyl chloride (XXI) (769 mg, 6.38 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction was poured into an ice water/saturated aqueous NaHCO3 mixture and stirred for 30 min. The precipitate was filtered, washed with cold water and dried at room temperature to yield N-(5-bromopyridin-3-yl)pivalamide (XXII) as an off-white solid (1.082 g, 4.22 mmol, 73.1% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.23 (s, 9H), 8.37 (d, J=2 Hz, 1H), 8.39 (t, J=2 Hz, 1H), 8.80 (d, J=2 Hz, 1H), 9.58 (brs, 1H); ESIMS found C10H13BrN2O m/z 258.9 (Br81M+H).
The following intermediates were prepared in accordance with the procedure described in the above Scheme 3.




N-(5-Bromopyridin-3-yl)isobutyramide (XXIII): Off-white solid, (71% yield). 1H NMR (CDCl3) δ ppm 8.55-8.35 (m, 3H), 7.32 (s, 1H), 2.59-2.48 (m, 1H), 1.28-1.27 (d, 6H); ESIMS found C9H11BrN2O m/z 242.9 (Br79M+H).




N-(5-Bromopyridin-3-yl)propionamide (XXIV): Off white solid (92% yield). 1H NMR (DMSO-d6) δ ppm 1.09 (t, J=7.54 Hz, 3H), 2.36 (q, J=7.54 Hz, 2H), 8.36 (m, 2H), 8.65 (d, J=2.07 Hz, 1H), 10.26 (s, 1H); ESIMS found C8H9BrN2O m/z 231.1 (Br81M+H).




N-(5-Bromopyridin-3-yl)butyramide (XXV): Yellow solid (2.1 g, 8.64 mmol, 88.8% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.02 (t, J=7.2 Hz, 3H), 1.74 (sxt, J=7.2 Hz, 2H), 2.40 (t, J=7.2 Hz, 2H), 8.35 (d, J=2 Hz, 1H), 8.46 (t, J=2 Hz, 1H), 8.63 (d, J=2 Hz, 1H); ESIMS found C9H11BrN2O m/z 243.1 (Br79M+H).




N-(5-Bromopyridin-3-yl)pentanamide (XXVI): Yellow solid (2.0 g, 7.78 mmol, 85.3% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 0.98 (t, J=7.4 Hz, 3H), 1.43 (sxt, J=7.4 Hz, 2H), 1.70 (quin, J=7.4 Hz, 2H), 2.43 (t, J=7.6 Hz, 2H), 8.35 (s, 1H), 8.45 (d, J=2 Hz, 1H), 8.64 (d, J=2 Hz, 1H); ESIMS found C10H13BrN2O m/z 256.9 (Br79M+H).




N-(5-Bromopyridin-3-yl)-3-methylbutanamide (XXVII): Off white solid, (67% yield), 1H NMR (CDCl3, 500 MHz) δ ppm 8.55-8.42 (m, 3H), 7.62 (s, 1H), 2.31-2.18 (m, 3H), 1.02-1.01 (d, J=6 Hz, 6H); ESIMS found C10H3BrN2O m/z 258.9 (Br81M+H).




N-(5-Bromopyridin-3-yl)-3,3-dimethylbutanamide (XXVIII): Yellow solid (1.7 g, 6.27 mmol, 78.6% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.10 (s, 9H), 2.29 (s, 2H), 8.36 (d, J=1.6 Hz, 1H), 8.46 (d, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C11H15BrN2O m/z 273.1 ((Br81M+H).




N-(5-Bromopyridin-3-yl)-2-phenylacetamide (XXIX): White solid (2.5 g, 8.59 mmol, 77.9% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 3.76 (s, 2H), 7.26-7.45 (m, 5H), 7.57 (brs, 1H), 8.33 (s, 1H), 8.37 (s, 2H); ESIMS found C13H11BrN2O m/z 292.8 (Br81M+H).




N-(5-Bromopyridin-3-yl)benzamide (XXX): White solid (2.7 g, 9.74 mmol, 60% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 7.40-7.52 (m, 2H), 7.52-7.62 (m, 1H), 7.86 (d, J=7.2 Hz, 2H), 8.39 (d, J=1.6 Hz, 1H), 8.46 (s, 1H), 8.55 (d, J=1.6 Hz, 1H), 8.57 (d, J=2.0 Hz, 1H); ESIMS found C12H9BrN2O m/z 278.8 (Br81M+H).




N-(5-Bromopyridin-3-yl)cyclopropanecarboxamide (XXXI): Off-white solid, (83% yield), 1H NMR (CDCl3, 500 MHz) δ ppm 8.46-8.39 (m, 3H), 7.54 (bs, 1H), 1.56-1.50 (m, 1H), 1.13-1.07 (m, 2H), 0.96-0.90 (m, 2H); ESIMS found for C9H9BrN2O m/z 240.9 (Br79M+H).




N-(5-Bromopyridin-3-yl)cyclobutanecarboxamide (XXXII): Yellow solid (2.1 g, 6.27 mmol, 86.6% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.80-1.99 (m, 1H), 1.99-2.15 (m, 1H), 2.16-2.30 (m, 2H), 2.30-2.45 (m, 2H), 3.25-3.35 (m, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.47 (s, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C10H11BrN2O m/z 257.1 (Br81M+H).




N-(5-Bromopyridin-3-yl)cyclopentanecarboxamide (XXXIII): Yellow solid (1.9 g, 7.06 mmol, 80.2% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.57-1.74 (m, 2H), 1.74-1.91 (m, 4H), 1.91-2.07 (m, 2H), 2.77-2.92 (m, 1H), 8.34 (d, J=1.6 Hz, 1H), 8.45 (s, 1H), 8.65 (d, J=2.0 Hz, 1H); ESIMS found C11H13BrN2O m/z 271.1 (Br81M+H).




N-(5-bromopyridin-3-yl)cyclohexanecarboxamide (XXXIV): Yellow solid (2.0 g, 7.06 mmol, 84.3% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.19-1.46 (m, 3H), 1.46-1.63 (m, 2H), 1.74 (d, J=11.6 Hz, 1H), 1.88 (t, J=14.0 Hz, 4H), 2.40 (tt, J=11.6 Hz, J=3.6 Hz, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.44 (t, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C12H15BrN2O m/z 285.1 (Br81M+H).




N-(5-bromopyridin-3-yl)-2-cyclohexylacetamide (XXXV): Yellow solid (261 mg, 0.878 mmol, 84.4% yield). ESIMS found C13H17BrN2O m/z 297.1 (Br81M+H).
Preparation of intermediate 5-bromo-N,N-dimethylpyridin-3-amine (XXXVII) is depicted below in Scheme 4.




Step 1

To a solution of 3,5-dibromopyridine (XXXVI) (2.37 g, 10.0 mmol) in dry DMF (20.0 mL) was added K2CO3 (4.5 g, 33 mmol) and dimethylamino hydrochloride (1.79 g, 22 mmol). The mixture was heated overnight at 200° C. in a sealed tube. The solution was cooled to room temperature and excess DMF was removed under vacuum. The residue was partitioned between EtOAc and water. The organic phase was separated. The aqueous phase was washed with EtOAc and the combined organic phases were dried over MgSO4, and concentrated to afford 5-bromo-N,N-dimethylpyridin-3-amine (XXXVII) as an off-white solid (1.78 g, 8.85 mmol, 88% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.94 (s, 6H), 7.25 (t, J=2 Hz, 1H), 7.91 (d, J=2 Hz, 1H), 8.07 (d, J=2 Hz, 1H); ESIMS found C7H9BrN2 m/z 201.1 (M+H).
Preparation of intermediate 5-bromo-N-isopropylpyridin-3-amine (XXXVIII) is depicted below in Scheme 5.




Step 1

To a solution of 5-bromopyridin-3-amine (XX) (535 mg, 3.09 mmol) in MeOH (62 mL) was added acetone (296 μL, 4.02 mL). The pH was adjusted to 4 using HOAc and stirred for 30 min. NaCNBH3 (272 mg, 4.33 mmol) was added and stirred at room temperature overnight. The MeOH was removed under vacuum and the residue was partitioned between EtOAc and saturated aqueous NaHCO3. The organic layer was dried over MgSO4 and evaporated under vacuum. The crude product was purified on a silica gel column (100% hexane→90:10 hexane:EtOAc) to produce 5-bromo-N-isopropylpyridin-3-amine (XXXVIII) as an oil which slowly solidified into an off-white solid (309 mg, 1.44 mmol, 47% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.12 (d, J=6.3 Hz, 6H), 3.55-3.59 (m, 1H), 6.03 (d, J=7.9 Hz, 1H), 7.05-7.06 (m, 1H), 7.75 (d, J=2 Hz, 1H), 7.90 (d, J=2 Hz, 1H); ESIMS found C8H11BrN2 m/z 215.1 (M+H).
Preparation of intermediate 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (XL) is depicted below in Scheme 6.




Step 1

Preparation of 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (XL) was performed following the procedure listed in Scheme 5, Step 1. Brown oil (1.20 g, 5.59 mmol, 45% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.15 (s, 6H), 3.43 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=1.1 Hz, 1H), 8.59 (d, J=2.2 Hz, 1H); ESIMS found C8H11BrN2 m/z 215 (MBr79+H) and 217 (MBr81+H).
Preparation of intermediate 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (XLI) is depicted below in Scheme 7.




Step 1

To a mixture of 5-bromopyridine-3-carbaldehyde (XXXIX) (6.00 g, 32.26 mmol, 1.0 eq), 3,3-difluoropyrrolidine (5.56 g, 38.71 mmol, 1.20 eq) and TEA (5.39 mL, 38.71 mmol, 1.2 Eq) in DCE (200 mL) was stirred at room temperature for 30 min, then added sodium triacetoxyborohydride (10.25 g, 48.38 mmol, 1.50 eq) in one portion at room temperature under N2. The mixture was stirred at room temperature for 6 hours. TLC showed the reaction was complete. The reaction was quenched with 1N NaOH (100 mL), extracted with DCE (100 mL×2). The combined organic layers were washed with brine (100 mL), dried and concentrated. The residue was purified by silica gel chromatography (column height: 50 mm, diameter: 50 mm, 300-400 mesh silica gel, DCM/MeOH=30/1→20/1) to give 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl) pyridine (XLI): Yellow oil (8.00 g, 28.9 mmol, 89.5% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 2.30 (spt, J=7.2 Hz, 2H), 2.75 (t, J=6.8 Hz, 2H), 2.91 (t, J=13.2 Hz, 2H), 7.85 (s, 1H), 8.45 (s, 1H), 8.59 (d, J=2 Hz, 1H); ESIMS found for C10H11BrF2N2 m/z 277.0 (M+H).
The following intermediates were prepared in accordance with the procedure described in the above Scheme 6 or Scheme 7.




3-Bromo-5-(pyrrolidin-1-ylmethyl)pyridine (XLI): Golden liquid (1.35 g, 97% yield). 1H NMR (DMSO-d6) 1.68-1.71 (m, 4H), 2.42-2.44 (m, 4H), 3.60 (s, 2H), 7.96 (s, 1H), 8.48 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C10H13BrN2 m/z 242.2 (M+H).




3-Bromo-5-(piperidin-1-ylmethyl)pyridine (XLII): Brown liquid (13.1 g, 94% yield). 1H NMR (DMSO-d6) 1.36-1.39 (m, 2H), 1.46-1.51 (m, 4H), 2.31-2.32 (m, 4H), 3.46 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C11H15BrN2 m/z 257.0 (M+H).




N-((5-Bromopyridin-3-yl)methyl)ethanamine (XLIII): Golden liquid (1.29 g, 6.00 mmol, 60% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 1.14 (t, J=7.2 Hz, 3H), 2.67 (q, J=7.2 Hz, 2H), 3.79 (s, 2H), 7.85 (t, J=2 Hz, 1H), 8.46 (d, J=1.6 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H); ESIMS found for C8H11BrN2 m/z 215.1 (M+H).




N-Benzyl-1-(5-bromopyridin-3-yl)methanamine (XLIV): Yellow oil (8.0 g, 28.9 mmol, 89.5% yield). 1H NMR (DMSO-d6, 400 MHz) δ ppm 3.71 (s, 2H), 3.74 (s, 2H), 7.18-7.28 (m, 1H), 7.28-7.40 (m, 4H), 8.04 (s, 1H), 8.52 (s, 1H), 8.58 (s, 1H); ESIMS found for C13H13BrN2 m/z 277.1 (M+H).
Preparation of intermediate tert-butyl (5-bromopyridin-3-yl)methyl (cyclopentylmethyl)carbamate (L) is depicted below in Scheme 8.




Step 1

To a solution of 5-bromonicotinaldehyde (XXXIX) (2.0 g, 10.8 mmol, 1 eq) in MeOH (20 mL) was added NaBH4 (2.4 g, 64.9 mmol, 6 eq) and the reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated in vacuo and the residue was diluted in water (15 mL), the aqueous phase was extracted with DCM (10 mL×3). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to afford (5-bromopyridin-3-yl)methanol (XLVI) (1.8 g, 9.57 mmol, 90.0% yield) as a colorless oil. 1H NMR (CDCl3, 500 MHz) δ ppm 4.73 (s, 2H), 7.90 (s, 1H), 8.47 (s, 1H), 8.57 (s, 1H). ESIMS found for C6H6BrNO m/z 188.0 (M+H).
Step 2
To a stirred solution of (5-bromopyridin-3-yl)methanol (XLVI) (1.60 g, 8.5 mmol, 1 eq), phthalimide (1.24 g, 8.5 mmol, 1 eq) and PPh3 (3.33 g, 12.75 mmol, 1.5 eq) in anhydrous THF (15 mL) was added DEAD (2.21 g, 12.75 mmol, 1.5 eq) dropwise at 0° C. under N2. Then the reaction mixture was stirred at room temperature for 6 h. The mixture was washed with saturated NaHCO3 solution (15 mL), water (15 mL) and brine (15 mL) subsequently. The organic layers were dried over MgSO4, concentrated under reduced pressure, the resultant residue was purified by flash chromatography on silica gel (PE:EtOAc=4:1) to give 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (XLVII) (2.5 g, 7.88 mmol, 82.3% yield) as a white solid. ESIMS found for C14H9BrN2O2 m/z 317.1 (M+H).
Step 3
A solution of 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (XLVII) (1.9 g, 6.0 mmol, 1 eq) and hydrazine hydrate (2.0 g, 40 mmol, 6 eq) in EtOH (20 mL) was heated at 70° C. for 3 h. The mixture was filtered through a Celite® pad and the filtrate was concentrated in vacuo, the crude product was dissolved in 1N HCl solution (15 mL) and concentrated to dryness, then it was washed with acetone (10 mL×3), the precipitate was collected by filtration, dried in vacuo to give (5-bromopyridin-3-yl)methanamine (XLVIII) (1.3 g, 6.95 mmol, 97.7% yield) as a white solid. 1H NMR (D2O, 500 MHz) δ ppm 4.34 (s, 2H), 8.56 (s, 1H), 8.75 (d, J=1.2 Hz, 1H), 8.91 (d, J=1.6 Hz, 1H). ESIMS found for C6H7BrN2 m/z 187.0 (M+H).
Step 4
A solution of (5-bromopyridin-3-yl)methanamine (XLVIII) (1.30 g, 5.8 mmol, 1.0 eq), cyclopentanecarbaldehyde (0.57 g, 5.8 mmol, 1.0 eq) and TEA (0.60 g, 5.8 mmol, 1.0 eq) in MeOH (15 mL) was stirred at room temperature for 2 h. Then NaBH3CN (1.98 g, 34.6 mmol, 6.0 eq) was added and the mixture was stirred at the same temperature for another 3 h. The solvent was removed under reduced pressure and the residue was diluted in water (20 mL) and extracted with DCM (10 mL×3), combined organic layers were dried over MgSO4 and concentrated in vacuo to give 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (XLIX) (1.23 g, 4.57 mmol, 79.3% yield) as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ ppm 1.07-1.23 (m, 2H), 1.47-1.67 (m, 4H), 1.70-1.84 (m, 2H), 2.02 (spt, J=7.6 Hz, 1H), 2.53 (d, J=7.2 Hz, 2H), 3.80 (s, 2H), 7.86 (s, 1H), 8.47 (s, 1H), 8.56 (d, J=2.0 Hz, 1H); ESIMS found for C12H17BrN2 m/z 269.1 (M+H).
Step 5
To a solution of 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl) methanamine (XLIX) (1.00 g, 3.7 mmol, 1 eq) and TEA (0.93 g, 9.2 mmol, 2.5 eq) in DCM (20 mL) was added portionwise (Boc)2O (0.85 g, 4.0 mmol, 1.1 eq) at 0° C., the reaction mixture was stirred at room temperature for 1 h. The mixture was washed with water (10 mL), brine (10 mL), the organic layer was separated, dried over MgSO4 and concentrated in vacuo to give tert-butyl (5-bromopyridin-3-yl)methyl (cyclopentylmethyl) carbamate (L) (1.25 g, 3.38 mmol, 91.9% yield) as a white solid. ESIMS found for C17H25BrN2O2 m/z 369.1 (M+H).
Preparation of intermediate 3-bromo-5-(cyclohexyloxy)pyridine (LIII) is depicted below in Scheme 9.




Step 1

To a solution of 5-bromopyridin-3-ol (LI) (523 mg, 3.01 mmol) in THF (30 mL) cooled to 0° C. were added triphenylphosphine (867 mg, 3.31 mmol) and cyclohexanol (LII) (331 mg, 3.31 mmol) followed by (E)-bis(4-chlorobenzyl) diazene-1,2-dicarboxylate (1.21 g, 3.31 mmol), added portionwise. The reaction mixture was then stirred at 25° C. overnight. The reaction was worked-up with a EtOAc-NaHCO3 extraction and the solid filtered off. The solvent was removed and the residue was purified by Isco (20% EtOAc-Hexanes) to give 3-bromo-5-(cyclohexyloxy)pyridine (LIII) (209 mg, 0.82 mmol, 27.2% yield) as a yellow oil. 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.21-1.31 (m, 1H) 1.34-1.48 (m, 4H) 1.49-1.57 (m, 1H) 1.70 (br dd, J=9.74, 4.25 Hz, 2H) 1.88-1.96 (m, 2H) 2.50 (dt, J=3.70, 1.72 Hz, 5H) 4.46-4.54 (m, 1H) 7.72 (t, J=2.20 Hz, 1H) 8.24 (d, J=1.92 Hz, 1H) 8.27 (d, J=2.47 Hz, 1H).
The following intermediate was prepared in accordance with the procedure described in the above Scheme 9.




tert-Butyl 4-((5-bromopyridin-3-yl)oxy)piperidine-1-carboxylate (L): Yellow oil (244 mg, 0.683 mmol, 23.2% yield). ESIMS found for C15H21BrN2O3 m/z 358.3 (M+H).
Preparation of intermediate 3-(benzyloxy)-5-bromopyridine (LVI) is depicted below in Scheme 10.




Step 1

To a solution of 5-bromopyridin-3-ol (LI) (174 mg, 1.0 mmol) in DMF (3 mL) was added potassium carbonate (415 mg, 3.0 mmol). The slurry was heated at 90° C. for 1 hour and then cooled to 25° C. The (bromomethyl)benzene (LV) (171 mg, 1.0 mmol) was added and the mixture was stirred at 25° C. overnight. The reaction was worked-up using a saturated sodium bicarbonate and ethyl acetate extraction. The product was purified by ISCO column eluted with 40-100% EtOAc-Hexanes. The 3-(benzyloxy)-5-bromopyridine (LVI) (105 mg, 0.398 mmol, 39.8% yield) was obtained as yellow oil. MS: 266.1. ESIMS found for C12H10BrNO m/z 266.1 (M+H).
The following intermediates were prepared in accordance with the procedure described in the above Scheme 10.




3-Bomo-5-(2-(pyrrolidin-1-yl)ethoxy)pyridine (LVII): Yellow oil ((97 mg, 0.358 mmol, 15.56% yield). ESIMS found for C11H15BrN2O m/z 272.2 (M+H).




2-((5-bromopyridin-3-yl)oxy)-N,N-dimethylethan-1-amine (LVIII): Yellow oil (97 mg, 0.396 mmol, 28.9% yield). ESIMS found for C9H13BrN2O m/z 245.1 (M+H).




1-(2-(3-bromo-5-fluorophenoxy)ethyl)pyrrolidine (LIX): Yellow oil (370 mg, 1.284 mmol, 85.8% yield). ESIMS found for C12H15BrFNO m/z 289.0 (M+H).




2-(3-bromo-5-fluorophenoxy)-N,N-dimethylethan-1-amine (LX): Yellow oil (364 mg, 1.389 mmol, 50.2% yield). ESIMS found for C10H13BrFNO m/z 263.9 (M+H).
Preparation of intermediate tert-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXII) is depicted below in Scheme 11.




Step 1

To a solution of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid (LXI) (3.4 g, 13.97 mmol) in DCM (10 mL) was added DMF (1 mL). The solution was cooled in ice-water to 0° C. Oxalyl chloride (1.835 mL, 20.96 mmol) was then added dropwise. The mixture was stirred for one hour at 25° C. The organic volatile was then removed under vacuum. The residue was dissolved in DCM (10 mL). DMAP (0.171 g, 1.397 mmol) and 5-bromopyridin-3-amine (XX) (2.418 g, 13.97 mmol) were added to the solution and cooled to 0° C. DIEA (4.88 ml, 27.9 mmol) was then added dropwise and the mixture was stirred for 2 hours at 25° C. The reaction was worked-up with DCM and saturated NaHCO3. The product was purified by ISCO eluted with 0-100% EtOAc-Hexanes. The tert-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXII) (2.82 g, 7.08 mmol, 50.7% yield) was obtained as yellow oil. ESIMS found for C17H24BrN3O3 m/z 343.1 (M-56).
The following intermediate was prepared in accordance with the procedure described in the above Scheme 11.




N-(5-Bromopyridin-3-yl)-2-(dimethylamino)acetamide (LXIII): Yellow oil (528 mg, 2.05 mmol, 19.0% yield). ESIMS found for C9H12BrN3O m/z 259.3 (M+H).
Preparation of tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-yl)carbamate (LXVI) is depicted below in Scheme 12.




Step 1

To a solution of tert-butyl azetidin-3-ylcarbamate hydrochloride (LXIV) (2 g, 9.58 mmol) in dry DMF (19.2 mL) was added DIPEA (8.37 ml, 47.9 mmol). To this mixture was added 2,6-dichloropyrazine (LXV) (1.428 g, 9.58 mmol) and the reaction was stirred at 95° C. for 3 hours. The reaction was quenched with water (20 mL) and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (40 g) (100% hexanes→hexanes:EtOAc 1:1) to yield tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-yl)carbamate (LXVI) (2.2882 g, 8.04 mmol, 83.9% yield) as a white solid. ESIMS found for C12H17ClN4O2 m/z 285.1 (M+H).
Preparation of intermediate 2-(3-fluorophenyl)pyridine-3,4-diamine (LXX) is depicted below in Scheme 13.




Step 1

A solution of 2-chloro-3-nitropyridin-4-amine (LXVII) (2.0 g, 11.5 mmol, 1.0 eq), (3-fluorophenyl)boronic acid (LXVIII) (1.93 g, 13.8 mmol, 1.2 eq), Pd(PPh3)4 (0.40 g, 0.34 mmol, 0.03 eq), Na2CO3 (2.44 g, 23.05 mmol, 2.0 eq) in a mixed solvent of toluene (20 mL), H2O (10 mL) and EtOH (4 mL) was stirred at 75° C. for 15 h under nitrogen atmosphere. Then the reaction mixture was washed with brine (30 mL) and dried over anhydrous Na2SO4, filtered and concentrated in vacuo, the resultant residue was purified by chromatography on silica gel (PE:EtOAc=1:1) to afford 2-(3-fluorophenyl)-3-nitropyridin-4-amine (LXIX) (1.91 g, 8.2 mmol, 71.2% yield) as a yellow solid. ESIMS found for C11H8FN3O2 m/z 234.2 (M+H).
Step 2
To a solution of 2-(3-fluorophenyl)-3-nitropyridin-4-amine (LXIX) (1.91 g, 8.19 mmol, 1.0 eq) in MeOH (100 mL) was added Pd/C (0.8 g) under nitrogen atmosphere. The mixture was stirred under 50 psi of H2 for 6 h at room temperature. The mixture was then filtered and concentrated in vacuo to afford 2-(3-fluorophenyl)pyridine-3,4-diamine (LXX) as a black solid (1.52 g, 7.48 mmol, 91.3% yield). 1H NMR (DMSO-d6, 400 MHz) δ ppm 4.30 (s, 2H), 5.55 (s, 2H), 6.44 (d, J=4.8 Hz, 1H), 7.07-7.19 (m, 1H), 7.33 (dd, J=4.4 Hz, J=2 Hz, 1H), 7.38-7.49 (m, 2H), 7.57 (d, J=4.8 Hz, 1H); ESIMS found C11H10FN3 m/z 204.0 (M+H).
The following intermediates were prepared in accordance with the procedure described in the above Scheme 13.




2-(4-Fluorophenyl)pyridine-3,4-diamine (LXXI): White Solid (1.56 g, 7.67 mmol, 92.0% yield). 1H NMR (CDCl3, 400 MHz) 3.38 (brs, 2H), 4.02 (brs, 2H), 6.57 (d, J=4.8 Hz, 1H), 7.15 (t, J=4.8 Hz, 2H), 7.59 (dd, J=8.4 Hz, J=5.6 Hz, 2H), 7.94 (d, J=5.2 Hz, 1H); ESIMS found for C11H10FN3 m/z 204.0 (M+H).




2-(2-Fluorophenyl)pyridine-3,4-diamine (LXXII): Yellow Solid (1.45 g, 7.14 mmol, 89.2% yield). 1H NMR (CDCl3, 400 MHz) 3.23 (brs, 2H), 4.12 (brs, 2H), 6.62 (d, J=4.89 Hz, 1H), 7.19 (t, J=9.03 Hz, 1H), 7.24-7.33 (m, 1H), 7.42 (d, J=6.02 Hz, 1H), 7.45-7.61 (m, 1H), 8.00 (d, J=4.89 Hz, 1H); ESIMS found for C11H10FN3 m/z 204.0 (M+H).




[2,3′-Bipyridine]-3,4-diamine (LXXIII): Black Solid (1.19 g, 6.39 mmol, 86.4% yield). ESIMS found for C10H10N4 m/z 187.1 (M+H).




2-(Thiophen-3-yl)pyridine-3,4-diamine (LXXIV): Yellow oil (1.12 g, 5.86 mmol, 96.7% yield). 1H NMR (CDCl3, 400 MHz) 3.53 (brs, 2H), 3.99 (brs, 2H), 6.55 (d, J=5.14 Hz, 1H), 7.40-7.49 (m, 2H), 7.56-7.62 (m, 1H), 7.93 (d, J=5.14 Hz, 1H); ESIMS found for C9H9N3S m/z 192.0 (M+H).




2-(Furan-3-yl)pyridine-3,4-diamine (LXXV): Yellow oil (1.32 g, 7.53 mmol, 95.2% yield). ESIMS found for C9H9N3O m/z 176.0 (M+H).




2-(Thiophen-2-yl)pyridine-3,4-diamine (LXXVI): Yellow oil (1.04 g, 5.44 mmol, 98.3% yield). 1H NMR (CDCl3, 400 MHz) 3.22 (brs, 2H), 4.11 (brs, 2H), 6.61 (d, J=4.8 Hz, 1H), 7.18 (t, J=9.0 Hz, 1H), 7.50 (d, J=6.8 Hz, 1H), 7.44-7.58 (m, 1H), 7.99 (d, J=4.8 Hz, 1H); ESIMS found for C9H9N3S m/z 192.0 (M+H).




2-(5-Fluorothiophen-2-yl)pyridine-3,4-diamine (LXXVII): Yellow oil (1.2 g, 5.74 mmol, 91.5% yield). ESIMS found for C9H8FN3S m/z 210.1 (M+H).




2-(5-Methylthiophen-2-yl)pyridine-3,4-diamine (LXXVIII): Yellow oil (1.20 g, 5.85 mmol, 86.0% yield). 1H NMR (CD3OD, 400 MHz) 2.55 (s, 3H), 6.62 (d, J=6 Hz, 1H), 6.87 (d, J=1.2 Hz, 1H), 7.23 (d, J=3.2 Hz, 1H), 7.63 (d, J=5.6 Hz, 1H); ESIMS found for C10H11N3S m/z 206.0 (M+H).




1-(5-(3,4-Diaminopyridin-2-yl)thiophen-2-yl)ethan-1-one (LXXIX): Yellow oil (1.20 g, 5.85 mmol, 86.0% yield). 1H NMR (DMSO-d6, 400 MHz) 2.52 (s, 3H), 4.84 (s, 2H), 5.83 (s, 2H), 6.46 (d, J=4.8 Hz, 1H), 7.57 (d, J=4.8 Hz, 1H), 7.66 (d, J=4 Hz, 1H), 7.88 (d, J=4 Hz, 1H); ESIMS found for C11H11N3OS m/z 234.0 (M+H).




3-(3,4-Diaminopyridin-2-yl)-5-fluorophenol (LXXX): White solid (320 mg, 1.46 mmol, 84.6% yield). ESIMS found for C11H10FN3O m/z 220.1 (M+H).




2-(3-Fluoro-5-methoxyphenyl)pyridine-3,4-diamine (LXXXI): White solid (501 mg, 2.148 mmol, 93.1% yield). ESIMS found for C12H12FN3O m/z 234.1 (M+H).




2-(3-Fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyridine-3,4-diamine (LXXXI): Black oil (167 mg, 0.528 mmol, 80.9% yield). ESIMS found for C17H21FN4O m/z 317.1 (M+H).




2-(3-(2-(Dimethylamino)ethoxy)-5-fluorophenyl)pyridine-3,4-diamine (LXXXII): Black oil (88 mg, 0.303 mmol, 20.83% yield). 1H NMR (DMSO-d6, 400 MHz); ESIMS found for C15H19FN4O m/z 291.1 (M+H).
Preparation of intermediate [2,4′-bipyridine]-3,4-diamine (LXXXVI) is depicted below in Scheme 14.




Step 1

To a solution of pyridin-4-ylboronic acid (LXXXIV) (2.00 g, 16.3 mmol), 2-chloro-3-nitropyridin-4-amine (LXVII) (2.35 g, 13.6 mmol), Na2CO3 (5.03 g, 47.5 mmol) and Pd(dppf)Cl2 (502.87 mg, 677.92 μmol) in dioxane (40 mL) and H2O (8 mL) was de-gassed and then heated to 80° C. overnight under N2. TLC (100% EtOAc) showed the starting material was consumed completely. The reaction mixture was poured into H2O (300 mL). The mixture was extracted with EtOAc (3×250 mL). The organic phase was washed with brine (300 mL), dried over anhydrous MgSO4, concentrated in vacuum to give a residue, which was purified by silica gel column chromatography (DCM/MeOH=20/1) to afford 3-nitro-[2,4′-bipyridin]-4-amine (LXXXV) (1.60 g, 7.4 mmol, 54.6% yield) as yellow solid. ESIMS found for C10H8N4O2 m/z 217.1 (M+H).
Step 2
To a solution of 3-nitro-[2,4′-bipyridin]-4-amine (LXXXV) (1.60 g, 7.4 mmol) in MeOH (30 mL), was added Fe (1.65 g, 29.6 mmol) and NH4Cl (3.10 g, 59.2 mmol) in one portion at rt. The mixture was stirred at rt. for 10 min. Then heated to 80° C. and stirred for 16 hours. TLC showed the reaction was completed. The mixture was cooled to rt. and concentrated in reduced pressure at 60° C. The combined organic phase was washed with saturated brine (100 mL×2), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The to give crude [2,4′-bipyridine]-3,4-diamine (LXXXVI) (1.20 g, 6.44 mmol, 87.1% yield) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) 4.52 (s, 2H), 5.69 (s, 2H), 6.50 (d, J=4.8 Hz, 1H), 7.62 (d, J=6 Hz, 2H), 7.63 (d, J=4.8 Hz, 1H), 8.61 (d, J=6 Hz, 2H); ESIMS found for C10H10N4 m/z 187.0 (M+H).
Preparation of intermediate [2,2′-bipyridine]-3,4-diamine (LXXXIX) is depicted below in Scheme 15.




Step 1

To a solution of 2-(tributylstannyl)pyridine (LXXXVII) (9.00 g, 24.5 mmol, 1.0 eq), 2-chloro-3-nitropyridin-4-amine (LXVII) (4.24 g, 24.5 mmol, 1.0 eq), Pd(PPh3)4 (28.25 g, 24.5 mmol, 1.0 eq) in dioxane (40 mL) was de-gassed and then heated to 100° C. for 1 h under N2. LC/MS showed that half of the starting material was consumed. The mixture was filtered and concentrated in vacuum to give a residue, which was purified by prep-HPLC (Base) to afford the 3-nitro-[2,2′-bipyridin]-4-amine (LXXXVIII) (0.70 g, 3.24 mmol, 13.2% yield) as a light yellow oil. ESIMS found for C10H8N4O2 m/z 217.1 (M+H).
Step 2
To a solution of 3-nitro-[2,2′-bipyridin]-4-amine (LXXXVIII) (700 mg, 3.24 mmol, 1.0 eq) in MeOH (15 mL) was added Pd/C (200 mg, 3.24 mmol, 1.0 eq). The mixture was stirred at 25° C. for 4 h. LC/MS showed that the starting material was completely consumed. The mixture was filtered and concentrated to give [2,2′-bipyridine]-3,4-diamine (LXXXIX) (450.0 mg, 2.42 mmol, 74.6% yield) as a light brown solid. 1H NMR (DMSO-d6, 400 MHz) 5.73 (brs, 2H), 6.52 (d, J=4.8 Hz, 1H), 6.76 (brs, 2H), 7.31 (dt, J=5.6 Hz, J=1.2 Hz, 1H), 7.52-7.58 (m, 1H), 7.82 (dt, J=8 Hz, J=1.2 Hz, 1H), 8.44 (d, J=8 Hz, 1H), 8.60 (d, J=6 Hz, 1H); ESIMS found for C10H10N4 m/z 187.1 (M+H).
Preparation of intermediate 2-(piperidin-1-yl)pyridine-3,4-diamine (XCI) is depicted below in Scheme 16.




Step 1

To a solution of 2-chloro-3-nitropyridin-4-amine (LXVII) (4.00 g, 23.5 mmol, 1.0 eq) and piperidine (5.89 g, 69.1 mmol, 3.0 eq) in DMF (60 mL) was added K2CO3 (9.56 g, 69.1 mmol, 3.0 eq) in one portion and the mixture was stirred at 120° C. under nitrogen overnight. The reaction mixture was diluted with EtOAc (30 mL) and washed with aqueous saturated NaHCO3 solution (80 mL). The organic phases were dried over Na2SO4 and concentrated in vacuo, the resultant residue was purified by silica gel column chromatography (PE:EtOAc=5:1→1:1) to give 3-nitro-2-(piperidin-1-yl)pyridin-4-amine (XC) (3.87 g, 5.42 mmol, 75.6% yield) as a black oil. ESIMS found for C10H14N4O2 m/z 223.1 (M+H).
Step 2
A mixture of 3-nitro-2-(piperidin-1-yl)pyridin-4-amine (XC) (3.87 g, 5.42 mmol, 1.0 eq) and Pd/C (0.80 g) in MeOH (20 mL) was stirred at room temperature under 50 psi H2 overnight. After the starting material was consumed completely, the mixture was filtered through a Celite pad and the filtrate was concentrated in vacuo to give the 2-(piperidin-1-yl)pyridine-3,4-diamine (XCI) (2.63 g, 13.7 mmol, 78.5% yield) as a black solid. ESIMS found C10H16N4 m/z 193.0 (M+H).
Preparation of intermediate 2-(4-methyl-1H-imidazol-1-yl)pyridine-3,4-diamine (XCV) is depicted below in Scheme 17.




Step 1

A solution of 2-methyl-3-nitropyridin-4-amine (XCII) (1.00 g, 5.76 mmol, 1.0 eq), 4-methyl-1H-imidazole (XCIII) (0.94 g, 11.5 mmol, 2.0 eq) in DMF (10 mL) was stirred at 80° C. for 3 h under microwave irradiation. The reaction was then quenched by water (15 mL). The mixture was extracted with EtOAc (20 mL×3), the organic layer were combined, washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo, the resultant residue was purified by chromatography on silica gel (PE:EtOAc=5:1→3:1) to afford 2-(4-methyl-1H-imidazol-1-yl)-3-nitropyridin-4-amine (XCIV) (700 mg, 3.19 mmol, 56.1% yield) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.13 (s, 3H), 6.88 (d, J=6 Hz, 1H), 7.03 (s, 1H), 7.54 (brs, 2H), 7.82 (s, 1H), 8.01 (d, J=5.6 Hz, 1H); ESIMS found for C9H9N5O2 m/z 220.1 (M+H).
Step 2
To a solution of 2-(4-methyl-1H-imidazol-1-yl)-3-nitropyridin-4-amine (XCIV) (700 mg, 3.19 mmol, 1.0 eq) in MeOH (20 mL) was added Pd/C (0.3 g) under a nitrogen atmosphere. The mixture was stirred under 50 psi of H2 for 12 h at room temperature. The mixture was the filtered and concentrated in vacuo to afford 2-(4-methyl-1H-imidazol-1-yl)pyridine-3,4-diamine (XCV) (500 mg, 2.64 mmol, 82.7% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) 2.17 (s, 3H), 4.36 (brs, 2H), 5.86 (brs, 2H), 6.51 (d, J=5.2 Hz, 1H), 7.14 (s, 1H), 7.43 (d, J=5.2 Hz, 1H), 7.77 (s, 1H); ESIMS found C9H11N5 m/z 190.1 (M+H).
Preparation of intermediate 2-(4-methylpiperazin-1-yl)pyridine-3,4-diamine (XCVIII) is depicted below in Scheme 18.




Step 1

A mixture of 1-methylpiperazine (XCVI) (20 mL) and 2-chloro-3-nitropyridin-4-amine (LXVII) (4.0 g, 23.1 mmol, 1.0 eq) was stirred at 50° C. for 1 h under microwave irradiation. The reaction mixture was diluted with water (100 mL) and filtered, the cake was washed with water (30 mL×3), dried in vacuo to give 2-(4-methylpiperazin-1-yl)-3-nitropyridin-4-amine (XCVII) (4.0 g, 16.9 mmol, 73.2% yield) as a yellow solid. ESIMS found for C10H15N5O2 m/z 238.1 (M+H).
Step 2
A mixture of 2-(4-methylpiperazin-1-yl)-3-nitropyridin-4-amine (XCVII) (4.0 g, 16.9 mmol, 1.0 eq) and Pd/C (0.5 g) in MeOH (200 mL) was stirred under 50 psi of H2 at room temperature overnight. The reaction was monitored by TLC. The mixture was filtered and the filtrate was concentrated in vacuo to give 2-(4-methylpiperazin-1-yl)pyridine-3,4-diamine (XCVIII) (3.13 g, 89.6% yield) as a black solid. 1H NMR (DMSO-d6, 400 MHz) 2.74 (s, 4H), 3.12 (s, 3H), 3.44 (brs, 4H), 5.19 (brs, 4H), 6.60 (d, J=6.4 Hz, 2H); ESIMS found C10H17N5 m/z 208.1 (M+H).
Preparation of intermediate N-(3-(3,4-diaminopyridin-2-yl)-5-fluorobenzyl) methanesulfonamide (CIV) is depicted below in Scheme 19.




Step 1

A solution of 3-bromo-5-fluorobenzonitrile (XCIX) (44.0 g, 220.0 mmol, 1.0 eq) was dissolved in THF (30 mL). BH3-Me2S (33.43 g, 440.0 mmol, 2.0 eq) was added to the solution at 20° C. Then it was stirred at 80° C. for 2 h, HCl (6 N, 100 mL) was added to the mixture slowly at 20° C. The mixture was stirred at 80° C. for 1 h, then it was washed with EtOAc (300 ml). The water phase was basified with 50% aqueous NaOH and it was extracted with EtOAc (300 mL×3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo to produce (3-bromo-5-fluoro-phenyl)methanamine (C) (24.0 g, 117.62 mmol, 53.5% yield). 1H NMR (CDCl3, 300 MHz) 3.86 (s, 2H), 7.01 (d, J=8 Hz, 1H), 7.12 (d, J=8 Hz, 1H), 7.28 (s, 1H); ESIMS found C7H7BrFN m/z 203.9 (Br79M+H).
Step 2
A solution of (3-bromo-5-fluoro-phenyl)methanamine (C) (23.0 g, 112.7 mmol, 1.0 eq) was dissolved in DCM (15 mL), TEA (34.22 g, 338.2 mmol, 3.0 eq) was added to the mixture. Then MsCl (13.44 g, 117.3 mmol, 1.04 eq) was added slowly to the solution at 0° C. It was stirred at 0-30° C. for 2 h. The reaction was washed with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and concentrated to give N-(3-bromo-5-fluorobenzyl)methanesulfonamide (CI) (34.0 g, 102.44 mmol, 90.9% yield, 85% purity) as an oil. 1H NMR (CDCl3, 300 MHz) 2.88 (s, 3H), 4.24 (d, J=4.5 Hz, 2H), 6.99 (d, J=9 Hz, 1H), 7.13 (dt, J=8.1 Hz, J=2 Hz, 1H), 7.25 (s, 1H); ESIMS found C8H9BrFNO2S m/z 282.0 (Br79M+H).
Step 3
A solution of N-(3-bromo-5-fluorobenzyl)methanesulfonamide (CI) (34.0 g, 102.4 mmol, 1.0 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (52.02 g, 204.9 mmol, 2.0 eq), KOAc (20.11 g, 204.9 mmol, 2.0 eq) was dissolved in dioxane (20 mL). Then Pd(dppf)Cl2 (7.60 g, 10.2 mmol, 0.1 eq) was added to the mixture. It was stirred at 90° C. for 2 h. Then the solvent was removed to get the residue which was purified by silica gel column (PE:EtOAc=10:1-100% EtOAc) to get N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)methanesulfonamide (CII) (30.0 g, crude). 1H NMR (CDCl3, 400 MHz) 1.37 (s, 12H), 2.92 (s, 3H), 4.34 (d, J=6.3 Hz, 2H), 7.19 (dt, J=9.3 Hz, J=2.1 Hz, 1H), 7.44 (dd, J=8.7 Hz, J=2.4 Hz, 1H), 7.54 (s, 1H); ESIMS found C14H21BFNO4S m/z 330.1 (M+H).
Step 4
A solution of N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzyl)methanesulfonamide (CII) (5.00 g, 15.19 mmol, 1.0 eq) and 2-chloro-3-nitropyridin-4-amine (LXVII) (2.64 g, 15.19 mmol, 1.0 eq), Cs2CO3 (9.90 g, 30.4 mmol, 2.0 eq) was dissolved in dioxane (40 mL) and water (8 mL). Then Pd(dppf)Cl2 (1.13 g, 1.52 mmol, 0.1 eq) was added to the mixture. The mixture was stirred at 100° C. for 10 h under N2. The solvent was removed to get the residue which was purified by silica column to get N-(3-(4-amino-3-nitropyridin-2-yl)-5-fluorobenzyl)methanesulfonamide (CIII) (3.00 g, 8.81 mmol, 58.0% yield) as an oil. ESIMS found C13H13FN4O4S m/z 341.1 (M+H).
Step 5
A solution of N-[[3-(4-amino-3-nitro-2-pyridyl)-5-fluoro-phenyl]methyl]methanesulfonamide (CIII) (3.00 g, 8.8 mmol, 1.0 eq), Fe (2.46 g, 44.1 mmol, 5.0 eq) and NH4Cl (2.36 g, 44.1 mmol, 5.0 eq) was dissolved in MeOH (35 mL). The mixture was stirred at 80° C. for 2 h. After filtration, the filtrate was concentrated to get N-(3-(3,4-diaminopyridin-2-yl)-5-fluorobenzyl)methanesulfonamide (CIV) (2.20 g, 7.09 mmol, 80.5% yield) as black solid. 1H NMR (CDCl3, 400 MHz) 2.96 (s, 3H), 4.28 (d, J=6 Hz, 2H), 5.33 (brs, 2H), 6.81 (d, J=6.5 Hz, 1H), 7.38-7.40 (m, 2H), 7.75 (d, J=6.5 Hz, 1H); ESIMS found C13H15FN4O2S m/z 311.1 (M+H).
Preparation of intermediate 5-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)pyridine-3,4-diamine (LXXXIX) is depicted below in Scheme 20.




Step 1

A solution of 3-bromo-5-fluorobenzaldehyde (CV) (20.0 g, 98.2 mmol, 1.0 eq) in MeOH (1.8 L) was added N1,N1-dimethylethane-1,2-diamine (21.5 mL, 196.4 mmol, 2.0 eq). The pH was adjusted to 6 using HOAc and stirred for 1 h. NaCNBH3 (8.6 g, 137.5 mmol, 1.4 eq) was added and stirred at room temperature overnight. The MeOH was removed under vacuum and the residue was partitioned between CHCl3 and saturated aqueous NaHCO3. The organic layer was dried over MgSO4 and evaporated under vacuum. The crude product was purified on a silica gel column (100% CHCl3→3:97 MeOH[7N NH3]:CHCl3) to produce N1-(3-bromo-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine (CVI) as a yellow oil (13.0 g, 49.9 mmol, 51% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.28 (s, 6H), 2.39 (t, J=4 Hz, 2H), 3.07 (q, J=6 Hz, 2H), 6.10 (t, J=5 Hz, 1H), 6.38 (td, J=12 Hz, J=2 Hz, 1H), 6.51 (td, J=8.6 Hz, J=2 Hz, 1H), 6.61 (t, J=2 Hz, 1H); ESIMS found C10H14BrFN2 m/z 261.0 (M+H).
Step 2
A solution of N1-(3-bromo-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine (CVI) (13.0 g, 49.9 mmol, 1.0 eq), bis(pinacolato)diboron (12.6 g, 59.9 mmol, 1.2 eq), KOAc (12.1 g, 124.3 mmol, 2.5 eq) and dioxane (600 mL) was purged with argon. Pd(dppf)Cl2 (2.0 g, 2.47 mmol, 0.05 eq) was added to the reaction and purged again with argon. The solution was heated at 90° C. for 2 h. Once TLC showed the disappearance of (CVI), the solution was cooled to room temperature and then concentrated under reduced pressure to produce crude N1-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine (CVII) (7.4 g, 24.0 mmol, 48.2% yield).
Step 3
To a solution of N1-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine (CVII) (2.00 g, 6.49 mmol, 1.2 eq), 2-bromo-3-nitropyridin-4-amine (CVIII) (1.18 g, 5.41 mmol, 1.0 eq), Na2CO3 (1.15 g, 10.82 mmol, 2.0 eq) and Pd(dppf)Cl2 (395.73 mg, 540.83 μmol, 0.1 eq) in dioxane (40 mL) and H2O (8 mL) was de-gassed and then heated to 80° C. overnight under N2. TLC (PE:EtOAc=1:1) showed the starting material was consumed completely. The reaction mixture was poured into H2O (300 mL). The mixture was extracted with EtOAc (3×250 mL). The organic phase was washed with saturated brine (300 mL), dried over anhydrous MgSO4, concentrated in vacuum to give a residue, which was purified by silica gel column chromatography (PE/EtOAc=5/1) to afford N1-(3-(4-amino-3-nitropyridin-2-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine (CIX) (1.50 g, 4.70 mmol, 86.9% yield) as a solid. ESIMS found for C15H18FN5O2 m/z 320.1 (M+H).
Step 4
To a solution of N1-(3-(4-amino-3-nitropyridin-2-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine (CIX) (1.50 g, 4.70 mmol, 1.0 eq) in MeOH (30 mL) was added Zn (1.54 g, 23.50 mmol, 5.0 eq) and NH4Cl (754.21 mg, 14.10 mmol, 3.0 eq) in one portion at room temperature. The mixture was stirred at room temperature for 10 min. TLC showed the reaction was completed. The mixture was filtered and concentrated in vacuum to afford 5-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)pyridine-3,4-diamine (CX) (1.2 g, 4.15 mmol, 4.15 mmol, 88.2% yield) as a yellow oil. 1H NMR (CD3OD, 300 MHz) 2.44 (s, 6H), 2.78 (t, J=5.25 Hz, 2H), 3.24-3.34 (m, 2H), 6.40-6.51 (m, 2H), 6.53 (d, J=1.5 Hz, 1H), 6.71 (d, J=6.3 Hz, 1H), 7.58 (d, J=6.6 Hz, 1H); ESIMS found for C15H20FN5 m/z 290.1 (M+H).
Example 1
Preparation of 3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (353) is depicted below in Scheme 21.




Step 1

A solution of 5-bromo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-carbaldehyde (XIX) (872 mg, 2.81 mmol, 1.0 eq), bis(pinacolato)diboron (898 mg, 3.37 mmol), and KOAc (824 mg, 8.4 mmol, 3.0 eq) in dry DMF (40 mL) was purged with argon. PdCl2(dppf)2 (120 mg, 0.14 mmol, 0.05) was added to the solution and purged again with argon. The solution was heated at 90° C. for 2 h under argon and cooled to the room temperature. The reaction mixture was diluted in water (30 mL) and extracted with DCM (30 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (CXI) which was used for the next step without further purification.
Step 2
A solution of 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (CXI) (1.0 g, 2.80 mmol, 1.0 eq), 3-bromo-5-(piperidin-1-ylmethyl)pyridine (XLIII) (717 mg, 2.80 mmol, 1.0 eq), Pd(dppf)Cl2 (144 mg, 0.196 mmol, 0.07 eq) and Na2CO3 (0.89 g, 8.40 mmol, 3.0 eq) in a mixed solvent of 1,2-dimethoxyethane (30 mL) and H2O (5 mL) was refluxed for 3 h under a nitrogen atmosphere. The reaction mixture was diluted in water (30 mL) and extracted with DCM (30 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo, the resultant residue was purified by flash chromatography on silica gel eluting with 100% EtOAc to give the 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (CXII) (1.04 g, 2.56 mmol, 91.3% for 2 steps) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ ppm 1.27 (t, J=7.6 Hz, 2H), 1.40-1.52 (m, 4H), 1.66-1.77 (m, 1H), 1.79-1.95 (m, 2H), 2.02-2.14 (m, 1H), 23.17-2.30 (m, 1H), 2.35-2.53 (m, 4H), 2.62-2.76 (m, 1H), 3.58 (s, 2H), 3.89 (dd, J=9.2 Hz, J=11.2 Hz, 1H), 4.08-4.24 (m, 1H), 6.30 (dd, J=2 Hz, J=10.4 Hz, 1H), 7.95 (s, 1H), 8.60 (s, 1H), 8.78 (s, 1H), 8.88 (s, 1H), 10.27 (s, 1H); ESIMS found C23H27N5O2 m/z 406.1 (M+H).
Step 3
A solution of 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (CXII) (100.0 mg, 0.25 mmol, 1.0 eq), 2-(5-methylthiophen-2-yl)pyridine-3,4-diamine (LXXIX) (50.6 mg, 0.25 mmol, 1.0 eq) and Na2S2O5 (56.3 mg, 0.30 mmol, 1.2 eq) in DMF (2 mL) was stirred at 120° C. for 24 h. LC/MS showed the starting material was consumed. Water (5 mL) was added in dropwise and the mixture was filtered. The filtrate was washed by MeOH (0.5 mL) and used for directly for next step without further purification.
Step 4
Crude 3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine (CXIII) was mixed with in HCl/EtOAc (15 mL) was stirred at 10-35° C. for 12 h. LC/MS showed the starting material was consumed. The mixture was concentrated to give a residue. The residue was purified by pre-HPLC (HCl) to give 3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl) pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (353) (11.0 mg, 0.02 mmol, 8.8% yield for 2 steps) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.33-1.49 (m, 1H), 1.68-1.77 (m, 1H), 1.78-1.96 (m, 4H), 2.57 (s, 3H), 2.92-3.05 (m, 2H), 3.42 (d, J=10.42 Hz, 2H), 4.45-4.53 (m, 2H), 7.06 (d, J=3.39 Hz, 1H), 7.65 (d, J=6.40 Hz, 1H), 8.28 (d, J=6.40 Hz, 1H), 8.54 (d, J=3.76 Hz, 1H), 8.83 (d, J=5.90 Hz, 2H), 9.03 (s, 1H), 9.11 (s, 2H), 11.26 (brs, 1H), 14.75 (brs, 2H); ESIMS found for C28H26N8S m/z 507.1 (M+1).
The following compound was prepared in accordance with the procedure described in the above Example 1.




N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide 1
White solid (31.0 mg, 0.06 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.15 (t, J=7.53 Hz, 3H), 2.45 (q, J=7.61 Hz, 2H), 7.28 (td, J=8.40 Hz, J=2.28 Hz, 1H), 7.57 (d, J=5.52 Hz, 1H), 7.66 (q, J=6.4 Hz, 1H), 8.47 (d, J=5.27 Hz, 1H), 8.61 (s, 1H), 8.77 (dd, J=7.78, 1.76 Hz, 3H), 8.82 (d, J=7.65 Hz, 1H), 9.04 (d, J=1.88 Hz, 1H), 9.11 (d, J=1.51 Hz, 1H), 10.31 (s, 1H), 13.87 (brs, 1H); ESIMS found for C26H19FN5O m/z 479.1 (M+1).




5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine 7
White solid (38.6 mg, 0.09 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 3.06 (s, 6H), 7.32 (td, J=8.28 Hz, J=2.28 Hz, 1H), 7.45 (brs, 1H), 7.53-7.62 (m, 2H), 8.22 (d, J=2.26 Hz, 1H), 8.33 (s, 1H), 8.47 (d, J=5.40 Hz, 1H), 8.73 (d, J=7.78 Hz, 1H), 8.83 (d, J=10.79 Hz, 1H), 9.06 (s, 1H), 9.09 (s, 1H), 13.83 (s, 1H), 14.54 (s, 1H); ESIMS found for C25H19FN8 m/z 451.1 (M+1).




1-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 13
White solid (3.2 mg, 0.007 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.81 (brs, 6H), 4.43-4.50 (m, 2H), 7.48-7.56 (m, 1H), 7.69-7.79 (m, 1H), 7.87 (brs, 1H), 8.52-8.61 (m, 3H), 8.69 (brs, 1H), 8.83 (d, J=1.51 Hz, 1H), 9.13 (s, 1H), 9.15 (d, J=2.01 Hz, 1H), 9.17 (d, J=1.63 Hz, 1H), 10.74 (brs, 1H), 14.64 (s, 1H), 14.84 (brs, 1H); ESIMS found for C26H21FN8 m/z 465.1 (M+1).




N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide 19
White solid (20.0 mg, 0.04 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.86-0.97 (m, 4H), 1.91-1.98 (m, 1H), 7.53 (qd, J=8.16 Hz, J=2.0 Hz, 1H), 7.82 (q, J=6.28 Hz, 1H), 7.98 (d, J=6.27 Hz, 1H), 8.50 (d, J=11.04 Hz, 1H), 8.54-8.62 (m, 2H), 8.80 (s, 1H), 8.90 (s, 1H), 8.95 (s, 1H), 8.99 (d, J=1.88 Hz, 1H), 9.07 (d, J=2.01 Hz, 1H), 11.22 (brs, 1H), 14.98 (brs, 1H), 14.94 (brs, 1H); ESIMS found for C27H19FN8O m/z 491.2 (M+1).




5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 25
White solid (12.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.60-2.73 (m, 2H), 3.86-3.98 (m, 4H), 4.65 (brs, 2H), 7.58 (td, J=8.34, 1.88 Hz, 1H), 7.78-7.87 (m, 1H), 8.01 (d, J=6.27 Hz, 1H), 8.52-8.70 (m, 3H), 8.81 (s, 1H), 8.95 (d, J=1.25 Hz, 1H), 9.08 (d, J=2.01 Hz, 1H), 9.18 (d, J=2.26 Hz, 1H), 9.20 (d, J=1.76 Hz, 1H), 14.97 (brs, 1H), 15.07 (brs, 1H); ESIMS found for C28H21F3N8 m/z 527.2 (M+1).




N-(5-(3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 28
White solid (25.0 mg, 0.05 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.00 (d, J=6.65 Hz, 6H), 2.15-2.26 (m, 1H), 2.35 (d, J=7.15 Hz, 2H), 7.68 (t, J=8.72 Hz, 2H), 7.97 (d, J=5.27 Hz, 1H), 8.58 (d, J=6.40 Hz, 1H), 8.68-8.76 (m, 2H), 8.83 (s, 2H), 8.87 (s, 1H), 8.99 (d, J=2.01 Hz, 1H), 9.12 (d, J=2.13 Hz, 1H), 10.67 (brs, 1H), 14.92 (s, 1H), 14.94 (brs, 1H); ESIMS found for C28H23FN8O m/z 507.1 (M+1).




N-(5-(3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide 34
White solid (50.0 mg, 0.10 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.33 (s, 9H), 7.66 (t, J=8.78 Hz, 2H), 7.96 (d, J=6.27 Hz, 1H), 8.57 (d, J=6.40 Hz, 1H), 8.68-8.76 (m, 2H), 8.86-8.93 (m, 2H), 9.00 (d, J=2.01 Hz, 1H), 9.02 (d, J=1.76 Hz, 1H), 9.11 (d, J=2.01 Hz, 1H), 9.97 (s, 1H), 14.92 (s, 2H); ESIMS found for C28H23FN8O m/z 507.2 (M+1).




3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine 40
White solid (9.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 2.00 (brs, 4H), 3.04 (brs, 4H), 4.20 (s, 2H), 7.30 (t, J=8.60 Hz, 2H), 7.56 (d, J=5.40 Hz, 1H), 8.33 (s, 1H), 8.38 (d, J=5.52 Hz, 1H), 8.43-8.50 (m, 2H), 8.56-8.66 (m, 2H), 8.71 (s, 1H), 8.97 (d, J=1.51 Hz, 1H), 9.01 (d, J=1.51 Hz, 1H), 9.17 (d, J=1.76 Hz, 1H); ESIMS found for C28H23FN8 m/z 491.2 (M+1).




N-(5-(3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide 46
White solid (8.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.81-1.94 (m, 1H), 1.94-2.06 (m, 1H), 2.14-2.26 (m, 2H), 2.28-2.39 (m, 3H), 7.70 (t, J=8.85 Hz, 2H), 7.96 (d, J=4.64 Hz, 1H), 8.58 (d, J=6.27 Hz, 1H), 8.69-8.76 (m, 2H), 8.78 (s, 1H), 8.82-8.89 (m, 2H), 9.00 (d, J=2.13 Hz, 1H), 9.12 (d, J=2.26 Hz, 1H), 10.48 (s, 1H), 14.91 (brs, 2H); ESIMS found for C28H21FN8O m/z 505.1 (M+1).




3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine 52
White solid (78.1 mg, 0.19 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 7.62 (t, J=8.60 Hz, 2H), 8.01 (d, J=6.15 Hz, 1H), 8.59 (d, J=6.40 Hz, 1H), 8.68 (brs, 2H), 9.10 (d, J=2.13 Hz, 1H), 9.17 (d, J=2.38 Hz, 1H), 9.31 (s, 1H), 9.34 (s, 2H), 14.95 (s, 1H), 15.03 (brs, 1H); ESIMS found for C22H13FN8 m/z 409.0 (M+1).




5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine 55
White solid (11.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 6.75 (s, 1H), 7.58-7.68 (m, 2H), 7.76-7.86 (m, 1H), 7.95 (brs, 1H), 8.12 (d, J=2.13 Hz, 2H), 8.18 (brs, 1H), 8.47 (s, 1H), 8.68 (d, J=6.40 Hz, 1H), 8.91 (brs, 1H), 9.03 (d, J=2.13 Hz, 1H), 15.02 (s, 1H), 15.06 (brs, 1H); ESIMS found for C23H15FN8 m/z 423.1 (M+1).




N-(5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide 61
White solid (12.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 300 MHz) δ ppm 1.20 (d, J=6.78 Hz, 6H), 2.65-2.77 (m, 1H), 7.52-7.64 (m, 2H), 7.67-7.80 (m, 1H), 8.04 (d, J=5.27 Hz, 1H), 8.16 (brs, 1H), 8.61 (brs, 1H), 8.66 (d, J=6.41 Hz, 1H), 8.69 (brs, 1H), 8.77 (d, J=1.88 Hz, 1H), 8.86 (brs, 1H), 9.04 (d, J=1.88 Hz, 1H), 10.35 (s, 1H), 14.85 (s, 1H); ESIMS found for C27H21FN8O m/z 493.2 (M+1).




N-(5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide 68
White solid (13.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.08 (s, 9H), 2.34 (s, 2H), 7.56-7.64 (m, 2H), 7.72-7.81 (m, 1H), 8.07-8.14 (m, 1H), 8.19 (brs, 1H), 8.66 (brs, 1H), 8.68 (d, J=6.40 Hz, 1H), 8.77 (brs, 1H), 8.84-8.94 (m, 2H), 9.04 (d, J=2.26 Hz, 1H), 10.64 (brs, 1H), 14.90-15.25 (m, 1H), 14.96 (brs, 1H); ESIMS found for C29H25FN8O m/z 521.2 (M+1).




N-(5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide 73
White solid (10.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 1.68-1.77 (m, 2H), 1.77-1.88 (m, 2H), 1.89-1.99 (m, 2H), 2.00-2.10 (m, 2H), 2.98 (quin, J=8.03 Hz, 1H), 7.54 (dd, J=10.48, 8.72 Hz, 1H), 7.63 (t, J=7.64 Hz, 1H), 7.79 (q, J=8.12 Hz, 1H), 8.17 (d, J=6.40 Hz, 1H), 8.30 (brs, 1H), 8.62 (d, J=6.53 Hz, 1H), 8.94 (s, 2H), 9.04 (s, 1H), 9.12 (s, 1H), 9.28 (brs, 1H); ESIMS found for C29H23FN8O m/z 519.2 (M+1).




5-(Pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 82
White solid (11.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 7.89 (d, J=5.40 Hz, 1H), 8.01-8.14 (m, 2H), 8.62 (d, J=5.90 Hz, 1H), 8.86 (d, J=7.91 Hz, 1H), 8.90 (d, J=5.27 Hz, 1H), 8.98 (d, J=4.52 Hz, 1H), 9.16 (d, J=2.13 Hz, 1H), 9.19 (d, J=1.88 Hz, 1H), 9.39 (s, 1H), 9.49 (brs, 1H), 10.06 (brs, 1H), 14.58 (s, 1H), 14.90 (brs, 1H); ESIMS found for C22H14N8 m/z 391.1 (M+1).




N-(5-(3-(4-(Pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide 87
White solid (12.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 300 MHz) δ ppm 1.19 (d, J=6.78 Hz, 6H), 2.65-2.79 (m, 1H), 7.79 (d, J=6.03 Hz, 1H), 7.96 (brs, 1H), 8.59 (d, J=6.03 Hz, 1H), 8.67 (s, 1H), 8.82 (brs, 3H), 9.00-9.11 (m, 2H), 9.41 (brs, 1H), 9.88 (brs, 1H), 10.37 (s, 1H), 14.37 (brs, 1H), 14.76 (s, 1H); ESIMS found for C26H21N9O m/z 476.3 (M+1).




N-Isopropyl-5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine 90
White solid (12.5 mg, 0.03 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 1.34 (d, J=6.40 Hz, 7H), 3.86 (spt, J=6.40 Hz, 1H), 8.03 (s, 1H), 8.09 (d, J=2.26 Hz, 1H), 8.13-8.20 (m, 2H), 8.43 (s, 1H), 8.70 (d, J=6.27 Hz, 1H), 9.02 (d, J=2.01 Hz, 1H), 9.05 (d, J=5.14 Hz, 1H), 9.17 (d, J=2.13 Hz, 1H), 9.27 (d, J=8.16 Hz, 1H), 10.01 (d, J=1.25 Hz, 1H); ESIMS found for C25H21N9 m/z 448.1 (M+1).




5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 93
White solid (13.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.36-1.47 (m, 1H), 1.68-1.76 (m, 1H), 1.78-1.90 (m, 4H), 2.93-3.04 (m, 2H), 3.45 (d, J=11.80 Hz, 2H), 4.57 (brs, 2H), 7.90 (d, J=5.77 Hz, 1H), 8.14 (dd, J=7.72, 5.71 Hz, 1H), 8.63 (d, J=5.90 Hz, 1H), 8.97 (s, 1H), 8.99-9.05 (m, 2H), 9.20 (s, 2H), 9.32 (d, J=1.76 Hz, 1H), 9.45-9.52 (m, 1H), 10.13 (brs, 1H), 11.24 (brs, 1H), 14.64 (s, 1H), 14.91 (brs, 1H); ESIMS found for C28H25N9 m/z 488.2 (M+1).




N-Benzyl-1-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine 101
White solid (9.3 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 4.31 (brs, 2H), 4.47 (brs, 2H), 7.40-7.49 (m, 3H), 7.61-7.67 (m, 2H), 7.88 (d, J=5.65 Hz, 1H), 8.07 (brs, 1H), 8.62 (d, J=5.90 Hz, 1H), 8.84-8.90 (m, 2H), 8.93 (d, J=5.15 Hz, 1H), 9.18 (s, 2H), 9.23 (s, 1H), 9.46 (brs, 1H), 10.08 (brs, 3H), 14.57 (brs, 1H), 14.88 (brs, 1H); ESIMS found for C30H23N9 m/z 510.1 (M+1).




5-(4-Methylpyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 109
White solid (55.3 mg, 0.14 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.63 (s, 3H), 7.84 (d, J=5.52 Hz, 1H), 8.05 (d, J=5.65 Hz, 1H), 8.64 (d, J=5.40 Hz, 1H), 8.83-8.91 (m, 2H), 9.01 (d, J=6.15 Hz, 2H), 9.05 (d, J=2.51 Hz, 2H), 9.30 (d, J=4.64 Hz, 2H), 14.34 (brs, 1H), 14.90 (brs, 1H); ESIMS found for C23H16N8 m/z 405.0 (M+1).




2-Phenyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide 114
White solid (14.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 3.85 (s, 2H), 7.21-7.28 (m, 1H), 7.33 (t, J=7.53 Hz, 2H), 7.42 (d, J=7.15 Hz, 2H), 7.83 (d, J=5.27 Hz, 1H), 8.66 (d, J=5.40 Hz, 1H), 8.83 (s, 1H), 8.86 (s, 1H), 8.93 (s, 1H), 9.07-9.16 (m, 4H), 9.35 (d, J=3.76 Hz, 2H), 11.02 (brs, 1H), 14.30 (brs, 1H), 14.81 (s, 1H); ESIMS found for C30H21N9O m/z 524.1 (M+1).




N-(5-(3-(4-(Pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide 121
White solid (39.0 mg, 0.08 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.98 (t, J=7.34 Hz, 3H), 1.71 (sxt, J=7.43 Hz, 2H), 7.83 (d, J=5.40 Hz, 1H), 8.65 (d, J=5.40 Hz, 1H), 8.97 (s, 2H), 9.01 (s, 1H), 9.08-9.16 (m, 4H), 9.34-9.43 (m, 2H), 10.98 (brs, 1H), 14.32 (brs, 1H), 14.83 (s, 1H); ESIMS found for C26H21N9O m/z 476.2 (M+1).




N-(5-(3-(4-(Pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide 126
White solid (8.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.19-1.39 (m, 4H), 1.41-1.54 (m, 2H), 1.62-1.72 (m, 1H), 1.79 (d, J=10.16 Hz, 2H), 1.93 (d, J=11.29 Hz, 2H), 7.84 (d, J=4.77 Hz, 1H), 8.65 (d, J=5.15 Hz, 1H), 8.97 (brs, 1H), 9.03 (brs, 2H), 9.07-9.17 (m, 4H), 9.37 (brs, 2H), 10.94 (brs, 1H), 14.35 (brs, 1H), 14.85 (brs, 1H); ESIMS found for C29H25N9O m/z 516.3 (M+1).




N-((5-(3-(4-(Pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine 136
White solid (11.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.30 (t, J=7.22 Hz, 3H), 3.01-3.13 (m, 2H), 4.36 (t, J=5.27 Hz, 2H), 7.83 (dd, J=7.34, 5.08 Hz, 1H), 8.10 (d, J=6.27 Hz, 1H), 8.36-8.45 (m, 1H), 8.62 (d, J=6.40 Hz, 1H), 8.83 (d, J=1.25 Hz, 1H), 8.87 (s, 1H), 9.01 (d, J=4.27 Hz, 1H), 9.18-9.28 (m, 3H), 9.60-9.73 (m, 3H), 15.07 (s, 1H), 15.22 (s, 1H); ESIMS found for C25H21N9 m/z 448.3 (M+1).




N-(5-(3-(4-(Pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide 141
White solid (12.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 7.59-7.67 (m, 3H), 7.72 (t, J=7.4 Hz, 1H), 8.12 (dd, J=10.35, 6.96 Hz, 3H), 8.41 (t, J=7.53 Hz, 1H), 8.61 (d, J=6.40 Hz, 1H), 8.96 (d, J=4.27 Hz, 1H), 9.16 (d, J=2.01 Hz, 1H), 9.19 (s, 1H), 9.38 (d, J=1.51 Hz, 1H), 9.42 (d, J=1.88 Hz, 1H), 9.49 (s, 1H), 9.77 (d, J=7.78 Hz, 1H); ESIMS found for C29H19N9O m/z 510.2 (M+1).




N-(5-(3-(4-(Pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide 148
White solid (38.0 mg, 0.08 mmol). 1H NMR (DMSO-d6, 300 MHz) δ ppm 0.93 (t, J=7.16 Hz, 3H), 1.38 (sxt, J=7.53 Hz, 2H), 1.65 (quin, J=7.53 Hz, 2H), 7.73 (brs, 1H), 8.12 (d, J=4.14 Hz, 1H), 8.47 (d, J=6.03 Hz, 1H), 8.62 (d, J=5.27 Hz, 1H), 8.88 (brs, 1H), 8.94 (brs, 2H), 8.97 (brs, 1H), 9.05 (s, 1H), 9.10 (brs, 1H), 9.50-9.59 (m, 1H), 11.23 (brs, 1H), 15.15 (brs, 1H), 15.34 (brs, 1H); ESIMS found for C27H23N9O m/z 490.3 (M+1).




N-(5-(3-(4-(Piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide 157
White solid (49.4 mg, 0.11 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.14 (t, J=7.53 Hz, 3H), 1.70 (brs, 6H), 2.42 (q, J=7.49 Hz, 2H), 4.22 (brs, 4H), 6.90 (brs, 1H), 7.78 (d, J=5.90 Hz, 1H), 8.66 (s, 2H), 8.71 (s, 1H), 8.93 (d, J=1.88 Hz, 1H), 9.03 (d, J=2.01 Hz, 1H), 10.31 (s, 1H), 13.61 (brs, 1H), 14.40 (brs, 1H); ESIMS found for C25H25N9O m/z 468.2 (M+1).




N,N-Dimethyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine 163
White solid (41.0 mg, 0.09 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.78 (brs, 6H), 3.16 (s, 6H), 4.34 (brs, 4H), 7.14 (d, J=6.78 Hz, 1H), 7.74 (d, J=6.65 Hz, 1H), 8.06 (brs, 1H), 8.26 (brs, 1H), 8.54 (brs, 1H), 8.97 (d, J=2.01 Hz, 1H), 9.15 (d, J=2.01 Hz, 1H), 13.30 (brs, 1H), 14.56 (s, 1H), 14.74 (s, 1H); ESIMS found for C24H25N9 m/z 440.1 (M+1).




N,N-Dimethyl-1-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine 169
White solid (10.6 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.69 (brs, 6H), 2.25 (s, 6H), 3.58 (brs, 2H), 4.17 (brs, 4H), 6.82 (d, J=5.40 Hz, 1H), 7.81 (d, J=5.52 Hz, 1H), 8.10 (s, 1H), 8.15 (brs, 2H), 8.56 (d, J=1.51 Hz, 1H), 8.95 (d, J=2.01 Hz, 1H), 8.98 (d, J=2.13 Hz, 1H), 9.06 (d, J=2.13 Hz, 1H), 13.35 (s, 1H), 14.32 (brs, 1H); ESIMS found for C25H27N9 m/z 454.2 (M+1).




N-(5-(3-(4-(Piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide 175
White solid (17.0 mg, 0.04 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.83-0.93 (m, 4H), 1.78 (d, J=7.40 Hz, 6H), 1.86-1.96 (m, 1H), 4.31 (brs, 4H), 7.11 (d, J=6.78 Hz, 1H), 7.71 (d, J=6.65 Hz, 1H), 8.67 (s, 1H), 8.75 (s, 2H), 8.83 (s, 1H), 9.07 (d, J=1.63 Hz, 1H), 10.86 (brs, 1H), 12.95 (brs, 1H), 14.44 (s, 1H), 14.62 (s, 1H); ESIMS found for C26H25N9O m/z 480.3 (M+1).




5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 181
White solid (8.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 1.82 (brs, 6H), 2.26-2.40 (m, 2H), 2.85 (t, J=6.84 Hz, 2H), 2.98 (t, J=13.11 Hz, 2H), 3.80 (s, 2H), 4.19 (brs, 4H), 6.97 (d, J=5.40 Hz, 1H), 7.60 (d, J=4.77 Hz, 1H), 8.09 (brs, 1H), 8.44 (d, J=1.76 Hz, 1H), 8.57 (s, 1H), 8.74 (brs, 2H), 8.83 (brs, 1H); ESIMS found for C27H27F2N9 m/z 516.3 (M+1).




3-Methyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide 184.
White solid (13.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.97 (d, J=6.65 Hz, 6H), 2.05-2.19 (m, 1H), 2.23 (s, 3H), 2.28 (d, J=7.03 Hz, 2H), 7.49 (d, J=5.65 Hz, 1H), 8.20 (d, j=5.40 Hz, 1H), 8.27 (s, 1H), 8.49 (s, 1H), 8.73 (s, 1H), 8.85 (d, j=1.51 Hz, 1H), 8.99 (d, J=3.14 Hz, 2H), 9.01 (s, 1H), 10.31 (s, 1H); ESIMS found for C26H24N10O m/z 493.2 (M+1).




N-(5-(3-(4-(4-Methyl-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide 190
White solid (7.8 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.25 (s, 9H), 2.53 (s, 3H), 6.79 (d, J=5.65 Hz, 1H), 6.99 (brs, 2H), 8.04 (d, J=5.77 Hz, 1H), 8.39 (t, J=2.20 Hz, 1H), 8.73 (d, J=2.01 Hz, 1H), 8.76 (d, J=2.13 Hz, 1H), 8.91 (d, J=2.26 Hz, 1H), 8.93 (d, J=2.13 Hz, 1H), 8.96 (s, 1H), 9.55 (s, 1H); ESIMS found for C26H24N10O m/z 493.2 (M+1).




3-(4-(4-Methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine 196
White solid (14.4 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.87-2.00 (m, 2H), 2.00-2.12 (m, 2H), 2.48 (s, 3H), 3.10-3.24 (m, 3H), 3.38-3.50 (m, 6H), 4.63 (brs, 2H), 7.72-7.77 (m, 1H), 8.33-8.38 (m, 1H), 8.66 (s, 1H), 8.90-9.00 (m, 2H), 9.20 (d, J=2.01 Hz, 1H), 9.27-9.35 (m, 2H), 10.37 (d, J=1.38 Hz, 1H), 11.74 (brs, 1H), 14.39 (brs, 1H), 14.82 (brs, 1H); ESIMS found for C26H24N10 m/z 477.1 (M+1).




5-(3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine 211
White solid (11.9 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.88 (s, 3H), 3.73 (d, J=12.30 Hz, 2H), 3.87 (brs, 2H), 5.32-5.47 (m, 2H), 6.74 (brs, 1H), 7.24 (d, J=5.52 Hz, 1H), 7.89 (d, J=6.53 Hz, 1H), 8.01 (s, 1H), 8.10 (d, J=2.01 Hz, 1H), 8.54 (s, 1H), 8.95 (d, J=1.63 Hz, 1H), 9.03 (d, J=2.01 Hz, 1H), 11.33 (brs, 1H), 14.48 (brs, 1H), 14.74 (brs, 1H); ESIMS found for C22H22N10 m/z 427.1 (M+1).




N-(5-(3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide 217
White solid (17.3 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.17 (d, J=6.78 Hz, 6H), 2.24 (s, 3H), 2.53 (brs, 4H), 2.68 (spt, J=6.87 Hz, 1H), 4.20 (brs, 4H), 6.87 (d, J=5.52 Hz, 1H), 7.84 (d, J=5.52 Hz, 1H), 8.17 (s, 1H), 8.65 (d, J=2.01 Hz, 1H), 8.72 (d, J=1.76 Hz, 2H), 8.91 (d, J=2.26 Hz, 1H), 9.01 (d, J=2.26 Hz, 1H), 10.28 (s, 1H), 13.38 (brs, 1H), 14.37 (brs, 1H); ESIMS found for C26H28N10O m/z 497.2 (M+1).




3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine 223
White solid (11.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.33-1.49 (m, 1H), 1.67-1.76 (m, 1H), 1.77-1.94 (m, 4H), 2.87 (d, J=4.14 Hz, 3H), 2.95-3.07 (m, 2H), 3.37-3.55 (m, 6H), 4.02 (t, J=12.99 Hz, 2H), 4.55 (d, J=4.77 Hz, 2H), 5.43 (d, J=13.80 Hz, 2H), 7.26 (d, J=6.78 Hz, 1H), 7.84 (d, J=6.78 Hz, 1H), 8.98 (s, 1H), 9.00 (d, J=2.01 Hz, 1H), 9.07 (brs, 1H), 9.19 (d, J=2.13 Hz, 1H), 9.33 (d, J=1.76 Hz, 1H), 11.48 (brs, 1H), 11.72 (brs, 1H), 14.62 (brs, 1H), 14.77 (brs, 1H); ESIMS found for C28H32N10 m/z 509.2 (M+1).




N-(5-(3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide 229
White solid (12.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 1.67-1.76 (m, 2H), 1.77-1.86 (m, 2H), 1.87-1.99 (m, 2H), 2.01-2.11 (m, 2H), 2.99-3.10 (m, 1H), 3.06 (s, 3H), 3.52-3.65 (m, 2H), 3.89-3.99 (m, 2H), 4.01-4.13 (m, 2H), 5.41-5.53 (m, 2H), 7.40 (d, J=6.78 Hz, 1H), 7.87 (d, J=6.90 Hz, 1H), 9.03 (d, J=1.88 Hz, 1H), 9.08 (s, 2H), 9.11 (d, J=1.88 Hz, 1H), 9.39 (s, 1H); ESIMS found for C28H30N10O m/z 523.3 (M+1).




3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine 234
White solid (4.8 mg, 0.01 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 3.07 (s, 3H), 3.51-3.68 (m, 2H), 3.78-3.91 (m, 2H), 3.93-4.09 (m, 1H), 5.36-5.55 (m, 1H), 7.42 (d, J=6.90 Hz, 1H), 7.87 (d, J=6.78 Hz, 1H), 9.03-9.09 (m, 2H), 9.25-9.31 (m, 3H); ESIMS found for C21H20N10 m/z 413.1 (M+1).




5-(4-Methylpyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 239
White solid (26.0 mg, 0.06 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.60 (s, 3H), 7.89-7.95 (m, 2H), 8.02 (d, J=5.77 Hz, 1H), 8.48 (d, J=6.53 Hz, 1H), 8.55 (d, J=5.02 Hz, 1H), 8.84 (d, J=5.77 Hz, 1H), 8.88 (d, J=2.01 Hz, 1H), 9.01 (s, 1H), 9.05 (d, J=2.26 Hz, 1H), 9.43 (d, J=1.26 Hz, 1H), 14.98 (brs, 1H), 15.02 (s, 1H); ESIMS found for C22H15N7S m/z 410.0 (M+1).




N-(5-(3-(4-(Thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide 245
White solid (33.0 mg, 0.06 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 7.56-7.63 (m, 2H), 7.67 (t, J=7.28 Hz, 1H), 7.87 (d, J=6.40 Hz, 1H), 7.90 (dd, J=5.08, 2.95 Hz, 1H), 8.13 (d, J=7.28 Hz, 2H), 8.44 (d, J=6.53 Hz, 1H), 8.52 (d, J=5.02 Hz, 1H), 9.03 (s, 1H), 9.08 (d, J=1.88 Hz, 1H), 9.09-9.14 (m, 2H), 9.19 (d, J=1.63 Hz, 1H), 9.40 (d, J=1.38 Hz, 1H), 11.10 (s, 1H), 14.93 (brs, 2H); ESIMS found for C28H18N8OS m/z 515.1 (M+1).




N-(5-(3-(4-(Thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide 251
White solid (14.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.97 (t, J=7.40 Hz, 3H), 1.70 (sxt, J=7.28 Hz, 2H), 2.46 (t, J=7.16 Hz, 3H), 7.90 (d, J=6.40 Hz, 1H), 7.98 (dd, J=5.08, 2.95 Hz, 1H), 8.48 (d, J=6.27 Hz, 1H), 8.52 (d, J=4.27 Hz, 1H), 8.87 (brs, 1H), 8.92 (d, J=1.25 Hz, 1H), 8.95 (brs, 1H), 9.07 (s, 1H), 9.10 (d, J=2.01 Hz, 1H), 9.36 (brs, 1H), 10.81 (brs, 1H), 14.88-15.04 (m, 2H); ESIMS found for C25H20N5OS m/z 481.2 (M+1).




N-Benzyl-1-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine 257
White solid (32.1 mg, 0.06 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 4.31 (brs, 2H), 4.47 (brs, 2H), 7.40-7.49 (m, 3H), 7.61-7.67 (m, 2H), 7.88 (d, J=5.65 Hz, 1H), 8.07 (brs, 1H), 8.62 (d, J=5.90 Hz, 1H), 8.84-8.90 (m, 2H), 8.93 (d, J=5.15 Hz, 1H), 9.18 (s, 2H), 9.23 (s, 1H), 9.46 (brs, 1H), 10.08 (brs, 3H), 14.57 (s, 1H), 14.88 (brs, 1H); ESIMS found for C29H22N8S m/z 515.2 (M+1).




N-((5-(3-(4-(Furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine 266
White solid (12.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.30 (t, J=7.28 Hz, 3H), 3.02-3.14 (m, 2H), 4.35 (t, J=5.83 Hz, 2H), 7.84 (s, 1H), 7.91 (d, J=6.65 Hz, 1H), 8.12 (t, J=1.76 Hz, 1H), 8.50 (d, J=6.53 Hz, 1H), 8.72 (s, 1H), 8.84 (d, J=1.76 Hz, 1H), 9.17 (d, J=2.13 Hz, 1H), 9.20 (d, J=2.01 Hz, 1H), 9.24 (d, J=2.01 Hz, 1H), 9.43 (brs, 2H), 9.47 (s, 1H), 14.97 (s, 2H); ESIMS found for C24H20N8O m/z 437.2 (M+1).




5-(3-(4-(Furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine 272
White solid (10.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 1.36 (d, J=6.53 Hz, 6H), 3.87-3.95 (m, 1H), 7.50 (dd, J=2.01, 0.75 Hz, 1H), 7.95-7.99 (m, 2H), 8.01-8.05 (m, 1H), 8.09 (d, J=2.51 Hz, 1H), 8.43 (d, J=0.75 Hz, 1H), 8.45 (d, J=6.52 Hz, 1H), 9.02 (d, J=2.01 Hz, 1H), 9.24 (d, J=2.26 Hz, 1H), 9.37 (s, 1H); ESIMS found for C24H20N8O m/z 437.1 (M+1).




N-(5-(3-(4-(Furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide 278
White solid (20.0 mg, 0.04 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.92 (t, J=7.40 Hz, 3H), 1.37 (sxt, J=7.52 Hz, 2H), 1.64 (quin, J=7.52 Hz, 2H), 2.42 (t, J=7.40 Hz, 2H), 7.55 (brs, 2H), 7.91 (brs, 1H), 8.39 (d, J=5.52 Hz, 1H), 8.61 (s, 1H), 8.78 (dd, J=7.28, 2.01 Hz, 2H), 8.98-9.05 (m, 1H), 9.02 (d, J=2.26 Hz, 1H), 9.07 (d, J=2.01 Hz, 1H), 10.40 (s, 1H), 14.05 (brs, 1H), 14.67 (brs, 1H); ESIMS found for C26H22N8O2 m/z 479.2 (M+1).




1-Cyclopentyl-N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine 284
White solid (11.7 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.16-1.38 (m, 2H), 1.44-1.67 (m, 4H), 1.81 (d, J=2.38 Hz, 2H), 2.22-2.36 (m, 1H), 2.97 (brs, 2H), 4.34 (brs, 2H), 7.86 (d, J=6.78 Hz, 2H), 8.00-8.14 (m, 1H), 8.38-8.51 (m, 1H), 8.71 (brs, 1H), 8.84 (brs, 1H), 9.05-9.23 (m, 3H), 9.34-9.58 (m, 3H), 14.92 (brs, 2H); ESIMS found for C28H26N8O m/z 491.2 (M+1).




N-(5-(3-(4-(Thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide 287
White solid (35.0 mg, 0.08 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.18 (t, J=7.53 Hz, 3H), 7.46 (t, J=4.52 Hz, 1H), 7.78 (d, J=6.40 Hz, 1H), 8.11-8.19 (m, 1H), 8.44 (d, J=6.27 Hz, 1H), 8.70 (d, J=2.89 Hz, 1H), 8.78 (d, J=2.01 Hz, 1H), 8.88 (s, 1H), 8.91 (s, 1H), 9.14 (d, J=2.12 Hz, 1H), 9.16 (d, J=2.13 Hz, 1H), 10.65 (s, 1H), 14.79 (brs, 1H), 14.87 (s, 1H); ESIMS found for C24H18N8OS m/z 467.1 (M+1).




N,N-Dimethyl-5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine 293
White solid (65.4 mg, 0.15 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 3.09 (s, 6H), 7.24 (dd, J=4.83, 3.70 Hz, 1H), 7.45 (d, J=5.52 Hz, 1H), 7.49 (s, 1H), 7.72 (d, J=4.89 Hz, 1H), 8.23 (d, J=2.63 Hz, 1H), 8.32 (d, J=5.52 Hz, 1H), 8.37 (s, 1H), 8.71 (d, J=2.63 Hz, 1H), 9.08 (d, J=2.13 Hz, 1H), 9.15 (d, J=2.13 Hz, 1H), 13.77 (s, 1H), 14.53 (s, 1H); ESIMS found for C23H18N8S m/z 439.1 (M+1).




N,N-Dimethyl-1-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine 299
White solid (25.0 mg, 0.06 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.82 (d, J=2.76 Hz, 6H), 4.51 (d, J=2.64 Hz, 2H), 7.45 (t, J=4.45 Hz, 1H), 7.82 (d, J=6.27 Hz, 1H), 8.18 (d, J=4.64 Hz, 1H), 8.44 (d, J=6.27 Hz, 1H), 8.70 (s, 1H), 8.82 (d, J=3.39 Hz, 1H), 8.91 (s, 1H), 9.15-9.22 (m, 3H), 11.19 (brs, 1H), 14.89 (brs, 1H), 14.92 (brs, 1H); ESIMS found for C24H20N8S m/z 453.1 (M+1).




N-(5-(3-(4-(Thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide 305
White solid (8.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.88-0.99 (m, 4H), 1.94-2.02 (m, 1H), 7.41-7.48 (m, 1H), 7.78 (d, J=6.27 Hz, 1H), 8.10 (d, J=4.52 Hz, 1H), 8.42 (d, J=6.40 Hz, 1H), 8.75 (d, J=3.01 Hz, 1H), 8.89 (brs, 2H), 8.90 (brs, 1H), 9.08-9.15 (m, 2H), 11.22 (brs, 1H), 14.84 (brs, 1H), 14.88 (s, 1H); ESIMS found for C25H18N8OS m/z 479.1 (M+1).




5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 311
White solid (22.0 mg, 0.04 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 2.25-2.40 (m, 2H), 2.86 (t, J=6.96 Hz, 2H), 3.01 (t, J=13.11 Hz, 2H), 3.80 (s, 2H), 7.09-7.16 (m, 1H), 7.25 (d, J=5.65 Hz, 1H), 7.54 (d, J=4.77 Hz, 1H), 8.04-8.11 (m, 2H), 8.36 (d, J=3.14 Hz, 1H), 8.55 (s, 1H), 8.73-8.82 (m, 2H), 8.94 (d, J=2.01 Hz, 1H); ESIMS found for C26H20F2N8S m/z 515.1 (M+1).




N-(5-(3-(4-(5-Fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 314
White solid (9.4 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.00 (d, J=6.53 Hz, 6H), 2.17 (non, J=6.40 Hz, 1H), 2.32 (d, J=7.15 Hz, 2H), 6.94 (dd, J=4.20, 1.82 Hz, 1H), 7.45 (d, J=5.52 Hz, 1H), 8.27 (d, J=5.40 Hz, 1H), 8.30 (s, 1H), 8.42 (t, J=3.95 Hz, 1H), 8.69-8.74 (m, 2H), 8.78 (d, J=1.76 Hz, 1H), 9.08 (s, 2H), 10.35 (s, 1H); ESIMS found for C26H21FN8OS m/z 513.1 (M+1).




N-(5-(3-(4-(5-Fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide 320
White solid (15.2 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.31 (s, 9H), 6.93 (dd, J=4.08, 1.94 Hz, 1H), 7.45 (d, J=5.40 Hz, 1H), 8.28 (d, J=5.65 Hz, 1H), 8.43 (t, J=4.02 Hz, 1H), 8.68 (t, J=2.01 Hz, 1H), 8.78 (d, J=1.88 Hz, 1H), 8.89 (d, J=2.13 Hz, 1H), 9.06-9.12 (m, 2H), 9.65 (s, 1H); ESIMS found for C26H21FN8OS m/z 513.1 (M+1).




5-(3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine 341
White solid (32.0 mg, 0.08 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.63 (s, 3H), 7.14 (d, J=2.64 Hz, 1H), 7.69 (d, J=6.27 Hz, 1H), 7.80-7.92 (m, 2H), 7.99 (brs, 1H), 8.10 (s, 1H), 8.32 (d, J=6.40 Hz, 1H), 8.41 (s, 1H), 8.59 (d, J=3.51 Hz, 1H), 8.85 (s, 1H), 14.41 (s, 1H), 14.69 (brs, 1H); ESIMS found for C22H16N8S m/z 425.0 (M+1).




N-(5-(3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide 347
White solid (18.0 mg, 0.04 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.17 (d, J=6.65 Hz, 7H), 2.56 (s, 3H), 7.12 (brs, 1H), 7.69 (d, J=4.77 Hz, 1H), 8.31 (d, J=5.27 Hz, 1H), 8.55 (brs, 1H), 8.76 (brs, 1H), 8.89 (brs, 1H), 9.03 (brs, 1H), 9.08 (brs, 2H), 10.87 (brs, 1H), 14.83 (brs, 2H); ESIMS found for C26H22N8OS m/z 495.2 (M+1).




N-(5-(3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide 359
White solid (20.0 mg, 0.04 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.53-1.65 (m, 2H), 1.66-1.84 (m, 4H), 1.87-1.99 (m, 2H), 2.55 (s, 3H), 2.94 (quin, J=7.87 Hz, 1H), 7.10 (d, J=3.26 Hz, 1H), 7.66 (d, J=6.40 Hz, 1H), 8.29 (d, J=6.40 Hz, 1H), 8.51 (d, J=3.64 Hz, 1H), 8.74 (s, 1H), 8.87 (s, 1H), 9.01 (d, J=2.01 Hz, 1H), 9.05 (brs, 2H), 10.86 (brs, 1H), 14.78 (brs, 2H); ESIMS found for C28H24N8OS m/z 521.3 (M+1).




1-(5-(2-(5-(Pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one 368
White solid (12.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.64 (s, 3H), 7.67 (d, J=5.14 Hz, 1H), 8.01-8.06 (m, 1H), 8.10 (d, J=3.26 Hz, 1H), 8.44 (d, J=5.14 Hz, 1H), 8.70 (d, J=3.64 Hz, 1H), 8.74-8.81 (m, 1H), 8.85-8.94 (m, 1H), 9.19 (d, J=1.38 Hz, 1H), 9.26 (s, 1H), 9.36 (s, 1H), 14.32 (s, 1H), 14.78 (s, 1H); ESIMS found for C23H15N7OS m/z 438.1 (M+1).




N-(5-(3-(4-(5-Acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide 374
White solid (9.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 2.63 (s, 3H), 3.86 (s, 2H), 7.25-7.31 (m, 1H), 7.35 (t, J=7.40 Hz, 2H), 7.39-7.43 (m, 2H), 7.86 (d, J=4.77 Hz, 1H), 8.05 (d, J=3.89 Hz, 1H), 8.39 (d, J=4.14 Hz, 1H), 8.44 (d, J=6.15 Hz, 1H), 8.72 (s, 1H), 8.90 (brs, 1H), 9.02 (s, 1H), 9.18 (brs, 1H), 9.31 (brs, 1H); ESIMS found for C31H22N8O2S m/z 571.2 (M+1).




N-(5-(3-(4-(5-Acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide 380
White solid (14.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.06 (s, 9H), 2.33 (s, 2H), 2.58 (s, 3H), 7.60 (d, J=5.27 Hz, 1H), 8.08 (d, J=4.14 Hz, 1H), 8.41 (d, J=5.40 Hz, 1H), 8.69-8.73 (m, 1H), 8.77 (d, J=3.89 Hz, 1H), 8.87 (d, J=5.52 Hz, 2H), 9.08 (d, J=2.26 Hz, 1H), 9.12 (d, J=2.38 Hz, 1H), 10.43 (s, 1H), 14.06 (s, 1H), 14.70 (s, 1H); ESIMS found for C29H26N8O2S m/z 551.2 (M+1).




N-(5-(3-(4-(5-Acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide 386
White solid (6.0 mg, 0.01 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.14-1.36 (m, 3H), 1.40-1.52 (m, 2H), 1.63-1.70 (m, 1H), 1.74-1.81 (m, 2H), 1.90 (d, J=11.04 Hz, 2H), 2.05-2.09 (m, 1H), 2.56 (s, 3H), 7.65 (d, J=5.77 Hz, 1H), 8.06 (d, J=3.89 Hz, 1H), 8.39 (d, J=5.77 Hz, 1H), 8.74 (d, J=3.89 Hz, 1H), 8.80 (brs, 1H), 8.96 (brs, 1H), 9.06 (s, 2H), 9.08 (brs, 1H), 10.80 (brs, 1H), 14.35 (s, 1H), 14.80 (brs, 1H); ESIMS found for C30H26N8O2S m/z 563.2 (M+1).




N-(3-Fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide 395
White solid (12.0 mg, 0.02 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 2.64 (s, 3H), 2.80 (s, 3H), 4.36 (s, 2H), 7.50 (d, J=8.78 Hz, 1H), 8.02 (d, J=9.04 Hz, 1H), 8.09-8.15 (m, 2H), 8.44 (s, 1H), 8.58 (d, J=6.53 Hz, 1H), 8.76-8.81 (m, 2H), 8.88 (s, 1H), 9.04 (d, J=2.01 Hz, 1H); ESIMS found for C26H21FN8O2S m/z 529.2 (M+1).




N-(5-(3-(4-(3-Fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide 401
White solid (16.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.87 (s, 3H), 4.31 (d, J=6.27 Hz, 2H), 7.31 (d, J=8.66 Hz, 1H), 7.58-7.64 (m, 2H), 7.65-7.70 (m, 1H), 7.76 (t, J=6.34 Hz, 1H), 7.88 (brs, 1H), 8.03-8.07 (m, 2H), 8.48 (brs, 1H), 8.57 (d, J=6.02 Hz, 2H), 8.77 (s, 1H), 8.92 (d, J=1.38 Hz, 1H), 9.10 (d, J=2.13 Hz, 1H), 9.12 (s, 1H), 9.15 (d, J=1.63 Hz, 1H), 10.78 (s, 1H), 14.66 (brs, 1H), 14.84 (brs, 1H); ESIMS found for C32H24FN9O3S m/z 634.1 (M+1).




N-(5-(3-(4-(3-Fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide 407
White solid (10.0 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.96 (t, J=7.34 Hz, 3H), 1.66 (sxt, J=7.28 Hz, 2H), 2.45 (t, J=7.28 Hz, 2H), 2.86 (s, 3H), 4.33 (d, J=5.90 Hz, 2H), 7.51 (d, J=9.03 Hz, 1H), 7.80 (t, J=6.15 Hz, 1H), 7.98 (d, J=6.27 Hz, 1H), 8.42 (d, J=9.03 Hz, 1H), 8.50 (brs, 1H), 8.58 (d, J=6.27 Hz, 1H), 8.77 (s, 1H), 8.98 (s, 1H), 9.01 (d, J=5.14 Hz, 2H), 9.12 (s, 1H), 11.04 (s, 1H), 14.96 (brs, 2H); ESIMS found for C29H26FN9O3S m/z 600.2 (M+1).




N-(3-(2-(5-(5-((Benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide 413
White solid (31.4 mg, 0.05 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.93 (s, 3H), 4.26 (t, J=5.46 Hz, 2H), 4.35-4.46 (m, 4H), 7.38-7.48 (m, 4H), 7.54 (d, J=9.41 Hz, 1H), 7.62 (dd, J=7.53, 1.76 Hz, 2H), 7.86 (t, J=6.21 Hz, 1H), 8.02 (d, J=6.27 Hz, 1H), 8.51 (brs, 2H), 8.61 (d, J=6.27 Hz, 1H), 8.84 (s, 1H), 8.92 (d, J=1.63 Hz, 1H), 9.13 (d, J=2.13 Hz, 1H), 9.17 (d, J=2.13 Hz, 1H), 9.24 (d, J=1.88 Hz, 1H), 10.11 (brs, 2H), 14.98 (brs, 2H); ESIMS found for C33H28FN9O2S m/z 634.3 (M+1).




N-(3-Fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide 416
White solid (20.1 mg, 0.04 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 2.95 (s, 3H), 4.38 (d, J=6.27 Hz, 2H), 7.53 (dd, J=10.67, 2.64 Hz, 1H), 7.82 (t, J=5.77 Hz, 1H), 7.97 (brs, 1H), 8.50 (brs, 2H), 8.60 (d, J=6.27 Hz, 1H), 9.11-9.19 (m, 2H), 9.29 (s, 1H), 9.34 (s, 2H), 14.92 (brs, 2H); ESIMS found for C24H18FN9O2S m/z 516.1 (M+1).




N1-(3-Fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine 428
White solid (26.0 mg, 0.05 mmol). 1H NMR (CD3OD, 400 MHz) δ ppm 1.33 (d, J=6.02 Hz, 6H), 2.98 (s, 6H), 3.47 (brs, 2H), 3.72 (brs, 2H), 3.81-3.94 (m, 1H), 6.85 (d, J=10.79 Hz, 1H), 7.43 (brs, 1H), 7.92 (brs, 1H), 7.98 (brs, 1H), 8.06-8.14 (m, 2H), 8.37 (s, 1H), 8.58 (dd, J=4.77, 1.00 Hz, 1H), 9.01 (s, 1H), 9.17 (brs, 1H); ESIMS found for C30H31FN10 m/z 551.2 (M+1).




N-(5-(3-(4-(3-((2-(Dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide 434
White solid (11.2 mg, 0.02 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 0.91 (t, J=7.34 Hz, 3H), 1.36 (sxt, J=7.40 Hz, 2H), 1.61 (quin, J=7.50 Hz, 2H), 2.11 (s, 6H), 2.32 (t, J=6.34 Hz, 2H), 2.39 (t, J=7.40 Hz, 2H), 3.09-3.17 (m, 2H), 5.86 (t, J=4.83 Hz, 1H), 6.48 (dt, J=11.70, 2.24 Hz, 1H), 7.53 (d, J=5.40 Hz, 1H), 7.92-8.04 (m, 2H), 8.19 (s, 1H), 8.40-8.46 (m, 2H), 8.72 (d, J=2.01 Hz, 1H), 8.87 (d, J=2.26 Hz, 1H), 8.97 (d, J=2.13 Hz, 1H), 9.07 (d, J=2.26 Hz, 1H), 10.28 (s, 1H), 13.80 (s, 1H), 14.58 (s, 1H); ESIMS found for C32H33FN10O m/z 593.3 (M+1).




N1-(3-(2-(5-(5-(((Cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine 440
White solid (17.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.20-1.34 (m, 2H), 1.44-1.65 (m, 4H), 1.75-1.87 (m, 2H), 2.24-2.36 (m, 1H), 2.80-2.90 (m, 6H), 2.95 (d, J=3.64 Hz, 2H), 3.38 (brs, 2H), 3.62-3.70 (m, 2H), 4.33 (brs, 2H), 6.81 (d, J=11.80 Hz, 1H), 7.77-7.89 (m, 1H), 8.00 (d, J=6.15 Hz, 1H), 8.56 (d, J=6.52 Hz, 1H), 8.76 (brs, 1H), 8.90 (s, 1H), 9.11 (d, J=1.13 Hz, 1H), 9.14-9.26 (m, 2H), 9.63 (brs, 2H), 10.62 (brs, 1H), 14.95 (brs, 1H), 15.04 (brs, 1H); ESIMS found for C34H37FN10 m/z 605.3 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine 885
Yellow solid (6.0 mg, 0.01 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.61-1.74 (m, 2H), 1.93 (br d, J=13.72 Hz, 2H), 2.70 (br t, J=11.11 Hz, 2H), 2.90 (br t, J=12.08 Hz, 1H), 3.13 (br d, J=11.25 Hz, 2H), 7.27-7.34 (m, 1H), 7.51 (d, J=5.49 Hz, 1H), 7.57-7.65 (m, 1H), 8.37 (d, J=5.49 Hz, 1H), 8.59 (d, J=2.20 Hz, 1H), 8.76-8.83 (m, 2H), 8.96 (br d, J=10.70 Hz, 1H); ESIMS found for C23H20FN7 m/z 414.2 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine 886
Yellow solid (42.0 mg, 0.03 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.64 (br s, 2H), 3.12 (br t, J=5.35 Hz, 2H), 3.55 (br s, 2H), 6.52 (br s, 1H), 7.31-7.39 (m, 1H), 7.56 (d, J=5.49 Hz, 1H), 7.58-7.67 (m, 1H), 8.47 (d, J=5.49 Hz, 1H), 8.70 (br d, J=7.96 Hz, 1H), 8.91 (s, 2H), 8.96 (br d, J=10.43 Hz, 1H); ESIMS found for C23H18FN7 m/z 412.2 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine 887
Yellow solid (4.0 mg, 0.01 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 7.36 (td, J=8.37, 2.20 Hz, 1H), 7.56 (d, J=5.49 Hz, 1H), 7.65 (td, J=7.96, 6.59 Hz, 1H), 8.10 (br s, 1H), 8.37 (br s, 1H), 8.47 (d, J=5.49 Hz, 1H), 8.72 (br d, J=7.68 Hz, 1H), 8.98-9.06 (m, 3H), 13.18 (br s, 1H), 13.77 (br s, 1H), 14.36 (br s, 1H); ESIMS found for C21H13FN8 m/z 397.1 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4, 5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine 888
Orange solid (7.1 mg, 0.02 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 3.95 (s, 3H), 7.33 (td, J=8.37, 2.47 Hz, 1H), 7.53 (d, J=5.21 Hz, 1H), 7.60-7.68 (m, 1H), 8.00 (s, 1H), 8.29 (s, 1H), 8.40 (d, J=5.49 Hz, 1H), 8.72 (br d, J=7.68 Hz, 1H), 8.93 (d, J=2.20 Hz, 1H), 8.99 (d, J=2.20 Hz, 1H), 9.03 (br d, J=12.08 Hz, 1H); ESIMS found for C22H15FN8 m/z 411.1 (M+1).




5-(1,2-Dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 889
Yellow solid (6.7 mg, 0.02 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.44 (s, 3H), 3.70 (s, 3H), 7.13 (s, 1H), 7.32 (td, J=8.23, 2.47 Hz, 1H), 7.56 (d, J=5.49 Hz, 1H), 7.61 (td, J=7.96, 6.59 Hz, 1H), 8.46 (d, J=5.49 Hz, 1H), 8.72 (br d, J=7.14 Hz, 1H), 8.77-8.83 (m, 2H), 8.88 (d, J=2.20 Hz, 1H), 13.82 (brs, 1H), 14.47 (br s, 1H); ESIMS found for C23H17FN8 m/z 425.2 (M+1).




1-(6-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine 890
Yellow solid (5.9 mg, 0.01 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 3.72-3.79 (m, 2H), 3.93 (br t, J=6.60 Hz, 1H), 4.32 (br t, J=7.55 Hz, 2H), 7.25 (t, J=8.53 Hz, 1H), 7.46 (br d, J=5.21 Hz, 1H), 7.52-7.61 (m, 1H), 7.85 (s, 1H), 8.24 (d, J=4.65 Hz, 1H), 8.53 (s, 1H), 8.86 (br d, J=7.68 Hz, 1H), 8.90 (br d, J=11.53 Hz, 1H), 9.16 (br s, 1H), 9.44 (br s, 1H); ESIMS found for C25H19FN10 m/z 479.2 (M+H).




5-(5-(Cyclohexyloxy)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 891
Off-white solid (56 mg, 0.105 mmol, 47.7% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.25-1.36 (m, 1H), 1.36-1.47 (m, 2H), 1.48-1.61 (m, 3H), 1.68-1.80 (m, 2H), 1.96-2.06 (m, 2H), 4.60-4.70 (m, 1H), 7.30 (td, J=8.37, 2.20 Hz, 1H), 7.54-7.64 (m, 2H), 7.86 (t, J=2.33 Hz, 1H), 8.38 (d, J=2.74 Hz, 1H), 8.47 (d, J=5.21 Hz, 1H), 8.63 (d, J=1.65 Hz, 1H), 8.76 (br d, J=7.96 Hz, 1H), 8.85 (br d, J=11.53 Hz, 1H), 9.09 (d, J=2.20 Hz, 1H), 9.14 (d, J=2.20 Hz, 1H), 13.85 (brs, 1H), 14.54 (brs, 1H); ESIMS found for C29H24FN7O m/z 506.2 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine 892
White solid (16 mg, 0.030 mmol, 33.4% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.51-1.63 (m, 2H), 2.02 (br dd, J=8.64, 3.98 Hz, 2H), 2.60-2.68 (m, 2H), 3.00 (dt, J=12.76, 4.19 Hz, 2H), 4.72 (dt, J=8.64, 4.46 Hz, 1H), 7.31 (td, J=8.44, 2.06 Hz, 1H), 7.53-7.63 (m, 2H), 7.88 (t, J=2.20 Hz, 1H), 8.39 (d, J=2.74 Hz, 1H), 8.45 (d, J=5.49 Hz, 1H), 8.64 (d, J=1.65 Hz, 1H), 8.77 (d, J=7.96 Hz, 1H), 8.85 (br d, J=10.43 Hz, 1H), 9.07 (d, J=2.20 Hz, 1H), 9.15 (d, J=2.20 Hz, 1H); ESIMS found for C28H23FN8O m/z 507.2 (M+1).




N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide 893
Yellow solid (11.3 mg, 0.02 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.08-1.29 (m, 2H), 1.67 (br d, J=14.00 Hz, 1H), 2.32 (br d, J=6.86 Hz, 1H), 2.95 (br d, J=12.62 Hz, 1H), 7.17-7.31 (m, 1H), 7.51 (d, J=4.40 Hz, 1H), 7.60 (br s, 1H), 8.35 (br s, 1H), 8.52 (br d, J=17.84 Hz, 1H), 8.74 (br s, 1H), 8.77-8.89 (m, 3H), 8.92 (br s, 1H), 9.12 (br d, J=5.21 Hz, 1H), 10.28-10.40 (m, 1H); ESIMS found for C30H26FN9O m/z 548.3 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine 894
Beige solid (9 mg, 0.016 mmol, 66.2% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.69 (dt, J=6.72, 3.22 Hz, 4H), 2.55 (br s, 4H), 2.87 (t, J=5.90 Hz, 2H), 4.30 (t, J=5.90 Hz, 2H), 7.30 (td, J=8.30, 2.61 Hz, 1H), 7.54-7.64 (m, 2H), 7.89 (t, J=2.20 Hz, 1H), 8.40 (d, J=2.74 Hz, 1H), 8.47 (d, J=5.49 Hz, 1H), 8.66 (d, J=1.65 Hz, 1H), 8.75 (br d, J=7.14 Hz, 1H), 8.86 (br d, J=11.25 Hz, 1H), 9.10 (d, J=2.20 Hz, 1H), 9.16 (d, J=2.20 Hz, 1H), 13.83 (brs, 1H), 14.52 (brs, 1H); ESIMS found for C29H25FN8O m/z 521.2 (M+1).




2-((5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine 895
Yellow solid (1.9 mg, 0.004 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.25 (s, 6H), 2.71 (t, J=5.76 Hz, 2H), 4.28 (t, J=5.76 Hz, 2H), 7.29 (td, J=8.30, 2.33 Hz, 1H), 7.53-7.64 (m, 2H), 7.88 (t, J=2.20 Hz, 1H), 8.39 (d, J=2.74 Hz, 1H), 8.44 (br d, J=5.21 Hz, 1H), 8.66 (d, J=1.65 Hz, 1H), 8.77 (br d, J=7.41 Hz, 1H), 8.88 (br d, J=10.15 Hz, 1H), 9.07 (d, J=1.92 Hz, 1H), 9.16 (d, J=2.20 Hz, 1H); ESIMS found for C27H23FN8O m/z 495.2 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine 896
Orange solid (16.8 mg, 0.04 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 3.98 (s, 3H), 7.32 (td, J=8.23, 2.20 Hz, 1H), 7.55-7.64 (m, 2H), 7.84-7.90 (m, 1H), 8.40 (d, J=2.74 Hz, 1H), 8.47 (d, J=5.21 Hz, 1H), 8.66 (d, J=1.92 Hz, 1H), 8.73 (br d, J=7.68 Hz, 1H), 8.87 (br d, J=10.70 Hz, 1H), 9.10 (d, J=2.20 Hz, 1H), 9.15 (d, J=1.92 Hz, 1H), 13.81 (br s, 1H), 14.54 (br s, 1H); ESIMS found for C24H16FN7O m/z 438.1 (M+1).




5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol 897
Yellow solid (4.6 mg, 0.01 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 5.38 (br s, 1H), 7.33 (td, J=8.23, 2.47 Hz, 1H), 7.55-7.65 (m, 3H), 8.25 (d, J=2.74 Hz, 1H), 8.47 (d, J=5.21 Hz, 1H), 8.54 (d, J=1.92 Hz, 1H), 8.78 (br d, J=7.68 Hz, 1H), 8.83 (br d, J=11.80 Hz, 1H), 9.02 (d, J=2.20 Hz, 1H), 9.11 (d, J=2.20 Hz, 1H), 10.19 (br s, 1H), 13.83 (br s, 1H), 14.46 brs, 1H); ESIMS found for C23H14FN7O m/z 424.1 (M+1).




5-(5-(Benzyloxy)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 898
Yellow solid (37 mg, 0.068 mmol, 66.0% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 5.33 (s, 2H), 7.22 (td, J=8.16, 2.33 Hz, 1H), 7.35-7.41 (m, 1H), 7.42-7.48 (m, 2H), 7.52-7.62 (m, 4H), 7.98 (t, J=2.33 Hz, 1H), 8.42-8.51 (m, 2H), 8.70 (d, J=1.65 Hz, 1H), 8.75 (d, J=7.68 Hz, 1H), 8.85 (br d, J=11.25 Hz, 1H), 9.11 (d, J=2.20 Hz, 1H), 9.17 (d, J=1.92 Hz, 1H), 13.83 (br s, 1H), 14.55 (br s, 1H); ESIMS found for C30H20FN7O m/z 514.2 (M+1).




2-Cyclohexyl-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide 899
Light yellow solid (24 mg, 0.042 mmol, 36.5% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 0.97-1.08 (m, 2H), 1.12-1.31 (m, 3H), 1.63 (br d, J=11.53 Hz, 1H), 1.68 (br d, J=12.62 Hz, 2H), 1.75 (br d, J=10.70 Hz, 2H), 1.83 (ddd, J=10.84, 7.27, 3.57 Hz, 1H), 2.30 (d, J=7.14 Hz, 2H), 7.21-7.30 (m, 1H), 7.58 (d, J=5.21 Hz, 1H), 7.61-7.69 (m, 1H), 8.48 (d, J=5.21 Hz, 1H), 8.60 (s, 1H), 8.74 (d, J=1.92 Hz, 1H), 8.76-8.86 (m, 3H), 9.02 (d, J=2.20 Hz, 1H), 9.09 (d, J=1.65 Hz, 1H), 10.29 (s, 1H), 13.87 (br s, 1H), 14.58 (s, 1H); ESIMS found for C31H27FN8O m/z 547.2 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine 900
Off-white solid (20.0 mg, 0.05 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 7.37 (td, J=8.30, 2.61 Hz, 1H), 7.56 (d, J=5.49 Hz, 1H), 7.60-7.68 (m, 1H), 7.84-7.91 (m, 3H), 8.00 (dd, J=8.78, 1.65 Hz, 1H), 8.47 (d, J=5.49 Hz, 1H), 8.69-8.76 (m, 3H), 9.01 (br d, J=11.25 Hz, 1H), 9.11 (s, 1H), 13.75 (s, 1H), 14.01 (s, 1H); ESIMS found for C23H14FN7 m/z 408.1 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine 901
Off-white solid (35 mg, 0.082 mmol, 38.2% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 7.35 (td, J=8.30, 2.06 Hz, 1H), 7.44-7.51 (m, 1H), 7.57 (d, J=5.49 Hz, 1H), 7.60-7.69 (m, 1H), 8.00 (td, J=7.68, 1.92 Hz, 1H), 8.18 (d, J=7.96 Hz, 1H), 8.47 (d, J=5.49 Hz, 1H), 8.74-8.83 (m, 2H), 8.93 (br d, J=11.53 Hz, 1H), 9.42 (d, J=2.20 Hz, 1H), 9.63 (d, J=1.92 Hz, 1H), 13.84 (br s, 1H), 14.51 (br s, 1H); ESIMS found for C23H14FN7 m/z 408.1 (M+1).




3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine 902
Yellow solid (54 mg, 0.126 mmol, 51.6% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 7.33 (td, J=8.30, 2.06 Hz, 1H), 7.55 (d, J=5.21 Hz, 1H), 7.62 (td, J=7.96, 6.59 Hz, 1H), 8.46 (d, J=5.21 Hz, 1H), 8.71 (d, J=2.47 Hz, 1H), 8.76 (br d, J=6.86 Hz, 1H), 8.82 (dd, J=2.47, 1.65 Hz, 1H), 8.88 (br d, J=10.15 Hz, 1H), 9.45 (dd, J=3.43, 1.78 Hz, 2H), 9.65 (d, J=1.92 Hz, 1H), 13.93 (br s, 1H), 14.43 (br s, 1H); ESIMS found for C22H13FN8 m/z 409.1 (M+1).




N-(5-(3-(4-(3-(2-(Dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 1192
Yellow solid (10 mg, 0.017 mmol, 26.6% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 0.96 (d, J=6.59 Hz, 6H), 2.04-2.18 (m, 7H), 2.27 (d, J=7.14 Hz, 2H), 2.42 (br s, 2H), 4.10 (t, J=5.63 Hz, 2H), 6.85-6.93 (m, 1H), 7.57 (d, J=5.21 Hz, 1H), 8.31 (br d, J=10.70 Hz, 1H), 8.43-8.53 (m, 3H), 8.71 (d, J=2.20 Hz, 1H), 8.88 (d, J=2.47 Hz, 1H), 8.98 (d, J=2.20 Hz, 1H), 9.05 (d, J=2.20 Hz, 1H), 10.27 (s, 1H), 13.85 (br s, 1H), 14.58 (br s, 1H); ESIMS found for C32H32FN9O2 m/z 594.3 (M+1).




N-(5-(3-(4-(3-Fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 1236
Yellow solid (11.4 mg, 0.018 mmol, 30.1% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 0.97 (d, J=6.59 Hz, 6H), 1.59 (dt, J=6.66, 3.12 Hz, 4H), 2.05-2.17 (m, 1H), 2.27 (d, J=7.41 Hz, 2H), 2.37 (br s, 4H), 2.56 (t, J=5.76 Hz, 2H), 4.12 (t, J=5.76 Hz, 2H), 6.88 (dt, J=10.57, 2.26 Hz, 1H), 7.57 (d, J=5.21 Hz, 1H), 8.30 (br d, J=10.15 Hz, 1H), 8.43-8.48 (m, 2H), 8.52 (br s, 1H), 8.71 (d, J=1.92 Hz, 1H), 8.88 (d, J=2.47 Hz, 1H), 8.97 (d, J=1.92 Hz, 1H), 9.06 (d, J=2.20 Hz, 1H), 10.28 (s, 1H), 14.23 (brs, 1H); ESIMS found for C34H34FN9O2 m/z 620.3 (M+1).




N-(5-(3-(4-(3-Fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 1280
Yellow solid (13.8 mg, 0.026 mmol, 20.3% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 0.98 (d, J=6.59 Hz, 6H), 2.12 (dquin, J=13.64, 6.81, 6.81, 6.81, 6.81 Hz, 1H), 2.28 (d, J=7.14 Hz, 2H), 6.64 (br d, J=10.15 Hz, 1H), 7.55 (d, J=5.21 Hz, 1H), 8.20 (s, 1H), 8.36 (br d, J=10.98 Hz, 1H), 8.42-8.48 (m, 2H), 8.75 (d, J=1.65 Hz, 1H), 8.87 (d, J=2.20 Hz, 1H), 9.00 (d, J=2.20 Hz, 1H), 9.13 (d, J=1.92 Hz, 1H), 9.99 (s, 1H), 10.23 (s, 1H), 13.82 (s, 1H), 14.57 (s, 1H); ESIMS found for C28H23FN8O2 m/z 523.2 (M+1).




N-(5-(3-(4-(3-Fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 1324
Yellow solid (49.3 mg, 0.092 mmol, 73.1% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 0.97 (d, J=6.59 Hz, 6H), 2.11 (dquin, J=13.67, 6.67, 6.67, 6.67, 6.67 Hz, 1H), 2.28 (d, J=7.14 Hz, 2H), 3.83 (s, 3H), 6.89 (dt, J=10.43, 2.33 Hz, 1H), 7.57 (d, J=5.49 Hz, 1H), 8.31 (br d, J=9.61 Hz, 1H), 8.44-8.50 (m, 2H), 8.59 (s, 1H), 8.72 (d, J=1.92 Hz, 1H), 8.87 (d, J=2.20 Hz, 1H), 8.98 (d, J=2.20 Hz, 1H), 9.09 (d, J=2.20 Hz, 1H), 10.27 (s, 1H), 13.86 (br s, 1H), 14.58 (s, 1H); ESIMS found for C29H25FN8O2 m/z 537.2 (M+1).




2-(Dimethylamino)-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4, 5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide 1367
Yellow solid (17 mg, 0.007 mmol). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.35 (s, 6H), 3.20 (s, 2H), 7.25-7.33 (m, 1H), 7.57 (d, J=5.21 Hz, 1H), 7.61-7.69 (m, 1H), 8.48 (d, J=5.49 Hz, 1H), 8.63 (s, 1H), 8.76-8.85 (m, 3H), 8.96 (d, J=2.20 Hz, 1H), 9.04 (d, J=2.20 Hz, 1H), 9.12 (d, J=2.20 Hz, 1H), 10.15 (s, 1H), 13.84 (br s, 1H), 14.57 (br s, 1H); ESIMS found for C27H22FN9O m/z 508.2 (M+1).
Example 2
The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) with a lentiviral construct that includes a Wnt-responsive promoter driving expression of the firefly luciferase gene.
SW480 colon carcinoma cells were transduced with a lentiviral vector expressing luciferase with a human Sp5 promoter consisting of a sequence of eight TCF/LEF binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a hygromycin resistance gene were selected by treatment with 150 μg/ml of hygromycin for 7 days. These stably transduced SW480 cells were expanded in cell culture and used for all further screening activities. For Sp5-Luc reporter gene assays, the cells were plated at 10,000 cells/well in 96-well plates with growth medium containing 10% fetal calf serum and incubated overnight at 37° C. and 5% CO2. Each compound was dissolved in DMSO as a 10 mM stock in standard j-vials and used to prepare compound source plates in dose-response format with 3-fold serial dilutions and a 10 mM top concentration. Compound transfer from serially diluted source plates to assay plates containing the cells was accomplished using a pintool (Multimek 96, Beckman equipped with V&P Scientific FP1S50H pins) based liquid handling protocol. This protocol used a slotted pin to transfer 50 nl of compound from a source plate well to an assay plate well containing 50 μl of cells in growth medium. The 1000-fold dilution resulted in a final DMSO concentration of 0.1% on the cells in each well. Control wells received 50 nl of DMSO treatment for normalization and calculating IC50 values. The treated cells were incubated at 37° C. and 5% CO2 for an additional forty-two hours. Following incubation, the growth medium was removed and 50 μl of BrightGlo luminescence reagent (Promega) was added to each well of the 96-well assay plates. The plates were placed on an orbital shaker for 5 min and then luminescence was quantified on the Victor3 (Perkin Elmer) plate reader. Readings were normalized to DMSO only treated cells, and normalized activities were utilized for IC50 calculations using the dose-response log (inhibitor) vs. response-variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 or 6.0. Table 2 shows the measured activity for selected compounds of Formula I as described herein.












TABLE 2





Com-
IC50
Com-
IC50
Com-
IC50 


pound
(μM)
pound
(μM)
pound
(μM)




















1
0.0058
184
0.0048
401
>10


7
0.0353
190
1.5760
407
0.0741


13
0.3388
196
0.5793
413
0.1432


19
0.005
211
0.3340
416
>10


25
0.0339
217
0.6728
428
0.015


28
0.0377
223
>10
434
0.0219


34
0.1522
229
1.5490
440
0.7520


40
>10
234
0.1791
885
3.865


46
0.005
239
0.018
886
3.700


52
0.1546
245
0.1016
887
0.006


55
0.0059
251
0.0099
888
0.012


61
0.028
257
0.3094
889
0.012


68
0.0957
266
0.3391
890
0.365


73
0.0602
272
0.013
891
0.935


82
0.0419
278
0.056
892
0.315


87
>10
284
0.8750
893
0.868


90
0.0797
287
0.0229
894
1.500


93
3.8830
293
0.0371
895
0.343


101
>10
299
1.4410
896
0.037


109
>10
305
0.009
897
0.023


114
>10
311
0.0228
898
3.265


121
>10
314
0.0063
899
1.970


126
1.1160
320
0.0093
900
>10


136
>10
341
0.0009
901
>10


141
>10
347
0.0208
902
0.705


148
6.155
353
0.5755
1192
0.400


157
0.1484
359
0.0299
1236
0.445


163
0.7769
368
0.0104
1280
0.090


169
2.2720
374
>10
1324
0.085


175
0.413
386
0.1878
1367
0.183


181
0.2432
395
0.008











Example 3
The above synthesized compounds were screened using primary human mesenchymal stem cells (hMSCs) to determine their ability to induce chondrogenesis (process by which cartilage is developed).
Human Mesenchymal Stem Cell Culture:
Primary human mesenchymal stem cells (hMSCs) were purchased from Lonza (Walkersville, Md.) and expanded in Mesenchymal Stem Cell Growth Media (Lonza). Cells between passage 3 and 6 were used for the experiments.
Compound Screening:
Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 6-point dose-response curves from 2700 nM to 10 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 96-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.03%. hMSCs were plated at 20,000 cells/well in 250 μL/well Incomplete Chondrogenic Induction Medium (Lonza; DMEM, dexamethasone, ascorbate, insulin-transferrin-selenium [ITS supplement], gentamycin-amphotericin [GA-1000], sodium pyruvate, proline and L-glutamine). TGF-β3 (10 ng/mL) was used as a positive control for differentiation while negative control wells were treated with 75 nL DMSO for normalization and calculating EC50 values. Cells were incubated at 37° C. and 5% CO2 for 6 days. To image chondrogenic nodules, the cells were fixed using 4% formaldehyde (Electron Microscopy Sciences), and stained with 2 μg/mL Rhodamine B (Sigma-Aldrich) and 20 μM Nile Red (Sigma-Aldrich) [Johnson K., et. al, A Stem Cell-Based Approach to Cartilage Repair, Science, (2012), 336(6082), 717-721]. The nodules imaged (4 images per well at 4× magnification) by excitation at 531 nm and emission at 625 nm and quantified using the CellInsight CX5 (Thermo Scientific). Number of nodules in each well was normalized to the average of 3 DMSO treated wells on the same plate using Excel (Microsoft Inc.). The normalized averages (fold change over DMSO) of 3 replicate wells for each compound concentration were calculated. Due to solubility limitations of some of the compounds, curve fitting was incomplete leading to inaccurate EC50 determinations.
Using TGF-β3 as a positive control, the concentration of test compounds required to induce equivalent levels of chondrogenesis is reported. In addition, the maximum activity of each compound and the respective dose that each compound reached maximum chondrogenesis activity is reported. Table 3 shows the activity of selected compounds as provided herein.














TABLE 3







Max.
Conc


Max.
Conc



Conc
Activ-
(nM) 

Conc
Activ-
(nM)



(nM) 
ity
of

(nM)
ity
of



of
as %
100%

of
as %
100%



Max.
TGF-
TGF-

Max.
TGF-
TGF-


Com-
activ-
β3
β3
Com-
activ-
β3
β3


pound
ity
activity
activity
pound
ity
activity
activity






















1
2700
300
117.0
341
2700
N/A
58.2


46
900
900
80.6
368
30
30
84.6


55
2700
N/A
32.2
395
10
10
92.8


184
100
N/A
5.4
428
30
30
82.9


251
900
N/A
52.8
888
30
30
74.9


272
30
30
72.0
889
100
100
151.7


305
10
N/A
54.9













Example 4
The above synthesized compounds were screened using primary human fibroblasts (derived from IPF patients) treated with TGF-β1 to determine their ability to inhibit the fibrotic process.
Human Fibroblast Cell Culture:
Primary human fibroblasts derived from IPF patients (LL29 cells) [1Xiaoqiu Liu, et. al., “Fibrotic Lung Fibroblasts Show Blunted Inhibition by cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation”, Journal of Pharmacology and Experimental Therapeutics (2005), 315(2), 678-687; 2Watts, K. L., et. al., “RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis”, Respiratory Research (2006), 7(1), 88] were obtained from American Type Culture Collection (ATCC) and expanded in F12 medium supplemented with 15% Fetal Bovine Serum and Penicillin/Streptomycin.
Compound Screening:
Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point dose-response curves from 10 M to 1.87 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. LL29 cells were plated at 1,500 cells/well in 80 l/well F12 medium supplemented with 1% Fetal Bovine Serum. One hour after addition of the cells, TGF-β1 (Peprotech; 20 ng/mL) was added to the plates to induce fibrosis (ref. 1 and 2 above). Wells treated with TGF-β1 and containing DMSO were used as controls. Cells were incubated at 37° C. and 5% CO2 for 4 days. Following incubation for 4 days, SYTOX green nucleic acid stain (Life Technologies [Thermo Fisher Scientific]) was added to the wells at a final concentration of 1 uM and incubated at room temperature for 30 min. Cells were then fixed using 4% formaldehyde (Electron Microscopy Sciences), washed 3 times with PBS followed by blocking and permeabilization using 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS. Cells were then stained with antibody specific to α-smooth muscle actin (αSMA; Abcam) (ref. 1 and 2 above) in 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS, and incubated overnight at 4° C. Cells were then washed 3 times with PBS, followed by incubation with Alexa Flor-647 conjugated secondary antibody (Life Technologies [Thermo Fisher Scientific]) and DAPI at room temperature for 1 hour. Cells were then washed 3 times with PBS and plates were sealed for imaging. αSMA staining was imaged by excitation at 630 nm and emission at 665 nm and quantified using the Compartmental Analysis program on the CellInsight CX5 (Thermo Scientific). Dead or apoptotic cells were excluded from analysis based on positive SYTOX green staining. % of total cells positive for αSMA were counted in each well and normalized to the average of 11 wells treated with TGF-β1 on the same plate using Dotmatics' Studies Software. The normalized averages (fold change over untreated) of 3 replicate wells for each compound concentration were used to create dose-responses curves and EC50 values were calculated using non-linear regression curve fit in the Dotmatics' Studies Software. The EC50 values are reported.
Table 4 shows the activity of selected compounds as provided herein.












TABLE 4






Inhibition

Inhibition 

Inhibition 



of

of

of


Com-
fibrosis
Com-
fibrosis
Com-
fibrosis


pound
EC50 (nM)
pound
EC50 (nM)
pound
EC50 (nM)




















1
0.062
163
0.009
359
4.849


7
0.365
169
0.888
368
0.241


13
0.030
175
0.859
374
0.427


19
0.027
181
1.130
386
0.053


28
0.881
196
9.990
395
0.009


34
3.060
211
9.990
401
9.990


40
9.990
223
9.990
416
9.990


46
0.253
239
0.024
428
0.020


55
0.283
245
0.280
434
0.013


61
>10
251
0.073
440
0.858


68
0.930
257
0.244
885
0.009


73
0.611
272
0.009
887
0.010


87
0.009
284
1.183
888
0.014


90
9.990
287
0.578
889
0.009


101
9.990
293
0.009
890
0.205


109
9.990
299
9.990
892
0.009


114
9.990
311
0.174
893
0.308


121
9.990
314
0.009
895
9.990


136
0.009
320
0.009
896
0.108


141
9.990
341
0.009
900
0.009


148
0.009
347
0.633
902
0.009


157
0.432
353
0.009
1367
0.186

## Claims

1. A method of treating a bone or cartilage disease selected from the group consisting of osteoarthritis, bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressive, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, bone/osteoporotic fractures, articular cartilage (chondral) defects, degenerative disc disease, osteochondritis dissecans, osteochondroma, osteopetrosis, relapsing polychondritis, and Salter-Harris fractures in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof:



wherein:
R1 is selected from the group consisting of -heteroaryl(R4)q and -heterocyclyl(R5)h;
R2 is selected from the group consisting of H and halide;
R3 is selected from the group consisting of -heteroaryl(R6)q, -heterocyclyl(R7)h, and -aryl(R8)k;
each R4 is one substituent attached to the heteroaryl and is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R9)h, —(C1-4 alkylene)pcarbocyclyl(R10)j, —(C1-4 alkylene)paryl(R11)k, —NHC(═O)R12, —NR13R14, —(C1-6 alkylene)NR15R16, and —OR22;
each R5 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
each R6 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —OCH3, —CN, and —C(═O)R17;
each R7 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —CN, and —OCH3;
each R8 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —CN, —OCH3, —(C1-6 alkylene)pNHSO2R17, —NR13(C1-6 alkylene)NR13R14, —(C1-6 alkylene)pNR13R14, and —OR25;
each R9 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, —(C1-4 alkyl), halide, —CF3, and —CN;
each R10 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
each R11 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
each R12 is independently selected from the group consisting of —(C1-9 alkyl), -heteroaryl(R18)q, -aryl(R19)k, —CH2aryl(R19)k, -carbocyclyl(R20)j, —CH2carbocyclyl(R20)j, —(C1-4 alkylene)pNR23R24, -heterocyclyl(R21)h, and —CH2heterocyclyl(R21)h;
each R13 is independently selected from the group consisting of H and —(C1-6 alkyl);
each R14 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j;
each R15 is independently selected from the group consisting of H and —(C1-6 alkyl);
each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j;
each R17 is a —(C1-6 alkyl);
each R18 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
each R19 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
each R20 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
each R21 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
R22 is selected from the group consisting of H, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R21)h, —(C1-4 alkylene)pcarbocyclyl(R20)j, —(C1-4 alkylene)paryl(R19)k, and —(C1-6 alkylene)pNR23R24;
each R23 is independently selected from the group consisting of H and —(C1-6 alkyl);
each R24 is independently selected from the group consisting of H and —(C1-6 alkyl);
R25 is selected from the group consisting of H, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R21)h, and —(C1-6 alkylene)pNR23R24;
each p is independently 0 or 1;
each q is independently 0 to 4;
each h is independently 0 to 10;
each k is independently 0 to 5; and
each j is independently 0 to 12.

2. The method of claim 1, wherein R1 is -heteroaryl(R4)q.

3. The method of claim 2, wherein R1 is selected from the group consisting of -pyridinyl(R4)q, -pyrimidinyl(R4)q, -pyrazolyl(R4)q, and -imidazolyl(R4)q.

4. The method of claim 2, wherein q is 0, 1 or 2.

5. The method of claim 3, wherein R4 is selected from the group consisting of —(C1-3 alkyl), —CH2heterocyclyl(R9)h, —NHC(═O)R12, —NR13R14, —CH2NR15R16, and —OR22.

6. The method of claim 1, wherein R3 is -aryl(R8)k.

7. The method of claim 6, wherein R3 is -phenyl(R8)k.

8. The method of claim 7, wherein k is 1 or 2.

9. The method of claim 8, wherein each R8 is independently selected from the group consisting of halide and —CH2NHSO2R17.

10. The method of claim 1, wherein R3 is -heteroaryl(R6)q.

11. The method of claim 10, wherein R3 is selected from the group consisting of -pyridin (R6)q, -imidazolyl(R6)q, -furanyl(R6)q, and -thiophenyl(R6)q.

12. The method of claim 11, wherein q is 0 or 1.

13. The method of claim 11, wherein q is 1 and R6 is selected from the group consisting of halide —(C1-3 alkyl), and —C(═O)R17.

14. The method of claim 1, wherein R3 is -heterocyclyl(R7)h.

15. The method of claim 14, wherein R3 is selected from the group consisting of -piperidinyl(R7)h, -morpholinyl(R7)h, and -piperazinyl(R7)h.

16. The method of claim 15, wherein h is 0, 1, or 2.

17. The method of claim 16, wherein each R7 is independently selected from the group consisting of a halide and —(C1-3 alkyl).

18. The method of claim 1, wherein R2 is H.

19. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [1];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [2];
5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [3];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [4];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [5];
N-((5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [6];
5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [7];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [8];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [9];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [10];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [11];
5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [12];
1-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [13];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [14];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [15];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [16];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [17];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [18];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [19];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [20];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [21];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [22];
N-benzyl-1-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [23];
1-cyclopentyl-N-((5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [24];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [25];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [26];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [27];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [28];
5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [29];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [30];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [31];
N-((5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [32];
5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [33];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [34];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [35];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [36];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [37];
5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [38];
1-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [39];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [40];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [41];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [42];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [43];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [44];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [45];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [46];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [47];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [48];
N-benzyl-1-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [49];
1-cyclopentyl-N-((5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [50];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [51];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [52];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [53];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [54];
5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [55];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [56];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [57];
N-((5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [58];
5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [59];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [60];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [61];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [62];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [63];
5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [64];
1-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [65];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [66];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [67];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [68];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [69];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [70];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [71];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [72];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [73];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [74];
N-benzyl-1-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [75];
1-cyclopentyl-N-((5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [76];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [77];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [78];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [79];
3-methyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [80];
5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [81];
5-(pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [82];
5-(4-methylpyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [83];
N-((5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [84];
N,N-dimethyl-5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [85];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [86];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [87];
2-phenyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [88];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [89];
N-isopropyl-5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [90];
N,N-dimethyl-1-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [91];
3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [92];
5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [93];
3,3-dimethyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [94];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [95];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [96];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [97];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [98];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [99]; and
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [100]; or a pharmaceutically acceptable salt thereof.

20. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-benzyl-1-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [101];
1-cyclopentyl-N-((5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [102];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [103];
3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [104];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [105];
3-methyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [106];
5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [107];
5-(pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [108];
5-(4-methylpyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [109];
N-((5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [110];
N,N-dimethyl-5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [111];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [112];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [113];
2-phenyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [114];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [115];
N-isopropyl-5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [116];
N,N-dimethyl-1-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [117];
3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [118];
5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [119];
3,3-dimethyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [120];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [121];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [122];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [123];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [124];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [125];
N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [126];
N-benzyl-1-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [127];
1-cyclopentyl-N-((5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [128];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [129];
3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [130];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [131];
3-methyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [132];
5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [133];
3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [134];
5-(4-methylpyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [135];
N-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [136];
N,N-dimethyl-5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [137];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [138];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [139];
2-phenyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [140];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [141];
N-isopropyl-5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [142];
N,N-dimethyl-1-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [143];
3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [144];
5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [145];
3,3-dimethyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [146];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [147];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [148];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [149];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [150];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [151];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [152];
N-benzyl-1-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [153];
1-cyclopentyl-N-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [154];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [155];
3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [156];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [157];
3-methyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [158];
5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [159];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [160];
5-(4-methylpyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [161];
N-((5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [162];
N,N-dimethyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [163];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [164];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [165];
2-phenyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [166];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [167];
N-isopropyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [168];
N,N-dimethyl-1-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [169];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [170];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [171];
3,3-dimethyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [172];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [173];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [174];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [175];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [176];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [177];
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [178];
N-benzyl-1-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [179];
1-cyclopentyl-N-((5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [180];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [181];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [182];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [183];
3-methyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [184];
5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [185];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [186];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [187];
N-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [188];
N,N-dimethyl-5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [189];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [190];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [191];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [192];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [193];
N-isopropyl-5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [194];
N,N-dimethyl-1-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [195];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [196];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [197];
3,3-dimethyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [198];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [199]; and
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [200]; or a pharmaceutically acceptable salt thereof.

21. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [201];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [202];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [203];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [204];
N-benzyl-1-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [205];
1-cyclopentyl-N-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [206];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [207];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [208];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [209];
3-methyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [210];
5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [211];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [212];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [213];
N-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [214];
N,N-dimethyl-5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [215];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [216];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [217];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [218];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [219];
N-isopropyl-5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [220];
N,N-dimethyl-1-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [221];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [222];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [223];
3,3-dimethyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [224];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [225];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [226];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [227];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [228];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [229];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [230];
N-benzyl-1-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [231];
1-cyclopentyl-N-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [232];
5-(5-((3,3-difluoropyrrolidin-1-yl)methy)pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [233];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [234];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [235];
3-methyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [236];
5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [237];
5-(pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [238];
5-(4-methylpyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [239];
N-((5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [240];
N,N-dimethyl-5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [241];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [242];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [243];
2-phenyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [244];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [245];
N-isopropyl-5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [246];
N,N-dimethyl-1-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [247];
5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [248];
5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [249];
3,3-dimethyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [250];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [251];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [252];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [253];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [254];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [255];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [256];
N-benzyl-1-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [257];
1-cyclopentyl-N-((5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [258];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [259];
5-(pyrimidin-5-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [260];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [261];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [262];
5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [263];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [264];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [265];
N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [266];
5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [267];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [268];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [269];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [270];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [271];
5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [272];
1-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [273];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [274];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [275];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [276];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [277];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [278];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [279];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [280];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [281];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [282];
N-benzyl-1-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [283];
1-cyclopentyl-N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [284];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [285];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [286];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [287];
3-methyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [288];
5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [289];
5-(pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [290];
5-(4-methylpyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [291];
N-((5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [292];
N,N-dimethyl-5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [293];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [294];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [295];
2-phenyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [296];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [297];
N-isopropyl-5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [298];
N,N-dimethyl-1-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [299]; and
5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [300]; or a pharmaceutically acceptable salt thereof.

22. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [301];
3,3-dimethyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [302];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [303];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [304];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [305];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [306];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [307];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [308];
N-benzyl-1-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [309];
1-cyclopentyl-N-((5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [310];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [311];
5-(pyrimidin-5-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [312];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [313];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [314];
5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [315];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [316];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [317];
N-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [318];
5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [319];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [320];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [321];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [322];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [323];
5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [324];
1-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [325];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [326];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [327];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [328];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [329];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [330];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [331];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [332];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [333];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [334];
N-benzyl-1-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [335];
1-cyclopentyl-N-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [336];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [337];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [338];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [339];
3-methyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [340];
5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [341];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [342];
5-(4-methylpyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [343];
N-((5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [344];
N,N-dimethyl-5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [345];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [346];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [347];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [348];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [349];
N-isopropyl-5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [350];
N,N-dimethyl-1-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [351];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [352];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [353];
3,3-dimethyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [354];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [355];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [356];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [357];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [358];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [359];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [360];
N-benzyl-1-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [361];
1-cyclopentyl-N-((5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [362];
5-(5-((3,3-difluoropyrrolidin-1-yl)methy)pyridin-3-yl)-1-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [363];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [364];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [365];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [366];
1-(5-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [367];
1-(5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [368];
1-(5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [369];
1-(5-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [370];
1-(5-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [371];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [372];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [373];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [374];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [375];
1-(5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [376];
1-(5-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [377];
1-(5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [378];
1-(5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [379];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [380];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [381];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [382];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [383];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [384];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [385];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [386];
1-(5-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [387];
1-(5-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [388];
1-(5-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [389];
1-(5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [390];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [391];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [392];
N-(3-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [393];
N-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [394];
N-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [395];
N-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [396];
N-(3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [397];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [398];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [399]; and
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [400]; or a pharmaceutically acceptable salt thereof.

23. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [401];
N-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [402];
N-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [403];
N-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [404];
N-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [405];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [406];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [407];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [408];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [409];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [410];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [411];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [412];
N-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [413];
N-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [414];
N-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [415];
N-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [416];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [417];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [418];
N1-(3-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [419];
N1-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [420];
N1-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [421];
N1-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [422];
N1-(3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [423];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [424];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [425];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [426];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [427];
N1-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [428];
N1-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [429];
N1-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [430];
N1-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [431];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [432];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [433];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [434];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [435];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [436];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [437];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [438];
N1-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [439];
N1-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [440];
N1-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [441];
N1-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [442];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [885];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [886];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [887];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [888];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [889];
1-(6-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [890];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [891];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [892];
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [893];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [894];
2-((5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [895];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [896];
5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [897];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [898];
2-cyclohexyl-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [899]; and
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [900];
or a pharmaceutically acceptable salt thereof.

24. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [901];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [902];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [903];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [904];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [905];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [906];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [907];
1-(6-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [908];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [909];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [910];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [911];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [912];
2-((5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [913];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [914];
5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [915];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [916];
2-cyclohexyl-N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [917];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [918];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [919];
3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [920];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [921];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [922];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [923];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [924];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [925];
1-(6-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [926];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [927];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [928];
N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [929];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [930];
2-((5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [931];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [932];
5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [933];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [934];
2-cyclohexyl-N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [935];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [936];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [937];
3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [938];
5-(piperidin-4-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [939];
3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [940];
5-(1H-pyrazol-4-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [941];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [942];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [943];
1-(6-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [944];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [945];
5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [946];
2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [947];
3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [948];
N,N-dimethyl-2-((5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [949];
5-(5-methoxypyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [950];
5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [951];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [952];
2-cyclohexyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [953];
3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [954];
5-(pyridin-2-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [955];
5-(pyrazin-2-yl)-3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [956];
5-(piperidin-4-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [957];
3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [958];
5-(1H-pyrazol-4-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [959];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [960];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [961];
1-(6-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [962];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [963];
5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [964];
2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [965];
3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [966];
N,N-dimethyl-2-((5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [967];
5-(5-methoxypyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [968];
5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [969];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [970];
2-cyclohexyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [971];
5-(pyridin-4-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [972];
5-(pyridin-2-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [973];
5-(pyrazin-2-yl)-3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [974];
5-(piperidin-4-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [975];
3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [976];
5-(1H-pyrazol-4-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [977];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [978];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [979];
1-(6-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [980];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [981];
5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [982];
2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [983];
3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [984];
N,N-dimethyl-2-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [985];
5-(5-methoxypyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [986];
5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [987];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [988];
2-cyclohexyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [989];
3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [990];
5-(pyridin-2-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [991];
5-(pyrazin-2-yl)-3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [992];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [993];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [994];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [995];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [996];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [997];
1-(6-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [998];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [999]; and
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1000]; or a pharmaceutically acceptable salt thereof.

25. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1001];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1002];
N,N-dimethyl-2-((5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1003];
5-(5-methoxypyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1004];
5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1005];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1006];
2-cyclohexyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1007];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1008];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1009];
3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1010];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1011];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1012];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1013];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1014];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1015];
1-(6-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1016];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1017];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1018];
N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1019];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1020];
N,N-dimethyl-2-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1021];
5-(5-methoxypyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1022];
5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1023];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1024];
2-cyclohexyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1025];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1026];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1027];
3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1028];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1029];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1030];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1031];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1032];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1033];
1-(6-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1034];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1035];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1036];
N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1037];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1038];
N,N-dimethyl-2-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1039];
5-(5-methoxypyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1040];
5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1041];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1042];
2-cyclohexyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1043];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1044];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1045];
3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1046];
5-(piperidin-4-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1047];
5-(1,2,3,6-tetrahydropyridin-4-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1048];
5-(1H-pyrazol-4-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1049];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1050];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1051];
1-(6-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1052];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1053];
5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1054];
2-(piperidin-4-yl)-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1055];
5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1056];
N,N-dimethyl-2-((5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1057];
5-(5-methoxypyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1058];
5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1059];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1060];
2-cyclohexyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1061];
5-(pyridin-4-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1062];
5-(pyridin-2-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1063];
5-(pyrazin-2-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1064];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1065];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1066];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1067];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1068];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1069];
1-(6-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1070];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1071];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1072];
N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1073];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl) ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1074];
2-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1075];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1076];
5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1077];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1078];
2-cyclohexyl-N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1079];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1080];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1081];
3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1082];
5-(piperidin-4-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1083];
5-(1,2,3,6-tetrahydropyridin-4-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1084];
5-(1H-pyrazol-4-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1085];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1086];
5-(1, 2-dimethyl-1H-imidazol-5-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1087];
1-(6-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1088];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1089];
5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1090];
2-(piperidin-4-yl)-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1091];
5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1092];
N,N-dimethyl-2-((5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1093];
5-(5-methoxypyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1094];
5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1095];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1096];
2-cyclohexyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1097];
5-(pyridin-4-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1098];
5-(pyridin-2-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1099]; and
5-(pyrazin-2-yl)-3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1100];
or a pharmaceutically acceptable salt thereof.

26. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1101];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1102];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1103];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1104];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1105];
1-(6-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1106];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1107];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1108];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1109];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1110];
2-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1111];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1112];
5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1113];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1114];
2-cyclohexyl-N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1115];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1116];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1117];
3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1118];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1119];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1120];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1121];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1122];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1123];
1-(6-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1124];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1125];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1126];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1127];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1128];
N,N-dimethyl-2-((5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1129];
5-(5-methoxypyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1130];
5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1131];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1132];
2-cyclohexyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1133];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1134];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1135];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1136];
1-(5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1137];
1-(5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1138];
1-(5-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1139];
1-(5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1140];
1-(5-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1141];
1-(5-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1142];
1-(5-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1143];
1-(5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1144];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1145];
1-(5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1146];
1-(5-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1147];
1-(5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1148];
1-(5-(2-(5-(5-hydroxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1149];
1-(5-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1150];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-cyclohexylacetamide [1151];
1-(5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1152];
1-(5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1153];
1-(5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [1154];
N-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1155];
N-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1156];
N-(3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1157];
N-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1158];
N-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1159];
N-(3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1160];
N-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1161];
N-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1162];
N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1163];
N-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1164];
N-(3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1165];
N-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1166];
N-(3-fluoro-5-(2-(5-(5-hydroxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1167];
N-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1168];
2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1169];
N-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1170];
N-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1171];
N-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [1172];
N1-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1173];
N1-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1174];
N1-(3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [1175];
N1-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1176];
N1-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [1177];
N1-(3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [1178];
N1-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [1179];
N1-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1180];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1181];
N1-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1182];
N1-(3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [1183];
N1-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1184];
5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1185];
N1-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [1186];
2-cyclohexyl-N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1187];
N1-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1188];
N1-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1189];
N1-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [1190];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [1191];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [1192];
5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [1193];
2-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1194];
2-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1195];
2-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1196];
5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [1197];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [1198];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [1199]; and
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [1200]; or a pharmaceutically acceptable salt thereof.

27. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [1201];
5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [1202];
2-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1203];
2-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1204];
2-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1205];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [1206];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [1207];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [1208];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [1209];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [1210];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [1211];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [1212];
2-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1213];
2-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1214];
2-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1215];
2-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1216];
2-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1217];
2-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1218];
2-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1219];
2-(3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1220];
2-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1221];
2-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1222];
1-(6-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1223];
2-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1224];
2-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1225];
N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1226];
2-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1227];
2-((5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1228];
2-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1229];
5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1230];
2-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [1231];
2-cyclohexyl-N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1232];
2-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1233];
2-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [1234];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [1235];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [1236];
5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [1237];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1238];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1239];
N-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [1240];
5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [1241];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [1242];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [1243];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [1244];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [1245];
5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [1246];
1-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [1247];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1248];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1249];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [1250];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [1251];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [1252];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [1253];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [1254];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [1255];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [1256];
N-benzyl-1-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [1257];
1-cyclopentyl-N-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [1258];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1259];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [1260];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1261];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1262];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1263];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1264];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1265];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1266];
1-(6-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1267];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1268];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1269];
N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1270];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1271];
2-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1272];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1273];
5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1274];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1275];
2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1276];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1277];
3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1278];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [1279];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [1280];
3-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1281];
3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1282];
3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1283];
3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1284];
3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1285];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [1286];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [1287];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [1288];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [1289];
3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1290];
3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1291];
3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1292];
3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1293];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [1294];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [1295];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [1296];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [1297];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [1298];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [1299]; and
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [1300]; or a pharmaceutically acceptable salt thereof.

28. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1301];
3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1302];
3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1303];
3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1304];
3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1305];
3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1306];
3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1307];
3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1308];
3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1309];
3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1310];
3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1311];
3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1312];
3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1313];
N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1314];
3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1315];
3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1316];
3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1317];
5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1318];
3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [1319];
2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1320];
3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1321];
3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [1322];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide [1323];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [1324];
5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [1325];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1326];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1327];
N-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [1328];
5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [1329];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [1330];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [1331];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [1332];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide [1333];
5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [1334];
1-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [1335];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1336];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1337];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [1338];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [1339];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [1340];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [1341];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [1342];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [1343];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [1344];
N-benzyl-1-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine [1345];
1-cyclopentyl-N-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [1346];
5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1347];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine [1348];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1349];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1350];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1351];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1352];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1353];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1354];
1-(6-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1355];
5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1356];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1357];
N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1358];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1359];
2-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1360];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1361];
5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [1362];
5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1363];
2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1364];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [1365];
3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1366];
2-(dimethylamino)-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1367];
2-(dimethylamino)-N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1368];
2-(dimethylamino)-N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1369];
2-(dimethylamino)-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1370];
2-(dimethylamino)-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1371];
2-(dimethylamino)-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1372];
2-(dimethylamino)-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1373];
2-(dimethylamino)-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1374];
2-(dimethylamino)-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1375];
2-(dimethylamino)-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1376];
2-(dimethylamino)-N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1377];
2-(dimethylamino)-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1378];
2-(dimethylamino)-N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1379];
2-(dimethylamino)-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1380];
N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-(dimethylamino)acetamide [1381];
2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1382];
2-(dimethylamino)-N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1383];
2-(dimethylamino)-N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1384];
2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1385];
2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1386];
2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide [1387];
4-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [1388];
3-(4-(4,4-difluoropiperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1389];
3-(4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1390];
4-(2-(5-(5-fluoropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [1391];
5-(5-fluoropyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1392];
3-(4-(4,4-difluoropiperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-fluoropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [1393];
5-(5-fluoropyridin-3-yl)-3-(4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1394];
5-(5-fluoropyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1395];
4-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [1396];
3-(4-(4,4-difluoropiperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1397];
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1398];
4-(2-(5-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [1399];
5-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1400];
5-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(4-(4,4-difluoropiperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1401];
5-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1402];
5-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1403];
4-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [1404];
3-(4-(4,4-difluoropiperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [1405]; and
5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [1406]; or a pharmaceutically acceptable salt thereof.

29. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [19];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [46];
5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [55];
N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [87];
N-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [136];
N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [148];
N,N-dimethyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [163];
3-methyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [184];
5-(4-methylpyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [239];
N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide [251];
5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [272];
N,N-dimethyl-5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [293];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [305];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [314];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [320];
5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [341];
N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide [347];
3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [353];
1-(5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [368];
N-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [395];
N1-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [428];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [434];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine [885];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [887];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [888];
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [889];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine [892];
5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-ol [897];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine [900]; and
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine [902]; or a pharmaceutically acceptable salt thereof.

30. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:
N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [19];
N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [46];
5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [55];
3-methyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide [184];
5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine [272];
N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [305];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [314];
N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide [320];
5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine [341];
1-(5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethanone [368];
N-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [395];
N1-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [428];
N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide [434];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [887];
3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine [888]; and
5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine [889]; or a pharmaceutically acceptable salt thereof.

31. The method of claim 1, wherein the bone or cartilage disease is osteoarthritis.

32. The method of claim 1, wherein the bone or cartilage disease is articular cartilage (chondral) defects.

33. The method of claim 1, wherein the bone or cartilage disease is degenerative disc disease.

34. The method of claim 1, wherein the bone or cartilage disease is relapsing polychondritis.

35. The method of claim 1, wherein the bone or cartilage disease is osteochondritis dissecans.

36. The method of claim 1, wherein the subject is a human.